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Abstract 
Mitochondrial diseases are one of the most common forms of inherited 
neuromuscular disease. The presentations of these diseases are highly variable 
with both neurological and systemic involvement . Despite progress in 
identifying mitochondrial DNA mutations that result in disease, the natural 
history of mitochondrial diseases still remains unclear and no effective 
treatments are currently available (Pfeffer et al., 2012). The use of numerous 
primary outcomes in studies has made comparisons between studies difficult. A 
recent Cochrane review recommended the use of measures that were more 
relevant to patients in studies. 
This thesis aims to explore the use physiological measures alongside functional 
measures and gait in mitochondrial disease. The studies demonstrated that all 
functional outcome measures were able to discriminate between participants 
with mitochondrial disease and control subjects. However, gait characteristics 
were also able to discriminate between the two different mitochondrial 
genotypes. An aerobic exercise intervention resulted in an improvement in 
exercise capacity. However, disease severity, functional ability and gait 
measures remained unchanged. 
The main findings from this thesis are that: Clinical functional measures and gait 
are relevant for use in the research and clinical management of mitochondrial 
disease to monitor disease burden. The improvement in exercise capacity 
following a cycling intervention was unable to be translated into an improvement 
in function or gait. Therefore further research into other types of interventions, 
which may improve activities relevant to patients, is required.  
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The outcome of any serious research can 
only be to make two questions grow where 
only one grew before. 
 
Thorstein Veblen 
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Chapter 1 Introduction 
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1.1. Introduction 
Mitochondrial diseases are one of the most common forms of inherited 
neuromuscular disease. The presentations of these diseases are highly variable 
with both neurological and systemic involvement (McFarland et al., 2002). 
Muscle involvement in mitochondrial disease is common resulting in a variety of 
symptoms such as fatigue, exercise intolerance and progressive muscle 
weakness all of which can lead to significant disability. Despite progress in 
identifying mitochondrial DNA mutations that result in disease, the natural 
history of mitochondrial diseases still remains unclear and no effective 
treatments are currently available (Pfeffer et al., 2012). The monitoring of 
disease progression and the evaluation of new treatments requires the use of 
accurate outcome measures; the use of multiple laboratory clinical measures in 
previous research studies has led to difficulty comparing studies and often the 
results have little meaning to patients (Pfeffer et al., 2012).  
Exercise therapy has proved beneficial in improving the exercise capacity of 
patients with mitochondrial disease (Taivassalo et al., 2001; Cejudo et al., 2005; 
Taivassalo et al., 2006; Murphy et al., 2008; Jeppesen et al., 2009). Previous 
exercise studies have relied on extensive laboratory testing and invasive 
muscle biopsies. Such investigations are limited to a few research centres and 
are not practical for all patients. To review the effects of mitochondrial disease 
on patients and the effectiveness of interventions in a greater number of 
patients, simpler methods of measurement are required that can be translated 
into clinical practise. 
The studies included in this thesis will investigate the measurement of various 
aspects of mitochondrial disease including impairments, activities and 
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participation (World Health Organization, 2001). The studies will assess 
exercise capacity, performance of functional tests and gait in a clinically 
affected group of patients. The aims of the studies are to demonstrate: 1) 
exercise is safe and beneficial in a discrete group of patients with mitochondrial 
disease and 2) simple functional outcome measures and gait analysis are valid 
tools in this population in both the clinical and research arenas. 
This introductory chapter will review 1) the function of mitochondria, the 
diagnosis, manifestation and management of mitochondrial diseases and the 
treatments that are currently available; 2) literature regarding the effects of 
aerobic exercise on patients with mitochondrial disease compared with the 
general population and 3) the clinical measures used in this thesis (functional 
outcome measures, dynamometry and gait analysis) and their use in other 
populations.  
Subsequent thesis chapters will discuss the individual studies contained within 
the thesis. Chapter 2 provides descriptions of all the methods contained within 
the four studies undertaken. Chapter 3 describes a cross-sectional study 
observing the use of physiological and functional measures in mitochondrial 
disease with chapter 4 describing a cross sectional study of gait characteristics 
in the two mitochondrial genotypes. Chapter 5 will provide a summary of the 
clinical measures contained in the two cross-sectional studies. Chapter 6 
describes the effect of an exercise intervention on exercise capacity and 
functional outcome measures in a case controlled study with chapter 7 
observing the effects of the same exercise intervention on gait characteristics. 
Finally, Chapter 8 will discuss the clinical implications of these studies and 
areas for future research.
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1.2. Mitochondrial Physiology 
Mitochondria are found in all nucleated cells within the body. There may be 
thousands of mitochondria within a cell, depending on its function. Their number, 
position, size and shape can adapt to the cells’ requirements and function 
(Tiivel et al., 2000; Taylor and Turnbull, 2005). Mitochondria are no longer seen 
as discrete organelles within the cell, but as dynamic units that are able to move 
throughout the cytosol, thus forming long moving chains with microtubules in 
the cytoskeleton of the cell (Chan, 2006b). Whilst moving they are constantly 
fusing and dividing (Margineantu et al., 2002) which enable the mitochondria to 
exchange genetic materials and maintain their function (Chan, 2006a). 
Knowledge of the function and structure of mitochondria is essential in the 
understanding of the consequences of mutations within the DNA of the 
mitochondria and therefore these are described below. 
1.2.1 Mitochondrial Function  
Mitochondria play many roles within the cell, though their main function is the 
production of Adenosine triphosphate (ATP). Mitochondria progressively reduce 
the products of other energy pathways to create an electron gradient, which is 
used to provide the energy to re-synthesise ATP from Adenosine diphosphate 
(ADP) and inorganic Phosphate (Pi).  
Other key roles of the mitochondria are the regulation of calcium levels within 
the cell and apoptosis (Hengartner, 2000). As such, mitochondria play a central 
role in cellular function, through the provision of energy and the process of cell 
death. 
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1.2.2 Mitochondrial structure 
Each mitochondrion has two highly specialised membranes; the two 
membranes create internal and external compartments within the mitochondria, 
known as matrices (Figure 1-1). 
Figure 1-1: The mitochondrion.  
(A) An electron microscope picture of the mitochondrion (Fawcett, 1994). (B) A 
typical schematic representation of the mitochondria, adapted from Stryer 
Biochemistry 4th edition (Stryer, 1995.). 
 
The outer membrane contains many transport proteins; these proteins form 
wide aqueous channels through the membrane and allow the membrane to be 
permeable to molecules of a certain size. The inner membrane is impermeable 
to the passage of ions and most small molecules, except where a path is 
provided by a transport membrane protein. The inner membrane of the 
mitochondrial membrane is highly convoluted forming cristae that project into 
the matrix. These cristae increase the surface area greatly, therefore providing 
a larger area for ATP production. The number of cristae varies according to the 
role of the cell and its energy requirements. The inner mitochondrial membrane 
contains proteins with three types of function; 1) proteins involved in the 
oxidation reactions of the electron transfer chain, 2) ATP synthase that makes 
ATP in the matrix, and 3) transport proteins that allow the passage of 
metabolites in and out of the matrix. 
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The matrix of the mitochondria contains enzymes that are involved in the 
breakdown of pyruvate and fatty acids (derivatives of glycolysis and fat beta 
oxidation). Each mitochondrion also contains within the matrix its own 
Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA) and complete 
transcription and translation system allowing the manufacture of proteins used 
within the mitochondria. 
The structure of mitochondria is specialised to its function; the presence of DNA 
within mitochondria is essential in the production of proteins used to generate 
energy within the mitochondria. Mitochondrial metabolism requires oxygen and 
two interrelated metabolic pathways to work together, the citric acid cycle (TCA 
cycle) and the electron transport chain (ETC).  
 Citric Acid Cycle 
The first stage of the Citric Acid Cycle (TCA Cycle) involves the transportation 
of Pyruvate (formed from glycolysis) across the inner membrane of the 
mitochondria into the inner matrix. Within the inner matrix it is combined with 
coenzyme A to form Acetyl CoA. This is then fed into the citric acid cycle where 
it is progressively broken down, producing key substrates for the electron 
transport chain (Figure 1-2). The energy from the cycle is temporarily held in 
high-energy electrons of NADH and FADH2. The TCA cycle in itself does not 
use oxygen, but will stall without its link to the ETC where oxygen is required as 
a terminal acceptor. The high-energy electrons produced (NADH and FADH2) 
are then used in the second stage of mitochondrial respiration, the electron 
transport chain (ETC). 
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Figure 1-2: The citric acid cycle. 
Acetyl CoA condenses with Oxaloactetate to form citrate. Then follow eight steps 
where electrons are removed and are donated to coenzymes NAD+ and FAD+ to 
form NADH, FADH2 and CO2. Each turn of the cycle generates three NADH, one 
FADH2, one ATP (from GTP) and two CO2 molecules .One additional NADH and CO2 
are generated by the oxidation of pyruvate prior to entering the cycle (Alberts et al., 
2004). 
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 The electron transfer chain  
The Electron transfer chain (ETC) is located along the inner membrane of the 
mitochondria and is present in many copies along the membrane. 
The inner membrane of the mitochondria contains over 40 proteins of which 15 
are directly involved in electron transport. Most of the proteins involved in the 
ETC are formed into five large respiratory enzyme complexes (Figure 1-3). 
High-energy electrons from NADH and FADH2 (from the citric acid cycle) enter 
the ETC and become oxidized to NAD+ and FAD. The energy released by the 
flow of electrons through the ETC is used to pump protons out of the 
mitochondrial inner membrane through complexes I, III and IV and create an 
electrochemical gradient across the membrane. This gradient allows protons to 
flow back into the mitochondrial matrix via a proton channel in complex V (ATP 
synthase) and enables ATP to be synthesized from ADP and Pi (Figure 1-3). 
The process is known as oxidative phosphorylation and is capable of making 
100’s of molecules of ATP a second.
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Figure 1-3: A schematic representation of the 5 respiratory complexes of the eletron transport chain embedded in the mitochondrial inner 
membrane. 
Electrons flow from NADH or succinate to complex I or II and then onto a ubiquinone pool. Electrons then flow from ubiquinnone through 
complexes III and IV.Simultaneously protons are moved across the membrane. The resulting proton gradient is used by complex V to generate 
ATP.Taken from (Mandavilli et al., 2002) 
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In summary, mitochondria play a key role in cellular function and longevity and 
are the primary site of ATP production from the breakdown of foodstuffs. The 
structure and position of mitochondria in the cell is very specific to the role of 
the cell. The consequences of impairments in mitochondrial function resulting in 
mitochondrial disease are discussed in the following section. 
1.3. Mitochondrial Disease 
Mitochondrial disease refers to a group of conditions where the mitochondria do 
not effectively break down metabolites to allow regeneration of ATP. As a result 
of the impaired ATP regeneration, mitochondrial disease normally presents in 
tissues requiring large amounts of energy, such as skeletal muscle, the heart 
and brain. 
To understand how mutations in mtDNA result in disease a brief description of 
the mitochondrial genome is provided below. 
1.3.1 Mitochondrial Genome  
The mtDNA molecule is much smaller than nucleic DNA with only 37 genes 
(Figure 1-4), which encode 13 polypeptides. All these polypeptides are units 
within the electron transfer chain and are found within the complexes I, III, IV, V 
of the electron transfer chain (Figure 1-3). The remaining protein subunits within 
the electron transfer chain are nuclear encoded with complex II being 
completely coded by nuclear genes. Mitochondrial diseases can be caused by 
mutations within both the mitochondrial or nuclear genome but this thesis will 
limit itself to the description of mutations of mitochondrial DNA. 
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Unlike nuclear DNA, mtDNA is strictly maternally inherited. It is thought that the 
higher mutation rates seen within the mitochondrial genome are due to 
oxidative damage caused by the genomes proximity to the respiratory chain in 
the inner mitochondrial membrane (Mandavilli et al., 2002). Within each cell the 
mtDNA is arranged in stable protein complexes termed nucleoids, which are 
exchanged between mitochondria during mitochondrial division. Division of 
mitochondria is independent of the cell cycle and is driven by the energy 
demand of the cell and the need to produce ATP (Bogenhagen and Clayton, 
1977). Although the exact mechanism of mitochondrial division is still a matter 
for debate, the process by which mitochondria divide is thought to affect the 
transmission and progression of mitochondrial diseases (Chan, 2006a; Chen 
and Chan, 2010; Picard et al., 2011). 
Each mitochondrion contains multiple copies of mtDNA. When the copies of 
mtDNA within a cell are identical it is known as a homoplasmy. The presence of 
more than one type of mtDNA within a cell is known as heteroplasmy. 
Heteroplasmy can occur when a mutation has occurred within the mtDNA, 
which is then replicated as mitochondria divide to produce a mixture of wild and 
mutant DNA within a cell (Larsson and Clayton, 1995). The percentage of 
mutant mtDNA can vary from cell to cell and tissue to tissue. The division of 
mitochondria and the ratio of wild to mutant mitochondria are important in 
understanding the transmission, manifestation and progression of mitochondrial 
diseases.  
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Figure 1-4: A schematic diagram of the mitochondrial genome  
The circular, double stranded human mitochondrial genome is shown with common 
mutations and associated clinical presentations highlighted. (CPEO-chronic 
progressive external opthalmoplegia, LHON-Leber hereditary optic neuropathy, LS-
Leigh syndrome, MELAS–mitochondrial myopathy, encephalopathy, lactic acidosis 
and stroke like episodes, MERRF-myoclonic epilepsy and ragged red fibres, MILS-
maternally inherited Leigh syndrome, NARP-neurogenic weakness, ataxia and 
retinitis pigmentosa, PS-Pearsons syndrome). (Tuppen et al., 2010). 
 
 
1.3.2 Mitochondrial Disease 
The first pathogenic mutation in mtDNA was identified in 1988 (Holt et al., 1988), 
since then over 250 others have been reported. Mitochondrial diseases are due 
to a wide variety of mutations and present with different phenotypes, and with 
different ages of onset (MITOMAP, 2009). The reported prevalence of these 
diseases has changed as the diagnosis of mitochondrial disease has improved 
and was recently estimated to be around 1 in 10,000 in the North East of 
England with a potential of a further 1 in 6,000 at risk (Schaefer et al., 2008; 
Gorman et al., 2015) and pathogenic mutations being reported in greater than 
1/200 live births (Elliott et al., 2008). The manifestation of disease may be 
dictated by number of factors. The threshold effect will be discussed below as it 
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relates to concerns voiced in previous exercise trials in patients with 
mitochondrial disease. 
 Threshold effect  
Within cells there is usually a mixture of wild and mutant types of mitochondrial 
DNA. Symptoms of mitochondrial disease only become apparent when the ratio 
of mutant and wild type mitochondria reaches a certain level. Once this 
threshold is reached a biochemical deficit can occur and the cell will cease to 
function correctly. The threshold required to produce clinical features varies 
from tissue to tissue but is typically 60-90%, although may be lower in tissues 
with high-energy requirements (Figure 1-5). It should be noted however, that 
this theory does not explain the whole presentation as an exact correlation 
between clinical severity of symptoms and proportion of mutant mtDNA is not 
always apparent (Wong, 2007).  
Figure 1-5: A diagram of mtDNA heteroplasmy and the threshold effect.  
Graph (a) shows the effect of increasing mtDNA mutation load on mitochondrial 
function (wild type mitochondria are shown as green circles, mutated mitochondria 
as red circles). When the level of mutated mtDNA reaches a critical threshold (70% 
in this example) biochemical activity is severely reduced leading to mitochondria 
dysfunction. This is illustrated in the transversely-orientated section of skeletal 
muscle (b) which has been reacted for cytochrome c oxidase cytochemical activity 
(McFarland and Turnbull, 2009). 
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The progress of a mutation to reach a threshold is thought to be affected by 
mitochondrial replication and a number of potential theories have been 
proposed but are beyond the remit of this thesis.  
So far this section has described the mitochondrial genome and how mutations 
within mtDNA can replicate and result in increasing levels of mutated mtDNA. 
This results in reduced cell function and progresses to disease manifestation. 
As well as levels of mutation, the variety of symptoms reported in mitochondrial 
disease can also be dictated by the position and type of mutation. 
1.3.3 Mitochondrial Mutations  
Mutations of mtDNA can occur in a variety of forms and locations as shown in 
Figure 1-4. There are two types of mitochondrial DNA mutation: 1) Point 
mutations are usually maternally inherited and mostly heteroplasmic and 2) 
rearrangements, which can be single or multiple. Single deletions usually occur 
sporadically and early in development and due to their size can span several 
genes. Multiple deletions vary in length, with the number and tissue distribution 
of the mtDNA with deletions being important rather than the size and location of 
the deletion (Zeviani et al., 1988; Moraes et al., 1995). Hence the manifestation 
of mitochondrial disease is highly unpredictable and dependent on a number of 
factors. These include the mutation position and type, mitochondrial segregation 
and replication, as well as the type of tissue the mutation occurs within and the 
energy requirement of that tissue.  
1.3.4 Clinical presentations of pathogenic mitochondrial mutations 
As mitochondria are present in all nucleated cells, mutations within the 
mitochondrial genome can produce a great variety of symptoms affecting a 
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number of the body’s systems, which are shown in Figure 1-6. Some of these 
symptoms have been classified into different clinical syndromes and 
phenotypes. A number of these syndromes have very specific features and are 
easy to diagnose whereas others are non-specific and may have multiple 
differential diagnoses.  
Figure 1-6: Clinical features of mitochondrial disease, by organ system. 
 (Pfeffer and Chinnery, 2013). 
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1.3.5 Diagnosis of mitochondrial disease 
The variety of presentations of mitochondrial disease makes diagnosis difficult. 
Therefore diagnosis is a multidisciplinary approach and requires clinical 
assessment alongside histochemical and biochemical testing using diagnostic 
algorithms (McFarland and Turnbull, 2009).  
Although some mitochondrial disorders can be diagnosed by molecular genetic 
screening of blood DNA, due to the tissue specific presentation of mitochondrial 
disease, the investigation of muscle biopsy tissue is often required to provide a 
correct and accurate diagnosis for the majority of patients (McFarland et al., 
2002) and remains the gold standard for detection of mitochondrial disease 
(Figure 1-7) (McFarland and Turnbull, 2009). The presence of ragged red fibres 
is a unique muscle biopsy finding in mitochondrial disease (Figure 1-7b). The 
application of various enzyme reactions enables identification of fibres with 
impaired mitochondrial function. Application of the succinate dehydrogenase 
(SDH) assay identifies disorders within complex II of the mitochondrial 
respiratory chain and is unaffected by abnormalities of the mtDNA (Figure 1-7c). 
This staining is used alongside cytochrome c oxidase (COX) staining which 
produces a brown fibre. The variety of COX activity between the different fibres 
is apparent in mitochondrial disorders and gives the typical mosaic pattern of 
COX activity that is indicative of a heteroplasmic mtDNA mutation (Figure 1-7d). 
The extremely pale fibres seen in COX histochemistry are easily observed 
when SDH staining is applied and are stained vivid blue when the fibre is COX 
deficient but retains SDH activity (Figure 1-7e). These muscle biopsy findings 
can also be useful in providing information concerning muscle function; 
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therefore muscle biopsies have been used in clinical trials concerning exercise 
capacity as well as for diagnosis (Murphy et al., 2012). 
Figure 1-7: Histochemical changes seen in a muscle biopsy section linked with 
Mitochondrial Disease.  
Two muscle fibres are highlighted with an asterisk and are shown in a series of 
transverse muscle sections; a) general muscle morphology; b) classical ragged red 
muscle fibres; c) SDH staining; d) COX histochemistry showing COX-deficient fibres 
within a population of normal fibres and a typical “mosaic” picture; e) SDH/COX 
histochemistry (Tuppen et al., 2010) 
 
In summary mitochondrial diseases remain difficult to diagnose due to the 
variety and the differing severity of symptoms. To attempt to reduce the 
variability of presentations seen in the studies in this thesis, the studies only 
included two genotypes: m.3243A>G and m.8344A>G. The following section 
will discuss these two genotypes in more detail.  
1.3.6 Disease manifestation of the m.3243A>G and m.8344A>G mutations 
The two genotypes (m.3243A>G and m.8344A>G) included in this thesis can 
result in a great variety of symptoms varying in severity (Figure 1-8). A common 
clinical feature to both genotypes is myopathy, present in over 50% of both 
genotypes (Chinnery et al., 1997).  
The m.3243A>G mutation is the most common mitochondrial point mutation, 
identified in 1990 in association with Mitochondrial Myopathy, Encephalopathy, 
Lactic Acidosis and Stroke-like Episodes (MELAS) (Goto et al., 1990; Wallace, 
1992) and is reported to occur in 80% of MELAS cases (Hammans et al., 1995). 
People with MELAS typically present with stroke-like episodes that do not 
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usually follow a recognised vascular distribution and are not the result of 
ischaemic lesions. Seizures are also a common symptom, although other 
symptoms such as migraine like headaches, encephalopathy, ataxia, and 
cognitive impairment are often present. The m.3243A>G mutation makes up 23% 
of the Mitochondrial Diseases Patient Cohort Study; which is the largest cohort 
of living patients with confirmed mitochondrial disease, although only 10 % of 
patients exhibited the classical MELAS phenotype (Nesbitt et al., 2013). Other 
phenotypes exhibited in the Newcastle cohort include maternally inherited 
deafness and diabetes (MIDD), progressive ophthalmoplegia (PEO), Leigh 
syndrome and isolated myopathy with another 28% of carriers not exhibiting 
symptoms consistent with any reported syndromes. Also some carriers of the 
m.3243A>G mutation do not present with clinically severe disease (Manwaring 
et al., 2007) whilst others demonstrate features consistent with the Myoclonic 
epilepsy with ragged red fibres (MERRF) phenotype which is typically caused 
by the m.8344A>G mutation (Hammans et al., 1993; Hammans et al., 1995).  
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Figure 1-8: Percentage frequency of clinical features associated with the 3243A>G 
and 8344A>G mitochondrial mutations.  
(Str-recurrent stroke like episodes; CPEO-chronic progressive external 
opthalmoplegia; Db-Diabetes; RP-pigmentary retinopathy; Df-Deafness; Dem-
dementia; Ep-Epilepsy; Myop-myopathy; ShSt-Short stature; Lip-Lipomata; OA-
Optic Atrophy; Neuro-neuropathy; Atax-ataxia; Myoc-myoclonnus. *p<0.05, ns-not 
statistically significant (Chinnery et al., 1997). 
 
Myoclonic epilepsy with ragged red fibres (MERRF) was originally described as 
progressive myoclonic epilepsy, ataxia and myopathy (Silvestri G et al., 1993) 
and is usually due to the m.8344A>G mutation (Hammans et al., 1993). MERRF 
and the m.8344A>G mutation are rare, representing 4% of all pathogenic 
mtDNA mutations (Remes et al., 2003; Schaefer et al., 2008). This condition 
often results in neuro-degeneration, which presents in late childhood or early 
adulthood following a normal childhood development. The presenting symptom 
is usually one of myoclonus, which then progresses to include proximal 
myopathy, epilepsy, cerebellar ataxia, optic atrophy and deafness. Non-
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neurological manifestations include cardiac symptoms such as Wolff-
Parkinsons-White syndrome and multiple lipomas. 
Clinical features in both genotypes are highly variable in terms of age of onset, 
severity of symptoms and organs involved (Graf et al., 1993). Although clear 
differences in frequency of clinical symptoms are usually reported between the 
two genotypes, deafness, dementia, short stature and myopathy are common to 
both mutations. The variability of clinical presentations is partially dependant on 
heteroplasmy levels, with clear relationships evident between clinical features 
for both m.3243A>G and m.8344A>G genotypes and the level of mutation 
within muscle tissue (Chinnery et al., 1997).  
1.3.7 Treatment of Mitochondrial Disease 
Although research into the mitochondrial genome and discovery of pathogenic 
mutations continues at a pace, treatment of mitochondrial disease remains 
essentially supportive in nature (Chinnery et al., 2006; Pfeffer et al., 2012). 
Management of mitochondrial conditions currently involves regular monitoring of 
symptoms by an extensive multi-disciplinary team. Despite no cure being 
available for mitochondrial disease, management of symptoms can improve 
quality of life and reduce morbidity (Rahman and Hanna, 2009). Numerous 
treatments are currently being used in mitochondrial disease and have been 
discussed in detail in recent reviews (Horvath et al., 2008; Pfeffer et al., 2012; 
Pfeffer and Chinnery, 2013). Full descriptions of all current treatments are 
beyond the scope of this thesis; the treatment chosen for this thesis is aerobic 
exercise and will be discussed in the following sections. 
21 
 
1.4. The effects of exercise on the body  
Exercise is known to improve exercise capacity, muscle strength and the 
performance of activities in daily life alongside providing some protection from 
chronic diseases (Stump et al., 2006; Wolfe, 2006; Ruiz et al., 2008). Exercise 
capacity has also been shown to be a prognostic indicator for cardio-vascular 
disease and more recently linked with all-cause mortality (Haskell et al., 2007; 
Kodama et al., 2009; Lee et al., 2012). 
This section will review the physiological and metabolic adaptations of acute 
and chronic exercise in healthy individuals. These changes will then be 
discussed in relation to the effects of exercise in people with mitochondrial 
disease. Exercise or physical activities take on many forms; aerobic exercise is 
the activity undertaken in this thesis and therefore discussion will concentrate 
on this type of activity. 
Exercise has a dose response relationship, with responses dependent on the 
type, duration, length and number of repetitions performed during exercise 
(Wenger and Bell, 1986). Aerobic exercise is low in intensity, performed over a 
long duration and depends primarily on the aerobic energy system; examples of 
aerobic exercise are activities such as walking, jogging and cycling (Powell et 
al., 2011). 
To aid the description of the body’s response to aerobic exercise the effects of 
exercise on three different body systems are described separately: 
Cardiovascular, respiratory and muscular systems.  
When moving from rest to exertion the energy requirements of exercising 
muscles are increased. ATP stores within the muscle are depleted within 
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seconds and therefore are required to be re-synthesized to provide continuous 
energy to the cell (ACSM, 2006; Mcardle et al., 2007). The increased energy 
requirement is met by an increase in the metabolic rate of the cell. The 
increased metabolic rate requires the increased delivery of oxygen and 
nutrients and the removal of waste by-products. To maintain cells equilibrium 
during exercise adaptation by the respiratory and cardiovascular systems is 
required. To ensure adequate O2 to the tissues changes occur in heart rate, 
stroke volume, cardiac output, blood flow, blood pressure, arteriovenous oxygen 
difference and pulmonary ventilation (ACSM, 2006; Mcardle et al., 2007). 
1.4.1 Cardiovascular response to acute exercise 
Cardiovascular changes in response to exercise are reflected in an increase in 
heart rate with work rate (WR) and O2 uptake. The maximum heart rate 
achievable is dependent on age, body position, fitness, disease and medication 
(ACSM, 2006). Neural control centres receive impulses from the motor cortex 
as it recruits the muscles required for the physical activity. This feed-forward 
mechanism coordinates a rapid increase of heart rate and altered blood vessel 
flow around the body to optimise tissue perfusion and maintain central blood 
pressure (Innes et al., 1992; Nóbrega et al., 1994; Stewart et al., 1998; Stockton 
et al., 2011). This therefore allows the heart to transition from beating at 75-80 
beats min-1 during ambulation to exceed 200 beats min-1 during maximal 
exercise (Bjørnstad et al., 1994). Alongside increased heart rate the stroke 
volume increases with work rate; at rest stroke volume is 60-100ml.beat -1 but 
during exercise it can raise to 100-120ml.beat -1. Cardiac Output is a product of 
heart rate and stroke volume. In healthy adults this also increases linearly with 
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work rate (WR). At rest it is 5L.min-1 and can increase to a maximum of around 
20L.min-1. 
Control of blood pressure (BP) is achieved by adjusting peripheral resistance. 
This can be achieved by various mechanisms; neural control directly on the 
arterioles, locally released substances called endothelial-derived relaxing 
factors (nitric oxide) and local changes in chemical concentrations within active 
skeletal muscle. During exercise systolic blood pressure (SBP) increases 
linearly with an 8-12 mm.Hg increase per metabolic equivalent (MET) of activity. 
As BP directly relates to Cardiac Output (CO) and peripheral resistance 
measurement of BP provides a non-invasive method of monitoring the pumping 
of the heart during exercise and is used during exercise testing. 
Arteriovenous Oxygen difference (a-vO2 diff) is the difference in O2 content of 
arterial and venous blood and therefore shows the level of extraction of oxygen 
by the tissues. This can go from 5ml.dl-1 to 15ml.dl-1during the transition from 
rest to maximum exercise (ACSM, 2006). This increase can be due to a number 
of factors such as an increase in the number of capillaries used surrounding 
each muscle fibre and enhanced activity of enzymes within the mitochondria. 
In summary a variety of cardiovascular changes occur in response to an acute 
bout of aerobic exercise; these can be both centrally and locally mediated 
(Ferretti, 2014). The integration of these responses allows tissues to receive the 
nutrients required during periods of increased energy demand, such as during 
exercise. The magnitude of response is governed by the type and duration of 
the exercise undertaken and the measurement of these responses can give an 
insight into the exercise capacity of the individual. If exercise is repeated, long-
term changes of the cardiovascular system occur and are described below. 
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Stroke Volume (SV) is increased with chronic exercise due to cardiac 
hypertrophy resulting in more forceful contractions. The increased SV allows the 
person to exercise at the same work rate but with a reduced HR and a reduced 
myocardial demand (C G Blomqvist and Bengt, 1983). Improvement in a-vO2 
difference occurs due to increased capillary density and improved mitochondrial 
activity (Holloszy and Coyle, 1984; Flück, 2006; Daussin et al., 2008). This 
adaptation may be relevant in mitochondrial disorders and will be discussed in 
greater depth in the section explaining the changes that occur in muscle as a 
result of exercise. 
1.4.2 Response of ventilation system to exercise 
In addition to cardiac adaptation to exercise, our breathing rate is adjusted by a 
number of mechanisms to meet the metabolic requirements of cells. A response 
occurs when neural circuits relay information from higher centres within the 
brain, lungs and throughout the body to coordinate a response in ventilation. 
Ventilation increases exponentially to reach a steady state dependant on the 
exercise intensity and once a steady state has been reached, fine-tuning of 
ventilation occurs dependant on peripheral sensory feedback mechanisms. 
These responses result in the following changes in ventilation: Minute 
Ventilation (VE) is increased by 15-25 fold during maximum exercise from 
approximately 6L.min-1 at rest. This increase in VE is directly proportional to the 
increase in the consumption of O2 (vO2) and level of CO2 produced (vCO2). At a 
critical intensity VE increases disproportionately relative to vO2. This coincides 
with increase in lactate and vCO2 (Davis et al., 1976). The disproportionate 
increase is due to the need to remove CO2 and is the result of increased 
buffering of lactate that has accumulated due to anaerobic glycolysis. The 
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increased CO2 exhaled causes the respiratory exchange ratio (RER=vCO2/vO2) 
to exceed 1.00. The rise in VE and rise of RER above 1 is thought to indicate 
that demands for energy have exceeded that which can be provided by 
mitochondrial respiration alone and has resulted in additional energy provision 
by anaerobic means. It should however be noted that confirmation of a link 
between these ventilatory changes and glycolytic events has proved difficult 
(Davis et al., 1976; Svedahl and MacIntosh, 2003).  
This threshold in practice is known as anaerobic, ventilatory or lactic threshold 
and has been used to provide a measure of fatigue resistance (Morris et al., 
2008). Exercise training has the potential to reduce blood lactate concentrations 
during sub-maximal exercise as a result of raising the workload intensity at 
which the threshold occurs, thus showing an improved exercise performance. 
Instead of an invasive method of measuring lactate, it is common to use the 
surrogate measure of ventilatory threshold, which can be inferred from the point 
at which vCO2 exhaled increases in relation to vO2 inhaled. This threshold 
occurs at 60-80% of vO2MAX but with training can increase by 10-25% (ACSM, 
2006). Changes in ventilation easily can be measured and give an indication of 
changes in physical performance and are used in this thesis as measurements 
of exercise performance. 
As ventilation appears to be increased due to the need to remove excess CO2 
rather than the need for O2, it is not thought that O2 delivery limits reaching peak 
exercise capacity in the healthy population (ACSM, 2006). As the pulmonary 
system has a fast acting response to exercise and does not limit maximum 
exercise capacity its requirement to adapt to continued training is less 
pronounced than the cardiovascular system. 
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1.4.3 Peripheral response to exercise  
Peripheral adaptations in muscle tissue occur alongside the central adaptations 
described above. Skeletal muscle is very malleable and has the ability to alter 
its structure according to the demands put upon it. This plasticity can be seen in 
the changes in muscle force, endurance and contractile velocity (Graham et al., 
2008). The plasticity of muscle is specific to the stimulus and is demonstrated 
by high repetition, low load training resulting in a differentiation of muscle fibres 
toward a fatigue resistant phenotype, whereas conversely training with high 
loads results in fibre hypertrophy (Pette and Staron, 2001). 
Prior to the 1960’s it was thought that central adaptations to exercise were 
solely responsible for the increased capacity to provide O2 to exercising muscle. 
Holloszy was the first to show that changes in mitochondrial content within the 
skeletal muscles of rats occurred with endurance exercise training (Holloszy, 
1967). Changes in mitochondrial content occur by a complicated pathway 
involving gene transcription and protein synthesis in response to acute and 
repeated exercise. Chronic endurance training results in high mitochondrial 
volume (Hood et al., 2006; Fritz and Lusardi, 2009), increased capillary density 
(Saltin and Gollnick, 1983) and a shift of character of the muscle fibre toward 
slow fibre type (Flück, 2006). Together these changes enable maximum levels 
of substrates to be delivered and efficiently used by the cell. 
Increased mitochondrial content in a cell is a result of increased mitochondrial 
biogenesis. Mitochondrial biogenesis occurs when signalling reactions activate 
proteins to increase gene transcription, these signals are dependent on the 
intensity and duration of contractile activity and fibre type (Favier et al., 2008). 
As a result protein synthesis is accelerated, and proteins are imported into the 
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mitochondria from the cytosol. Once in the mitochondria the proteins act as 
either metabolic enzymes forming part of the electron transfer chain complexes, 
or become transcription factors for mtDNA. Therefore, mitochondrial biogenesis 
results in an expansion of the mitochondrial network leading to an increase in 
the capacity for the cell to produce energy.  
Chronic exercise leads to an increased mitochondrial content within muscle, 
which in turn results in improved muscular endurance and reduced fatigability in 
muscle during normal activities. However the converse is also true, 
maintenance of muscle mass and oxidative capacity of a muscle is reliant on 
contractile stimuli. Without stimulation, muscle function deteriorates and results 
in reductions in mitochondrial content and respiratory chain enzyme activity 
(Taivassalo and Haller, 2004). This de-conditioning of muscle can be seen 
during periods of inactivity, such as bed rest or sedentary behaviour. As 
sedentary behaviour is common within people with mitochondrial disease the 
effects of deconditioning may also have a part to play in determining the 
exercise capacity in the mitochondrial disease population and is discussed in 
the section describing exercise in mitochondrial disease. 
In conclusion, adaptations of the body to exercise take place both centrally and 
peripherally and are likely to improve some of the symptoms of mitochondrial 
disease. Adaptations are dependent on the type, intensity and duration of 
exercise.  
1.5. Exercise and mitochondrial disease 
Various types of exercise have shown promise in mitochondrial disease 
although it remains debatable whether benefits are due to changes in the 
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primary biochemical defect or the reversal of low levels of activity (Taivassalo 
and Haller, 2004; Taivassalo et al., 2006; Tarnopolsky, 2014). The following 
section will discuss the results of previous exercise studies in neuromuscular 
conditions and in particular mitochondrial disease. The results of these studies 
lay the foundation for the intervention included in this thesis.  
1.5.1 Aerobic training  
Aerobic training in a disease free population as previously reported provides 
benefits to the cardiovascular and muscular systems. Large numbers of patients 
(>20%) with a mitochondrial disorder report exercise intolerance as a symptom 
(Mancuso et al., 2012). Exercise intolerance in the mitochondrial population 
may be a result of a primary biochemical defect but is likely exacerbated by a 
sedentary lifestyle (Taivassalo and Haller, 2004). Activity levels have been 
shown to be decreased in people with a variety of Neuromuscular Diseases 
(Tudor-Locke et al., 2009) and the same is true in mitochondrial disease, where 
it was recently demonstrated that 78% of participants performed less than the 
recommended 10, 000 daily steps (Apabhai et al., 2011). The causes of a 
sedentary lifestyle in patients with mitochondrial disease are likely to be 
multifactorial and may include: excessive fatigue at low levels of activity; 
avoidance of activities that exacerbate symptoms of muscle weakness along 
with pain and historical advice to conserve energy (Tarnopolsky, 2014).  
Due to the rarity of the majority of neuromuscular conditions, initial research on 
the effects of exercise tended to group all neuromuscular conditions together 
(Wright et al., 1996; Taivassalo et al., 1999a; Kilmer, 2002b; Kilmer, 2002a). 
The results of these studies were often flawed due to the varied responses to 
exercise of different conditions, with some conditions responding negatively to 
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exercise (Kilmer DD, 2002). As the responses of neuromuscular conditions to 
exercise were diverse and dependent on the type of exercise undertaken and 
the condition being investigated, subsequent research studies were performed 
on individual neuromuscular diseases. 
One of the first exercise studies involving patients with mitochondrial disease 
included a patient with a cytochrome c oxidase deficiency. This patient after 8 
weeks of aerobic training (supervised cycling 3-4 times a week, at 60-80% of 
Heart rate reserve) demonstrated an improvement in exercise capacity (70% 
from baseline) despite a basic metabolic defect. It was therefore surmised that 
aerobic training was able reduce the effects of chronic deconditioning, partially 
improve exercise capacity and therefore had the potential to improve the 
patient’s condition (Taivassalo et al., 1996). However this was only in one 
patient so further research was required. 
The same research group progressed to investigate10 patients with a variety of 
mitochondrial disorders due to both mitochondrial and nuclear DNA mutations. 
This study included directly supervised treadmill training (with the participant 
attending the facility to exercise initially) 3-4 times per week at 60-80% of heart 
rate reserve (HHR = maximal heart rate–resting heart rate, maximal heart 
rate=220-age) for 20 -30 minutes .It was noted that not all patients were able to 
increase to or maintain heart rate within the ranges set without muscle pain and 
therefore some participants performed interval type training with rests until 20 
minutes of training had been completed. Exercise was then progressed at rates 
tailored to the individual, with exercise being extended towards a 30 minute 
continuous exercise session. Exercise intensity was then increased with either 
an increased treadmill speed or elevation to maintain exercise in the set heart 
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rate range. Alongside measures of exercise capacity, this study measured ADP 
recovery time using Magnetic Resonance Spectroscopy and quality of life using 
the SF36 quality of life questionnaire. This program of exercise led to 
participants performing very different levels of absolute training and may in part 
explain the very varied responses to the exercise intervention. No adverse 
responses were detected and improvements were seen in both central and 
peripheral adaptation, with a reduction in heart rate at rest, during sub-maximal 
(15%) and peak exercise (10%), improvement in ADP recovery, reduced lactate 
levels at rest and post exercise testing and no increase in Creatine Kinase (a 
marker of muscle damage). From this study it was hypothesised that peripheral 
limitations in mitochondrial patients were improved by training due to the large 
response reported in the ADP recovery time post exercise (Taivassalo et al., 
1998 ). These results were reported as different to the responses previously 
seen in healthy populations, where increased capacity to exercise was 
explained by an increase in cardiac output with peripheral adaptation being 
smaller. 
Despite the improvements in exercise capacity and oxygen utilisation inferring 
an improvement in mitochondrial function, concern remained over potential 
preferential proliferation of mutant mitochondrial DNA alongside wild type and 
the long-term effects of such proliferation (Taivassalo et al., 1998 ). To address 
these concerns further trials were necessary to identify the mechanisms for the 
improved exercise capacity reported in these studies, hence the previous study 
was repeated with the addition of analysis of muscle biopsies pre and post 
intervention (Taivassalo et al., 2001). In this study again 10 patients with 
heterogeneous clinical, biochemical and molecular presentations of 
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mitochondrial disease were recruited. Exercise in this study was performed on a 
stationary bike with heart rate and duration of exercise monitored using a 
POLAR watch. Intensity was at 70-80% of maximum heart rate (220-age ), 
duration was 30 minutes for the first 7 weeks (3-4 times/ week), then 40 minutes 
for the remaining 7 weeks (3-4 times per week), equating to 50 sessions. Peak 
exercise testing was performed twice and either the performance averaged or 
the better performance was presented, alongside the results of submaximal 
testing. Exercise testing post exercise again showed a significant increase in 
work capacity (30%) along with an increased capacity to extract oxygen (20%) 
and a normalisation of the hyperkinetic (exaggerated heart rate) response to 
exercise previously reported with a reduction in the ratio between cardiac output 
and oxygen uptake (Haller et al., 1989; Tarnopolsky, 2004), with Magnetic 
Resonance Spectroscopy reporting an increased oxidative capacity in muscle. 
In addition muscle biopsy results demonstrated an increase in citrate synthase 
(CS) (49%), Succinate Dehydrogenase (SDH) (43%) and Cytochrome complex 
(COX) activity alongside mitochondrial proliferation, although the percentage of 
mutant mtDNA was variable. The basis for the improvement in work rate was 
shown to be enhanced skeletal muscle oxidation with increased oxygen uptake 
and increased respiratory chain enzyme activity. Unfortunately the increase in 
mitochondrial volume reported was greater than the increase in enzyme activity; 
therefore this disproportionate increase was thought to be due to a greater 
proliferation of mutant DNA. It was also noted that the variable response to 
exercise was dependant on the type of mutation, with a negative response seen 
in patients with mutations affecting complex III. A summary of these results is 
shown in Figure 1-9. The response to exercise was again varied which in part 
may be due variety of clinical presentations and genotypes reported in the study. 
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No record of variations in exercise delivery were reported and exercise was 
tailored to maximal heart (220–age) not performance at baseline, which will 
have delivered similar levels absolute exercise by all participants. Despite 
performing similar levels of absolute exercise versus relative reductions in the 
variability of responses of individuals was not seen.  
Figure 1-9: Changes in physiological, biochemical and molecular genetic variables 
in 10 patients with mtDNA defects following 14 weeks of endurance exercise 
training  
(Taivassalo and Haller, 2004). 
 
The increase in mitochondrial volume thought to be due to preferential 
proliferation of mutant mtDNA continued to raise concerns over the long term 
effects of exercise, as disease progression was thought to be linked to the 
accumulation of mutant mtDNA leading to increases in the number of 
respiratory incompetent fibres (Chinnery et al., 2003). Further work therefore 
was required to examine the effects of long-term exercise and whether 
proliferation of the mutant DNA varied in specific areas along a single muscle 
fibre or between fibres. 
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Whilst studies continued to evaluate the effect of exercise in mitochondrial 
disease, Taviassalo et al (2003) also reported great variation in exercise 
capacity in mitochondrial patients. The exercise capacity of 40 patients with a 
variety of mitochondrial disorders was compared to healthy volunteers. Of the 
40 patients 23% had a level of mutation load reported. This work confirmed that 
the peak work capacities of patients with mitochondrial disease were 
significantly lower than that reported in healthy controls. Although a third were 
equivalent to healthy sedentary controls and one was comparable to a healthy 
control. The range of exercise performance was very broad, with two thirds of 
the participants unable to perform activity above 5 METS, where a MET 
(metabolic equivalent) is the physiological measure indicating the energy cost of 
the physical activity in relation to 1 MET= 3.5 ml.O2.kg.min. This level of 
impairment is important to note as performance below this level would lead to 
impairment in daily activities such as moderate speed walking (3 METS) and 
climbing of stairs (3-6 METS). This study also confirmed relationships between 
exercise capacity and varying levels of oxidative impairment and that exercise 
capacity was directly proportional to the ability to extract and utilise oxygen (a-
vO2 difference) not cardiac output (Taivassalo et al., 2003). As the level of 
variability in exercise capacity reported in this study was broad, the study 
recommended that future work in this area should attempt to reduce the 
heterogeneity of participant groups by limiting the genotypes involved in future 
studies. 
A common criticism and limitation of the exercise studies reported thus far is the 
lack of blinding or randomisation performed. This has meant that only one 
exercise study has been included in the Cochrane review of treatments in 
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mitochondrial disease (Pfeffer et al., 2012). The blinding of participants in 
exercise studies is difficult, if not impossible in such a sedentary population, 
where even the performance of a “sham” exercise intervention is likely to have a 
response (Lee et al., 2008). Although not blinded, one exercise trial did 
randomise participants to an exercise intervention (Cejudo et al., 2005). This 
trial confirmed the beneficial effect of aerobic training reported in previous 
studies alongside an improvement in an exercise field test; the shuttle walking 
test (Singh et al., 1992). Changes reported were similar to previous studies; 
vO2MAX increased by 28 %, peak workload by 16%, although no information was 
provided concerning termination of exercise test (e.g. maximum heart rate, RPE 
or symptom limited). The increase in peak heart rate on retesting could imply 
that participants may have worked harder on retesting. This is unlikely as 
improvement was also seen in the anaerobic threshold (improved by 22%). As 
in previous studies, this study included patients (n = 20) with a variety of 
mitochondrial mutations, with participants performing a cycling exercise (70% of 
baseline work rate, 12 weeks, 3 sessions / week) along with some upper limb 
activities, therefore sessions lasted longer than previous studies (1 hour) and 
also were directly supervised. Unfortunately the study did not have the capacity 
to investigate mutation loads and the histological and biochemical changes in 
response to exercise, so was unable to further inform the mechanisms of 
improved exercise capacity and allay fears of preferential proliferation in 
mutated mtDNA. Another study by Trenell et al also used a field test for 
exercise capacity to investigate the effects of aerobic exercise in mitochondrial 
disease. This study included 10 patients with mixture of presentations and 10 
disease free participants matched for age, gender and physical activity. 
Exercise was again cycling; at 70-80% age predicted maximal heart rate for 30 
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minutes. However it did report that exercise was tailored to the individual and 
supervised with participants completing 95% of sessions. Alongside exercise 
testing and phosphorus magnetic resonance spectroscopy this study used the 
6-minute walk distance (6MWD). This study demonstrated an improvement in 
muscle mass, cross-sectional muscle area, along with improved rates of 
oxidation and phosphocreatine (PCr) recovery. The improvements reported 
from the imaging data were replicated in the distance walked over 6 minutes, 
oxygen extraction and peak work rate during a maximal exercise test (Trenell et 
al., 2006). Although this study was able to show the potential of novel non-
invasive methods in monitoring changes in mitochondrial function it was unable 
to shed further light on the proliferation of mutant mitochondrial DNA.  
To allay fears and allow the recommendation of exercise as a potential therapy 
in mitochondrial disease long-term exercise studies were still required. This was 
achieved in two studies with the effects of long-term exercise being investigated 
in two different populations of patients.  
Jeppeson et al. (2006) compared a group of 20 patients with 4 different 
mutations. These patients included eight relatives of the index case with 
m.3243A>G, 4 of which were unaffected, against 13 sedentary control 
participants (Jeppesen et al., 2006b). This study included patients with low 
levels of mitochondrial mutation to ensure that any changes in mutation load 
would not be impaired by a ceiling effect. Following a 12-week home based 
exercise program monitored by a weekly phone call. The exercise again was 
cycling; 30 minutes, heart rate corresponding to 65-75% of baseline vO2MAX, to 
complete 50 sessions. Thirteen participants stopped exercising and were re-
tested after 8 weeks of deconditioning. Participant’s performance following an 
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exercise intervention replicated the findings of previous studies with an increase 
in maximum exercise capacity (26%) and workload post training (29%), and 
self-reported physical activity, which post deconditioning returned to pre 
exercise levels. The percentage increase in exercise performance reported in 
the participants with mitochondrial disease was higher than in the healthy 
controls and reassuringly the mutation load remained the same. The 
mitochondrial DNA quantity increased in the mitochondrial group, but returned 
to pre training levels post deconditioning, and showed no relationship to pre 
training levels or maximum exercise capacity. Levels of respiratory chain 
enzymes were similar in both healthy and mitochondrial disease groups, 
increased with training and returned to pre training levels post deconditioning, 
however the increase was not related to training response (change in vO2). As 
no changes were reported in mutation load, Creatine Kinase levels, muscle 
regeneration and apotosis, the study provided the necessary reassurance for 
exercise to be considered safe in the management of mitochondrial disease. 
This study was the first study to report the number of participants that were 
unable to complete the study (n=10), eight of these were due to failure to 
complete 50 % of the exercise sessions. 
At the same time another study in a different group of patients also addressed 
the concern of preferential proliferation of the mutant mtDNA. This study 
investigated the hypothesis that habitual inactivity in patients with mitochondrial 
disease led to further reduction of mitochondrial volume and therefore further 
restricted the oxidative capacity in patients (Taivassalo et al., 2006). The study 
chose eight patients with a large-scale deletion of their mtDNA with exercise 
intolerance ranging from mild to severe. All participants completed a 14 week 
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exercise program (home based cycling); Sessions were monitored by heart rate 
(POLAR watch), 30 minutes, 3 times a week for the first 7 weeks and increased 
to 40 minutes for the last 7 weeks at 70 -80% of heart rate maximum. Four 
participants then continued for a prolonged intervention of a further 14 weeks 
whilst the other four discontinued training. At three different time points (week 0, 
14 and 28) exercise testing was recorded along with evaluation of proportion, 
distribution and copy number of mutant and wild type mtDNA in muscle. As in 
other trials, increases were noted in work capacity (26%), oxygen uptake (11%) 
and utilization (11%) after 14 weeks training. Continued training maintained 
these and further improvement was reported in a-vO2 difference. Patients who 
stopped training exhibited the opposite response with exercise parameters 
returning to baseline levels. Histo-chemical analysis showed no change in COX 
negative fibres after 14 or 28 weeks. Biochemical analysis demonstrated only a 
trend toward increased activity in respiratory chain complexes with training due 
to considerable variation and small numbers, which was compatible with 
previous studies and was thought to represent an increase in mitochondrial 
activity. No change was reported in percentage mutation loads in all arms of the 
study, with the use of PCR (Polymerase chain reaction) and Southern blot also 
reporting no change in the amount of deleted mtDNA with training or detraining. 
This study also reported one injury, although this was in the detraining group. 
The findings of these two studies provided reassurance concerning the use of 
exercise as a therapy in the genotypes studied. The reduction in mtDNA copy 
number in COX deficient fibres with detraining supported the theory that COX 
deficiency is associated with the amount of wild type not mutated mitochondria 
38 
 
(Durham et al., 2005; Murphy et al., 2012) and emphasised the detrimental 
effect of reduced levels of activity in mitochondrial disorders. 
As exercise is likely to be a continued intervention throughout the lifetime of a 
patient, further trials have been performed to assess the effects of lengthier 
training protocols. This was attempted in a study of four patients with different 
mutations trained over a period of two years with analysis of muscle biopsies 
and exercise testing (Jeppesen et al., 2009). Training was performed for 3 
months (5 times per week) then stopped for 3-12 months then training restarted 
for 12 months. All training was performed on a stationary bike at an intensity of 
70% of baseline vO2MAX as previous trials by this group and supervised by 
phone. The three patients who completed all the training periods reported 
increased exercise capacity and workload, whilst deconditioning again resulted 
in a return to baseline values. The mutation load was unchanged over the two-
year period along with the number of COX negative, apoptotic or necrotic fibres. 
Citrate synthase increased after the first three months then plateaued whereas 
the capillary density did not increase until after 12 months as compared to 3 
months in the healthy normal population. All these parameters indicated that 
endurance training was safe in patients when performed for up to 12 months. 
Although these results were promising for the long-term use of exercise, the 
numbers were very small, with recruitment impaired by repeated muscle 
biopsies and motivation to continue with training. These problems also have 
also been seen in long-term exercise studies attempted in Newcastle 
(unpublished).  
The above trials repeatedly report improvement in exercise performance 
following an exercise intervention, albeit the reporting is difficult to compare due 
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to the wide range of outcomes used. The variability of response is likely due to 
the small numbers involved and the great variety of clinical presentations and 
mitochondrial mutations included in studies. This said the variability could also 
be due to the type and intensity of training and the method of exercise testing. 
The studies reviewed here set exercise intensity from variables such as: age 
predicted heart rate, percentage of exercise capacity at baseline or % of heart 
rate reserve all of which may result in different levels of exercise intensity being 
performed. Studies also reported different methods of testing exercise capacity 
(maximal, sub-maximal), with and without familiarisation, following different 
protocols with different criteria for ceasing exercise testing. Consensus between 
groups involved in exercise testing of patients with mitochondrial disease may 
result in less variability and allow comparisons to be made between studies 
(Tarnopolsky, 2014).  
The limiting of types of mutations used in exercise studies has been also been 
recommended to reduce the variability of response to interventions. This may 
not be successful due to the variety of presentations even within a genotype 
and therefore limiting the types of phenotypes included or stratifying participants 
by levels of disease severity may be more successful. This would require 
greater adoption of the NMDAS and recording of mutation loads than has been 
done in the studies discussed here. 
In summary, exercise can play an important role in accelerating mitochondrial 
biogenesis and may have the potential to reduce the effects of mitochondrial 
dysfunction seen with age, disuse and muscle disease (Hood, 2009). The use 
of exercise in mitochondrial disease has been shown to be beneficial, improving: 
exercise capacity, muscle strength and quality of life. The adaptations to 
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exercise in mitochondrial patients appear to be peripheral, with improved 
oxygen utilisation due to increased mitochondrial copy number and respiratory 
enzyme activity. Exercise does not appear to affect mutation load as no adverse 
events have been reported and therefore exercise has been deemed safe in the 
majority of patients with a point mutation or single deletion. However the safety 
of exercise as a therapy in all mitochondrial patients has yet to be fully proven. 
Despite this lack of proof increased physical activity is being recommended in 
clinical practice for all patients as reduced activity has been shown to be 
detrimental to mitochondrial function. 
1.6. Dynamometry 
In addition to the peak exercise testing performed in previous exercise studies 
the studies in this thesis measure muscle strength with isokinetic dynamometry. 
A common symptom of mitochondrial disease in the two genotypes investigated 
is proximal myopathy and this is ameliorated with exercise therapy (Cejudo et 
al., 2005; Murphy et al., 2008). Measurement of muscle strength by isokinetic 
dynamometry has been shown to be reliable (Claiborne et al., 2009); 
reproducible (Sapega, 1990) and relate to function. Muscle strength is also 
assessed in the studies by manual muscle testing as part of the Newcastle 
Mitochondrial Disease Assessment Scale (NMDAS). 
All methods of muscle testing have their strengths and weaknesses but 
isokinetic dynamometry provides an optimal loading of muscles through a 
dynamic movement at a selected speed (Baltzopoulos and Brodie, 1989). 
These features allow the safe and accurate measurement of a great variety of 
conditions including the extremely weak patient (Tiffreau et al., 2007). Good 
stabilisation and placement of body parts, consistent instruction and 
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familiarisation with equipment allow isokinetic dynamometers to accurately 
measure torque and have good retest reliability with speeds between 30-60 
degrees per second being effective in revealing muscle deficits (Sapega, 1990). 
Isokinetic dynamometers due to their size and cost will have a limited use in the 
clinical world, but their capacity to measure a wide range of abilities from very 
weak neuromuscular participants to healthy controls (Burnett et al., 1990; Julia 
et al., 2010; Lerario et al., 2012; El Mhandi and Bethoux, 2013) make their use 
within neuromuscular research fundamental.  
Alongside measures of exercise performance relatively few exercise studies 
have measured function and quality of life. The studies in this thesis evaluate 
the use of such measures in mitochondrial diseases alongside established 
measures of exercise capacity. The following section will discuss the current 
use of functional measures in clinical and research settings in populations with 
and without mitochondrial disease, with specific reference to the measures used 
in this thesis. 
1.7. Functional outcome measures in clinical and research settings. 
Functional outcome measures are quick and inexpensive to deliver and are 
commonly used in clinical practise by therapists to either describe status, 
document change, explain performance or to predict outcome (Bohannon, 
1989). As stated earlier, previous studies into mitochondrial disease have 
utilised numerous measures of impairment including: respiratory enzyme 
activity, mitochondrial copy number, exercise capacity and muscle strength. 
Unfortunately a limited number have used recognised measures that record the 
activity or participation of patients (World Health Organization, 2001). A recent 
Cochrane review of interventional studies in mitochondrial disease noted that 
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the numerous primary outcomes used made comparisons between studies 
difficult and that researchers need to include outcomes that matter to patients 
as well as outcomes that are of interest to the researcher (Pfeffer et al., 2012).  
Functional outcome measures became popular in the 1990’s when they were 
introduced to evaluate the effects of therapy. Functional measures can be 
described as disease specific (Loewen and Anderson, 1988; Bérard et al., 2005) 
or they can be non-specific. Non-specific measures include the many timed 
tests used in clinical practice and allow comparisons between different disease 
groups.  
Numerous outcome measures are available for use in clinical practise and 
research, with the choice of measure used dependent upon the population 
being measured, their abilities and the intervention being performed. The choice 
of measure is very important, as a common complaint with these types of 
measures are their “floor and ceiling effects”. These effects mean that often 
more than one measure is required to capture the abilities of the majority of 
patients (Guralnik et al., 2000).  
The outcome measures chosen for this thesis relate to the symptoms often 
present in mitochondrial disease such as proximal myopathy, reduced exercise 
tolerance and fatigue. To measure the effects of these impairments on 
functional tasks the following measures were chosen: Timed up and Go (TUG), 
five times sit to stand (5XSTS), 10-metre timed walk (10MTW) and the 6-minute 
walk distance (6MWD). Of these measures the 6-minute walk distance is the 
only one to have previously been used in this population.  
43 
 
The 10m-timed walk (10MTW) is commonly used in clinical practice and 
measures the time taken to walk, steps taken and cadence over 10 metres. This 
test provides a measure of gait speed and steps taken (Holland et al., 2006). 
Gait speed has been shown to correlate to a number of other measures and 
health outcomes such as; chair rise (Whitney et al., 2005) community walking in 
the elderly (Busse et al., 2006), hospitalisation (Rabadi and Blau, 2005), falls 
(De Rekeneire et al., 2003), dementia (Atkinson et al., 2007; Bohannon and 
Williams Andrews, 2011) and mortality (Ostir et al., 2007; Studenski et al., 
2011). The test is a simple and robust measure and has been regularly used in 
research, in fact it has been described as an almost perfect measure (Wade, 
1992 ). However it does have its limitations, as it only gives a picture of walking 
over 10 meters in one direction in a controlled environment and therefore may 
not reflect the difficulties patients have when walking in a community setting. 
Sit to stand measures have been reported to be potential surrogate measures 
for lower limb strength and therefore may have the potential to measure the 
common symptom of proximal myopathy in mitochondrial disease (Gross et al., 
1998; Inkster et al., 2003). Although dispute exists in the literature over whether 
the measurement of sit to stand does correlates to muscle power alone and 
which muscles are important in the movement of sit to stand. Bohannon et al 
have demonstrated correlations between knee extensors strength and the 
ability to sit to stand (Bohannon, 1998), whilst other researchers feel that other 
muscle groups such as those around the hip to be important (Gross et al., 1998). 
Despite the debate over which muscles are most important in this movement, sit 
to stand remains an important indicator of daily function and therefore is a 
valuable and simple function to measure (Bohannon et al., 2007). 
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The timed up and go (TUG) measure includes the movement from sitting to 
standing, along with walking with a change of direction and therefore may more 
accurately reflect patients day to day activity (Bohannon et al., 2007). This test 
has the added benefit over other measures of sit to stand as it allows use of 
upper limbs, therefore patients with severe proximal myopathy are able to 
perform it. The TUG is well documented as a good predictor of functional 
mobility and risk of falling in the elderly (Podsiadlo D et al., 1991 ) and has more 
recently been used in other diverse populations such as muscular dystrophies 
and cancer (Scholtes et al., 2008; Willis et al., 2011).  
Exercise intolerance and fatigue are common symptoms of mitochondrial 
disease (Mancuso et al., 2012) and can be measured in the clinical setting by 
measuring the distance walked over six minutes. The six minute walk (6MWD) 
is reported to measure the integrated response of all systems involved during 
exercise, but does not enable analysis of which organ or system is impaired 
(2002). The measure was initially used to measure sub maximal exercise 
capacity in patients with heart and lung related diseases. More recently this 
measure has been used in other populations including neuromuscular 
conditions such as Duchene Muscular Dystrophy and Spinal muscular atrophy 
as a surrogate marker of disease severity (Takeuchi et al., 2008; McDonald et 
al., 2010). One previous study within a population of patients with mitochondrial 
disease has used the 6MWD to demonstrate an improvement following an 
exercise intervention (Trenell et al., 2006). The possible relationship between 
exercise capacity and function in this population meant it was an ideal measure 
to include in this thesis. 
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The number of outcome measures available for use in clinical and research 
settings is vast and cover a wide range of activities. The measures chosen for 
this thesis relate to the common manifestations of mitochondrial disease. Some 
of the measures overlap to allow the measurement of patients with a wide 
variety of abilities. The investigation of functional measures is imperative in this 
disease group to enable easy measurement of functional capabilities. 
Measurement of function will provide valuable data concerning disease 
progression and help evaluate the effects of interventions in a way that is 
meaningful to patients. The studies in this thesis will for the first time evaluate 
the use of functional measures in mitochondrial disease. 
1.8. The use of gait analysis in clinical and research settings. 
Functional outcome measures provide quick and simple measures of function 
but do not specifically identify the mechanisms for any change in function. More 
precise analysis of gait can provide improved discrimination concerning the 
cause of walking impairments and better identify possible interventions. The 
inclusion of gait analysis in the studies in this thesis will provide preliminary 
information concerning the walking impairments that are a result of 
mitochondrial disease and therefore provide guidance for future interventions. 
Locomotion is critical to the independent day-to-day functioning of people, with 
walking still being the primary method of moving from place to place. Walking in 
healthy people is generally automatic with integration occurring between motor, 
sensory and cognitive systems (Jahn et al., 2010) with impairments in walking 
resulting in reduced levels of activity and participation in the community (Schmid 
et al., 2007; Fritz and Lusardi, 2009). 
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Gait speed is a key measure in clinical and rehabilitative settings and has been 
shown to relate to functional ability (Studenski et al., 2003), community 
ambulation (Busse et al., 2006), independence and falls in both elderly and 
neurological populations (Verghese et al., 2009). Changes in gait speed 
represent a common endpoint for alterations in multiple gait characteristics, but 
remain a crude measure with little indication to the causes of change (Lord and 
Rochester, 2005). Measurement of components of the gait cycle can provide an 
understanding of the causes for this loss of walking speed and have been 
shown to be  sensitive markers of ageing (Jahn et al., 2010), pathology and 
disease progression (Lord et al., 2011; Mirelman et al., 2011; Galna et al., 
2013b; Galna et al., 2014; Rochester et al., 2014b). 
The rhythmic patterns of gait are generated in centres within the spinal cord, 
which interact with the sensory systems and are under the control of the 
locomotor areas of the brain. It appears that gait is controlled primarily by the 
pre motor and motor areas of the frontal cortex, with connections to the basal 
ganglia, locomotor areas of the brain stem and cerebellum which link with the 
spinal generators. These connections allow us to remain still, commence 
walking and change speed or direction in relation to our environment (Figure 
1-10). Many of these areas of the central nervous system can be affected in 
mitochondrial disease and therefore patients are very likely to exhibit difficulties 
with walking (Turnbull et al., 2010; Galna et al., 2013b). 
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Figure 1-10: The current concept of the supraspinal control of gait. 
Impulses from the motor and pre motor areas of the frontal cortex disinhibit 
brainstem locomotion areas via the basal ganglia. To initiate or altar a pattern of 
movement signals travels from the midbrain to the spinal generators. The 
cerebellum modulates the rhythm and speed of gait. Afferent signals from the limbs 
(blue) are able to alter the gait pattern through feedback loops by way of 
spinocerebellothalamic connections. (CLR-cerebellar locomotor region; CPG-central 
pattern generators; MLR-midbrain locomotor region; PMRF-pontomedullary reticular 
formation; SLR-subthalamic locomotor region)(Jahn et al., 2010). 
 
Measurement of gait can be performed in a variety of ways and has evolved 
over time from walking along paper recording footprints to electronic walkways 
and the use of 3 dimensional motion analyses. Despite this progress, gait 
analysis has had limited uptake in clinical practise due to the costs and 
expertise required to perform (Toro et al., 2003). The section below will explain 
the various parameters measured using gait analysis in this thesis and how 
changes in these parameters can provide insights into the mechanisms 
resulting in gait impairment. 
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1.8.1 Models of gait analysis 
Gait measurement can be grouped into two areas: Spatiotemporal measures 
that record a typical gait cycle (Figure 1-11A) and dynamic features of gait 
(Figure 1-11B), which show the variations of the spatiotemporal measures 
between steps (Lord et al., 2013a). Spatiotemporal measures of gait have been 
shown to be reliable and valid (Bohannon, 1997; Lim et al., 2005), but the 
reliability of dynamic features of gait has yet to be established despite 
demonstrating validity (Lord et al., 2011). Also gait analysis can be performed 
alongside measurement of O2 consumption to provide additional information 
concerning the efficiency of walking (Newman et al., 2007; Wert et al., 2010). 
Although this involves repeated walking over electronic walkways and treadmill 
testing with cumbersome equipment and harnesses and as such may not reflect 
normal community ambulation (Dawes et al., 2004). 
Finally measurement of gait has also been used to assess non-motor attributes 
of disease with changes in gait being reported alongside impaired executive 
function, attention and general cognitive decline (Verghese et al., 2008; Yogev-
Seligmann et al., 2008) and directly linked with pathology (Rochester et al., 
2012). These findings have led to gait being recognised as a surrogate marker 
of cognitive function (Lord et al., 2013b). 
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Figure 1-11: An illustration of spatiotemporal gait parameters. 
A-The most common temporal measures are shown on the left, and spatial 
variables on the right (SLS-single limb support time; DLS-double limb support time). 
B Stride time variability is illustrated for 100 consecutive strides for a healthy 
example and an individual with Parkinson’s disease (Lord et al., 2013a). 
 
Multiple protocols have been outlined in gait studies, with testing including 
different distances dependent on gait characteristics and conditions investigated 
(Lord et al., 2013b), with walking being performed either continuously or 
intermittently and with or without a dual task. The dual tasks used are often 
cognitive but can include activities such as: changing pace or direction and 
talking whilst walking. The value of the addition of a secondary (dual) task 
activity is that it places further stress on the locomotor systems whilst walking 
and is likely to be more representative of walking in the community. In some 
conditions it has been noted that secondary tasks lead to a reduction in 
cognitive compensation and result in latent motor deficits being revealed. This 
has been reported in Parkinson’s disease, where a slowing of gait with 
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increased variability was reported with the addition of a dual task (Hausdorff et 
al., 2003; Rochester et al., 2004; Yogev et al., 2005; Lord et al., 2011; Kelly et 
al., 2012b). Although it should be noted that these changes have also been 
reported as normal features of ageing (Rochester et al., 2014a). 
Unfortunately the use of different protocols and different dual tasks makes direct 
comparisons between trials difficult (Al-Yahya et al., 2011). To enable better 
interpretation of patterns of gait impairment attempts have been made to place 
characteristics into conceptual models. The model used in this thesis is based 
upon a model devised by Lord et al (2013b). This model represented 84.6 % of 
the variance of gait in Parkinson’s disease patients and controls and resulted in 
16 variables being defined within the five domains of: pace; rhythm; variability; 
asymmetry and postural control. The model uses spatial, temporal and dynamic 
aspects of gait assessment, so capturing all possible gait impairments that may 
result from mitochondrial disease. 
1.8.2 Gait analysis in neurological conditions 
Involvement of the central nervous system in mitochondrial disease is common 
(McFarland et al., 2002; Turnbull et al., 2010). Gait analysis has not previously 
been performed in this disease group, but use of gait analysis in other 
neurological conditions provides insights into its potential use in mitochondrial 
disease. Due to the selective nature of gait impairments particular neurological 
conditions and symptoms appear to demonstrate specific changes in gait 
characteristics. Patients with Parkinson’s disease have been reported to 
demonstrate reduced stride length and speed, plus increased variability of stride 
length (Hausdorff et al., 1998; Morris et al., 1998; Stolze et al., 2001; Galna et 
al., 2014), patients with ataxia show an increase in gait variability even in a so 
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called pre–clinical state (Ilg et al., 2007; Mirelman et al., 2011; Rochester et al., 
2014b) and gait asymmetry is common following stroke (Schmid et al., 2007).  
The reduced levels of activity seen in patients with mitochondrial disease were 
previously thought to be due to muscle symptoms resulting in reduced exercise 
tolerance and excessive fatigue. However it should not be ruled out that 
limitations in activity might also be due to primary neurological pathology or 
secondary compensatory mechanisms leading to inefficient and impaired gait. 
Therefore the measurement of gait in patients with mitochondrial disease may 
be of value as impairments may be detectable before they are detectable by the 
naked eye. As no previous studies have been performed on this population it is 
not possible to predict what gait impairments may be prevalent, but due to the 
multisystem nature of mitochondrial disease it is likely that gait will be affected 
in this population.  
To summarise, gait speed can be seen to deteriorate with pathology and age 
but provides little indication of the mechanisms that lead to this decline. The 
measurement of individual gait characteristics is a more sensitive and selective 
method of interpreting gait impairments and is capable of identifying gait 
impairments not seen by observation of walking alone. Early detection of gait 
impairments may allow earlier intervention before compensations have been 
entrenched and are potentially more amenable to treatment. If these attributes 
are demonstrable within a mitochondrial disease population the use of gait 
analysis may be a valid tool for use in future clinical trials. 
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1.8.3 Executive summary  
This review of mitochondrial disease, exercise and relevant methodology has 
reiterated the difficulty in researching this highly variable disease involving 
multiple bodily systems. The variability of genotype and phenotype expression, 
along with variability of symptoms and rate of disease progression, makes the 
evaluation of treatments in mitochondrial disease problematic. Currently no cure 
is available for mitochondrial disease, although on-going management of 
symptoms is critical to prevent unnecessary complications of disease, 
deterioration of function and to maintain quality of life.  
Exercise therapy has been shown to be beneficial in improving the exercise 
capacity and quality of life of patients with mitochondrial disease and the initial 
concerns over its safety appear to have been allayed. The multitude of 
genotypes involved and the numerous primary outcomes used in exercise 
studies in mitochondrial patients have made comparisons between studies 
difficult. Previous research into the effects of exercise has involved lengthy, 
expensive and invasive techniques. The high participant burden of these 
exercise trials has led to difficulties in recruitment and retention to studies. The 
use of more simple and patient relevant measures may enable a greater insight 
into the day-to-day consequences of mitochondrial disease on our patients. 
In light of this information the studies that make up this thesis aim to answer the 
following research questions  
1. What are the effects of an aerobic exercise intervention on the exercise 
capacity, disease burden, quality of life and performance of functional tasks 
in a discreet group of mitochondrial patients? 
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2. Are measures of disease burden, exercise capacity and functional ability 
associated in mitochondrial disease?  
3. Can gait characteristics discriminate between patients with mitochondrial 
disease, a sedentary control group and between mitochondrial genotypes? 
4. Can improvements in exercise capacity be translated to improvements in 
gait?  
5. Can evaluation of different clinical measures provide clinicians and 
researchers with a limited battery of measures suitable for use in research 
and the clinical management of mitochondrial disease?  
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Chapter 2 Methods and materials
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 Introduction 
This chapter will describe the methods and materials used in the four studies 
included in this thesis. An outline of the method and materials used in each 
individual study will be included in the relevant study chapters. 
The studies included in this thesis form part of a larger body of work 
investigating the cardiac adaptations to exercise in patients with mitochondrial 
disease. Participants were required to perform further investigations as part of 
this larger body of work, which will not be described here but did affect the 
inclusion criteria to the studies contained in this thesis (Bates et al., 2013). 
  Recruitment 
Participants were recruited from the MRC Centre for Neuromuscular Diseases 
Mitochondrial Disease patient Cohort Study (RES/0211/7552). Eligible 
participants had: a biopsy proven mitochondrial disease; age 18-60 (years); BMI 
20-35 kg/m2 and did not take part in regular exercise. Sixty patients were 
identified, sent a patient information sheet outlining the trial and invited to make 
contact if they wished to participate.  
Healthy controls were recruited from advertisements posted throughout 
Newcastle University and on the University home page. Participants were asked 
to contact if they wished to participate in an exercise trial and were not already 
performing formal exercise or considered themselves sedentary.  
  Consent and Ethical Process 
Potential recruits were given the relevant patient or participant information sheet 
(Appendix A) prior to attending for their initial visit. This gave participants time to 
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read the information and to formulate any questions to ask at their initial 
appointment. 
During the initial visit, details of the study were explained, and any potential 
risks discussed. The researcher also answered any questions regarding 
participation in the study at this visit. If the volunteer was happy to proceed with 
taking part in the study and met the inclusion criteria, they were asked to sign a 
consent form (Appendix B). At this point, participants were made aware that 
their GP would be informed about their participation in the study and also, that 
they may withdraw at any point without affecting their future healthcare. 
Institutional ethical approval (Ref 09/H0904/58) was obtained and the study 
complied with the Declaration of Helsinki. 
2.3.1 Inclusion criteria 
All eligible patients were verbally invited to participate based on the following 
clinical inclusion criteria: (i) clinical stability for >6 months; (ii) ability to use an 
upright stationary bicycle ergometer; (iii) no current participation in regular 
physical activity (≤1 weekly session); (iv) reported exercise intolerance and 
fatigue.  
Sedentary controls participants (performed less than 10,000 steps or performed 
no formal exercise) required a normal ECG and no history of cardiovascular or 
metabolic disease. Control participants were matched to mitochondrial group by 
age, gender.  
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2.3.2 Exclusion criteria  
Participants were excluded if they had a known cardiac involvement, co 
morbidities precluding exercise training, and contra-indications to Magnetic 
Resonance Imaging.  
2.3.3 Trial design 
All participants attended an initial visit over two days. This initial assessment 
formed the two cross-sectional studies included in this thesis (chapter 3 and 4). 
Following the initial visit, 12 patients with mitochondrial disease and the 11 
sedentary volunteers went forward to complete a case controlled intervention 
(exercise) study (chapter 6 and 7). 
 Initial Visit  
All assessments for the initial visit took place between 2 centres: The Clinical 
Research Facility, Royal Victoria Infirmary, Newcastle and the Clinical Ageing 
Research Unit, Newcastle University. 
Both initial and final visits included numerous assessments over 2 days. The 
following section will describe the assessments performed as part of both the 
cross-sectional and case controlled exercise studies reported in this thesis. 
2.4.1 Physical Examination 
All volunteers underwent a physical examination comprising: auscultation of the 
heart and lungs, evaluation of the abdomen for any abnormalities, inspection of 
the lower extremities for oedema and arterial pulses, inspection of the skin and 
assessment of reflexes. 
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Disease severity in patients with mitochondrial disease was assessed and 
disease burden established using the Newcastle Mitochondrial Disease Adult 
Scale (Schaefer et al., 2006) and mitochondrial mutation load was derived from 
urinary epithelial cells (Shanske et al., 2004; Whittaker et al., 2009). 
2.4.2 Physical Activity Readiness Questionnaire (PARQ) 
The PARQ, endorsed by the American College of Sports Medicine (ACSM), 
includes medical history, medication, current activity levels, and identifies 
whether the volunteer feels there are any barriers that may prevent them from 
exercising. 
Participants completed the PARQ, then were stratified based on medical history 
and current “fitness” levels into one of three risk categories: high, moderate, and 
low. The PARQ identified volunteers for who exercise testing required medical 
supervision and where intervention was inappropriate (Appendix C). 
Anyone found to have contraindications to exercise or exercise testing was 
excluded at this point and a letter written to their GP containing the relevant 
findings (see Risk Definition and Standard Operating Procedures for Exercise 
Testing for further details) based on ACSM guidelines. 
2.4.3 Blood samples 
Fasting blood samples were analysed in a Clinical Pathology Accredited 
laboratory (Newcastle Upon Tyne Hospital NHS Foundation Trust, Department 
of Clinical Biochemistry) for: liver enzymes (ALT, AST, GGT), lipid profile (total 
cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerols, haematology), 
HbA1c, creatine kinase.  Serum samples were collected in silica clot activator 
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polymer gel containing vacutainers (BD Diagnostics, Plymouth, England) - total 
cholesterol, triglycerols, and liver enzymes were measured using a Roche 
Modular P and test kits (Roche Diagnostics Ltd, Burgess Hill, UK). HbA1c was 
measured using a TOSOH HLC-723G7 (Tosoh Corporation, Tokyo, Japan). 
These results are reported as part of a thesis by Dr. M. Bates to investigate the 
cardiac adaptions in mitochondrial disease. 
2.4.4 Cognitive Testing 
Cognitive function was tested using the revised Addenbrookes Cognitive 
Examination (ACE-R). The ACE-R takes between 12 and 20 min to administer 
and score in a clinical setting. It contains 5 sub-scores, each one representing 
one cognitive domain: attention/orientation, memory, fluency, language and 
visuospatial ability. The ACE-R maximum score is 100, calculated by the 
addition of the all domains. A score below 88 was indicative of mild cognitive 
impairment (Eneida et al., 2006). 
2.4.5 Anthropometry 
Height was measured without shoes and using a standard rigid stadiometer to 
the nearest 0.1cm. Weight was measured to the nearest 0.2kg on calibrated 
scales without shoes (Seca medical 769 column scale, USA). Body mass index 
was calculated (weight divided by the square of the participant’s height). 
2.4.6 Whole Body Composition  
Whole body composition was determined using air displacement 
plethysmography using a BodPod (Life Measurement Inc., Concord, CA, USA) 
(Figure 2-1). This was calibrated before each measurement using the known 
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calibration standard. The technique has been validated against the reference 
standard of hydrostatic weighing, dual-energy X-ray absorptiometry and 
bioelectrical impedance in healthy and overweight/obese adults (Sardinha et al., 
1998; Biaggi et al., 1999; Fields DA et al., 2005). All patients had their body 
composition measured whilst fasted, wearing tight fitting underwear and the 
provided lycra cap. This minimised the effects of hydration/recent food intake 
and air trapping respectively. The manufacturers indicate that the general error 
range of the Bodpod is 1-2% (the same as hydrostatic weighing). 
Figure 2-1: Image of Bodpod used to measure body composition  
 
2.4.7 Measurement of resting substrate metabolism 
Following an overnight fast (≥ 8 hours with no food or beverages) resting 
substrate oxidation was determined by expired gas analysis (CORTEX 
Biophysik, Leipzig, Germany) using a Hans Rudolf breathing mask while 
participants lay supine for 30 minutes in a quiet room, without speaking or 
sleeping and with minimal movement. The calorimeter gas analysers were 
calibrated before every measurement for gas volume and composition, and 
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ambient air pressure. Twenty minutes of recording were used to calculate 
substrate oxidation from oxygen consumption and carbon dioxide production 
values using stoichiometric equations  
VO2 (l/min) = 0.746c + 2.03f + 6.04n 
VCO2 (l/min) = 0.746c + 1.43f + 4.89n (Frayn, 1983).  
Where c is grams of carbohydrate oxidised per minute, f grams of fat per minute 
and n is grams of urinary nitrogen excreted per minute (Frayn, 1983).  
2.4.8 Maximal Aerobic Capacity 
The gas analysis system (Metalyzer 3B; Cortex, Leipzig, Germany) was allowed 
to warm up for a minimum of 2 hours before the test; calibration (volume and 
gas) was undertaken on the day of each test and documented. 
A progressive exercise test was undertaken to assess peak oxygen 
consumption and work rate, anaerobic threshold and oxygen extraction, using 
an electronically braked recumbent cycle ergometer (Corival Lode BV, 
Groningen, The Netherlands).  
Volunteers underwent a resting 12-lead electrocardiogram (ECG; Custo med 
GmbH, Ottobrunn, Germany) and blood pressure monitoring (Suntech Tango+, 
Suntech Medical Ltd, Oxford, UK) in a recumbent seated position, to measure 
normal cardiac function prior to, and throughout, the exercise test. An ECG was 
used to continuously monitor heart rhythm, and blood pressure was measured 
every 2 minutes during the exercise test. Both ECG and BP were monitored for 
at least 5 minutes after the exercise test had been terminated.  
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Exercise protocols used differed for control participants and patients with 
mitochondrial disease to allow all participants to achieve a VO2PEAK within ≈ 15 
minutes of the onset of the exercise test.  
 Control protocol 
After a 5 minute warm up at 25W, resistance was increased by 1W every 8 
seconds until the participant could no longer maintain a cadence of 60 rpm, 
chose to stop, or continuing was contraindicated (Risk Definition and Standard 
Operating Procedures for Exercise Testing for further details). 
 Mitochondrial protocols  
Patients with MD performed one of three exercise protocols (Table 2-1). The 
protocol performed was dependent upon subjective assessment of the 
participant’s physical function. Three protocols were necessary due to the 
variability in the abilities of subjects with mitochondrial disease. These protocols 
were based on protocols used in a previous exercise study; Exercise training in 
patients with mitochondrial disease: Assessing the benefits (unpublished).  
The same protocol was repeated in all progressive exercise tests performed by 
that individual. The test was terminated under the same circumstances as the 
control subjects. A member of the MRC Muscle Performance and Exercise 
Training Laboratory conducted exercise testing. All staff members were certified 
to undertake exercise tests and Cardiopulmonary Resuscitation. 
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Table 2-1: Progressive exercise test protocols for participants with mitochondrial 
disease. 
Time (minutes) Work Rate (Wattage) 
 Low Medium  High  
0 0 40 90 
1 5 45 95 
2 10 50 100 
3 15 55 105 
4 20 60 110 
5 25 65 115 
6 30 70 120 
7 35 75 125 
8 40 80 130 
9 45 85 135 
10 50 90 140 
11 55 95 145 
12 65 100 150 
13 70 105 155 
14 75 110 160 
15 80 115 165 
16 85 120 170 
17 90 125 175 
18 95 130 180 
19 100 135 185 
20 105 140 190 
2.4.9 Cardiac output estimates 
Cardiac output was measured at rest and during exercise testing continuously 
using bio-reactance techniques (NICOM, Cheetah Medical, Deleware, USA). 
Four dual-surface electrodes were used to establish electrical contact with the 
body; two were applied over the trapezius muscle on either side of the upper 
torso and two on the lower posterior torso lateral to the margin of the latissimus 
dorsi muscle (Jakovljevic et al., 2012, ; Jones et al., 2015). Electrode 
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connections were secured with medical tape and all connecting wires supported 
to ensure minimal movement artefact. 
Cardiac output was then calculated as the product of stroke volume and heart 
rate. Arterial-venous difference was calculated theoretically and cardiac output 
was determined for a given oxygen uptake using the equation previously 
suggested by Stringer and colleagues (Stringer et al., 1997). 
2.4.10 Physical Activity  
Physical activity and energy expenditure were assessed objectively using a 
validated multi-sensor array (SenseWear Pro3, Bodymedia Inc, Pennsylvania, 
USA 2.5) (St-Onge et al., 2007; Moore et al., 2012). Participants were asked to 
wear the armband on their right upper arm (at the mid-humerus point on the 
triceps) for seven days (Figure 2-2). All subjects were instructed to remove the 
armband only for bathing/showering purposes or any water activity. 
The armband uses a 2-axis accelerometer, a heat flux sensor, a galvanic skin 
response sensor, and a near-body ambient temperature sensor to capture data. 
The participants’ date of birth, height, body weight, sex, hand dominance and 
smoking status (smoker or non-smoker) were also used by the device to 
calculate energy expenditure. 
The armband produced the following data as units per day: total energy 
expenditure; active energy expenditure; average metabolic equivalents (METs); 
duration of sedentary time (≤ 2.9 MET); duration of physical activity (> 3.0 MET); 
duration of moderate physical activity (3.0-5.9 MET); duration of vigorous 
activity (6.0-9.0 MET); duration of very vigorous activity (≥ 9.0 MET); number of 
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steps; sleep duration; and duration armband worn. This data was then averaged 
over the seven days worn to provide daily activity levels.  
Figure 2-2: An image of a Sensewear activity monitor. 
 
Participants also completed the International Physical Activity Questionnaire 
(IPAQ) for the same seven days the SenseWear armband was worn. The IPAQ 
asks participants to recall their physical activity over the previous seven days. 
The IPAQ includes four activity domains: work-related physical activity, 
transportation, household, recreation and leisure time activity and also reports 
time spent sitting. The IPAQ was scored using guidelines produced by the IPAQ 
Group (www.ipaq.ki.se/scoring.pdf). The IPAQ has been demonstrated to have 
comparable levels of validity to other physical activity self-report measures 
(Craig CL et al., 2003) (Appendix D). 
2.4.11 Muscle strength testing  
Hip flexor and extensor strength was measured using an isokinetic 
dynamometer (CSMI HUMAC®/NORM testing and rehabilitation system). 
Calibration of the CSMI Norm system was done as stated in the user manual; 
100lbs of weight were dropped with the arm at a pre-set length to verify the 
accuracy of torque measures. Calibration was done preceding each test and 
recorded in a calibration log. 
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Testing was performed in a supine position with the participant stabilized with a 
waist and torso strap. The axis of rotation was aligned with the participant’s 
greater trochanter of the femur of the test leg. The lever arm was positioned on 
the lower third of the quadriceps just superior to the patella. The starting 
position was recorded, noting position of the bed along with the position and 
length of the dynamometer arm. This starting position was repeated on any 
subsequent visits (Julia et al., 2010). 
A concentric hip flexor/extensor pattern was chosen at a velocity of 60 
degree/sec. The range of motion of hip movement was set for each individual 
participant. Participants underwent 6 sub-maximal contractions to familiarize 
themselves with the range of movement followed by a minute’s rest. To prevent 
the participant from sliding up the bed, the tester provided further stabilization at 
the participant’s shoulders. The participant then performed six maximal 
repetitions with consistent verbal encouragement. Both left and right sides were 
tested with a minutes rest between each test. Peak torque measurements were 
recorded for hip flexion and hip extension movements at the end of the test. 
No dynamometry testing was performed within a few hours of the maximal cycle 
test and preferably testing was performed on a separate day. Due to the 
extensive testing included in visits, dynamometry was not always performed at 
the same time of day (Guette et al., 2005).  
2.4.12 Functional Outcome Measures  
All functional outcomes and gait measurements were performed at the same 
time in the gait laboratory in the Clinical Aging Research Unit. The short “10m 
walks” (single and dual task conditions); “Timed up and go” and “Sit to stand” 
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tests were completed in a counterbalanced order (Appendix E). The 6-minute 
walk always occurred last in the testing session to avoid fatigue affecting other 
measures. 
 Five times sit to stand (5XSTS)  
Using a standard chair (height 43 – 46 cm) the participant was timed (seconds) 
completing the task of sitting to standing 5 times. 
The procedure was explained to the patient prior to testing. Participants were 
asked to: cross both arms across their chest, begin in a seated position, stand 
up (knees fully extended) and sit down (full weight through chair). Instructions to 
the participant were: “I want you to stand up and sit down 5 times as quickly as 
you can when I say ‘Go’” (Lord et al., 2002; Whitney et al., 2005). Participants 
were informed to begin and the timer was started, the timer was stopped on the 
return to the seated position following the fifth sit to stand movement. 
 Timed up and Go Test (TUG) 
The timed up and go (TUG) test measures, in seconds, the time taken by an 
individual to stand up from a standard armed chair (approximate seat height 
43–46cm), walk at a comfortable speed a distance of 3 meters, turn, walk back 
to the chair and sit down again (Podsiadlo D et al., 1991 ).  
Instructions to the participant “When I say ‘go’ I want you to stand up and walk 
to the line, turn, walk back to the chair and sit down again. Walk at your normal 
pace.” 
Participants were able to use the arms of the chair to assist them when standing. 
Regular footwear was used and they were able to use their customary walking 
aid. However no physical assistance was given. The patient walked through the 
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test once before being timed in order to familiarise themselves with the 
procedure. 
The time taken for the patient to complete the test (i.e. from the word ‘go’ until 
the patient was seated back in the chair) is recorded in seconds using a 
stopwatch. The test was completed three times, whereby the mean of the three 
performances was recorded.  
 10 meter timed walk (10MTW)  
Participants were asked to walk a 10m distance; walking speed was tested at 
the subject’s comfortable speed and three repetitions were carried out. The 
participant was able to walk without assistance of another person, although use 
of a walking aid was permitted if necessary (Wade, 1992 ). 
 Six Minute Walk Distance (6MWD) 
The patient sat in a chair located near the start position for at least 10 minutes 
before starting the test to allow for recovery from previous testing. 
Participants were instructed as follows: “The object of this test is to walk as far 
as possible for 6 minutes. You will walk around the course marked (Figure 2-3). 
Six minutes is a long time to walk so you will be exerting yourself. You may get 
out of breath or become exhausted. You are permitted to slow down, to stop 
and to rest as necessary. You may lean against the wall while resting or sit 
down on the chair, but resume walking as soon as you are able. 
You will be walking back and forth around the cones; you should not hesitate as 
you walk around the cones. Now I am going to show you”. 
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Figure 2-3: Gait laboratory set up for 6-minute walk. 
 
A lap of the walking course was demonstrated. This was followed by: “Are you 
ready to do that? I am going to keep track of the number of laps you complete. I 
will tick a box each time you pass this starting line. Remember that the object is 
to walk AS FAR AS POSSIBLE for 6 minutes, but don’t run or jog. Start now or 
whenever you are ready”. This test was based upon "American Thoracic 
Society Statement: Guidelines for the Six-Minute Walk Test." (2002). 
The therapist notified the participant when each minute had elapsed. When six 
minutes had elapsed on the stopwatch the participant was requested to stop 
and the distance walked was recorded.  
2.4.13 Assessment of Gait  
Gait was assessed using a 7m long × 0.6m wide instrumented mat (Platinum 
model Gaitrite, software version 4.5, CIR systems, USA). Previous studies have 
verified the Gaitrite mat to be a valid and reliable method for measuring mean 
gait characteristics in young and old adults with and without pathology (Menz et 
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al., 2004; Kuys et al., 2011). Data for individual steps for each condition was 
extracted from the Gaitrite database using Microsoft Access 2007. 
Participants were asked to perform 3 different walking tasks (intermittent walks 
± dual task and a continuous walk over 6 minutes). During the intermittent walks 
participants were instructed to perform three 12m walks at their “comfortable 
pace”. The mat was placed in the centre of the 12 m walkway to ensure that 
steady gait speed was measured (Figure 2-4). 
Figure 2-4: Gait laboratory set up for testing single and dual walks. 
 
 The concurrent cognitive task for the dual task condition consisted of a digit 
span task. The participant listened to a string of digits and repeated them back 
whilst walking. The strings of digits consisted of a range of pre-recorded random 
strings of digits spoken at a cadence of one digit per second. The length of the 
strings of digits played during walking was assessed prior to testing with the 
participant in a seated position. In sitting strings of an increasing number of 
digits were played (starting from strings of 2 digits) until the participant failed to 
correctly recall two strings of the same length.  
The continuous walks involved participants walking continuously around a 25m 
oval circuit, instructions provided were as stated above for the 6 minute timed 
walk, where participants were encouraged to walk as far as possible for 6 
minutes and were provided with prompts every minute (Society, 2002). Gait 
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characteristics were repeatedly recorded as they walked over a mat placed on 
one side of the circuit (Figure 2-3). 
Gait was quantified for all three walking tasks (single task, dual task and 
continuous walks) using a predefined model with five domains hypothesized to 
reflect independent features of neural control and characterise the features of 
gait associated with mitochondrial disease and its genotypes (Lord et al., 
2013b). This model included: pace (step velocity and step length); rhythm 
(cadence); variability (step time and step length variability); asymmetry (step 
time asymmetry); and postural control (step width, step width variability, step 
length asymmetry) (Figure 2-5). 
Gait variability, otherwise known as gait dynamics, was measured to 
characterise the step-to-step fluctuations over the walking task. Gait variability 
was calculated for step length, step time, step width (Galna et al., 2013a).  
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Figure 2-5: Illustration of step length; step width and step timing characteristics 
measured in this study. 
Step velocity (walking speed) was also measured (calculated as step length divided 
by step time). 
 
 
 
73 
To avoid confounding variability with gait asymmetry variability was calculated 
as the combined within-persons variance of the left and the right steps as in 
equation 1 (Galna et al., 2013a). Hence the Standard Deviation of Left & Right 
steps was the combined within-person standard deviation calculated from the 
left steps and the right steps. The variance of left steps and right steps was 
calculated separately for each person. 
Equation 1   
Asymmetry was calculated as the absolute difference between the left and right 
step length and step time. 
 Aerobic training intervention  
Upon completion of baseline tests, 24 participants undertook 16 weeks of 
aerobic exercise therapy (13 patients with MD and 12 sedentary controls). 
Exercise sessions were conducted at a local gym or on a recumbent bike at 
home. Each session consisted of working towards 45 minutes recumbent 
cycling at a heart rate corresponding to ≈ 60-70% VO2PEAK and were performed 
3 times a week (48 sessions in total). The intensity of exercise sessions were 
tailored to the individual and increased progressively over the 16 weeks. 
Stretches were performed prior to exercising and gentle upper body exercises 
using resistance bands were included as part of the training schedule. During 
each session a heart rate monitor was worn (RS400, Polar, Finland) and the 
exercise was recorded in an exercise diary. 
2
)(
 = SD Right &Left 
StepsRightStepsLeft VarianceVariance 
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 Interim Visit  
At 8 weeks a maximal progressive exercise test was repeated using the same 
protocol as the initial test. The exercising heart rate range was reassessed and 
altered as required (to remain at 70% of VO2PEAK). Individual exercise goals 
were reset and the importance of adherence to the program emphasised.  
Data from the Polar heart rate monitors was downloaded and matched against 
reported exercise sessions recorded in an exercise diary. 80% exercise session 
adherence was required. Monitored via diary and downloaded data from 
POLAR watch and weekly telephone calls. 
Participants with mitochondrial disease provided another blood sample to check 
the Creatine Kinase (CK) level.  
 Final Visit  
All the assessments performed at the initial visit were repeated at the final visit 
except assessment of physical activity (Sensewear, IPAQ). Every attempt was 
made to repeat the timings of the initial visit. Exercise diary and POLAR watch 
were retrieved from participants.  
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Chapter 3 The use of physiological and functional 
measures in mitochondrial disease. 
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 Introduction  
Mitochondrial diseases are a group of neuromuscular disorders, which affect up 
to 8,000 adults in the UK (Schaefer et al., 2008). Recording the natural history 
and evaluating interventions in this group of diseases has proved problematic 
due to multi-system involvement and the lack of correlation between 
mitochondrial genotype and phenotype. A recent Cochrane review (Pfeffer et al., 
2012) commented on the multitude of primary outcomes used in studies of 
mitochondrial disease and how this has made comparison between studies 
difficult. The review advised that future studies should investigate sub-groups of 
mitochondrial diseases and include the use of outcomes that have clinical 
meaning for patients and their quality of life. 
The purpose of this study is to evaluate the relationships between biological, 
clinical and functional measures by assessing disease burden, exercise 
capacity and functional ability within two specific mitochondrial genotypes. 
Currently disease severity can be determined by, i) levels of mitochondrial DNA 
mutation found in tissues such as muscle (Chinnery et al., 1997) or urine 
(McDonnell et al., 2004; Shanske et al., 2004; Whittaker et al., 2009) and ii) 
clinically by using the Newcastle Mitochondrial Disease Adult Scale (NMDAS) 
(Schaefer et al., 2006). These investigations can be invasive, time consuming 
and costly. Previously the exercise capacity of patients with mitochondrial 
disease has been used as a proxy measure of mitochondrial function (Jeppesen 
et al., 2003; Taivassalo et al., 2003; Tarnopolsky, 2004). Functional outcome 
measures are quick and inexpensive to deliver and are commonly used in 
clinical practice by therapists (Yoward et al., 2008). More recently functional 
outcome measures have been adopted by the research community to measure 
many aspects of disease such as; disease severity, natural history, prediction of 
 
77 
future levels of disability and the effects of interventions in neurological and 
neuromuscular populations (Takeuchi et al., 2008; Ries et al., 2009; McDonald 
et al., 2010). 
Demonstration of relationships between these three types of assessment 
(disease severity, exercise capacity and functional ability) may enable 
professionals to use simple functional outcome measures in the clinical setting 
as potential proxy measures of disease burden. The wider use of outcome 
measures in clinical practice will provide more detailed information concerning 
the natural history of mitochondrial diseases and reflect how our patients’ daily 
lives are affected by mitochondrial disease.
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 Study aim and hypothesis 
 Aim  
The aim of this study is to assess the usefulness of physiological and functional 
measures in mitochondrial disease. 
 Primary hypothesis 
Physiological and functional measures will be able to discriminate between 
mitochondrial patients and a sedentary control group.  
 Secondary hypotheses 
Exercise capacity will be impaired within a discreet group of mitochondrial 
patients (two genotypes m.3243A>G, m.8344A>G) when compared to a 
sedentary control group. 
Measures of exercise capacity and functional ability will demonstrate 
relationships to disease severity in mitochondrial disease. 
Dynamometry will be able to detect proximal muscle weakness in a group of 
mitochondrial patients. 
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 Subjects and Methods 
Full descriptions of the subjects and methods used in this study are contained 
within Chapter 2. A brief outline of methods and subjects included in this cross-
sectional study are described below.  
Twenty-four patients with mitochondrial disease (MD) clinically identified and 
laboratory confirmed as due to the m.3243A>G or m.8344A>G mitochondrial 
DNA mutation were recruited from the Newcastle Mitochondrial Disease Cohort. 
Twelve untrained healthy controls with normal ECG and no history of 
cardiovascular or metabolic disease were recruited through local advertisement 
(Figure 3-1).  
Institutional ethical approval (Ref 09/H0904/58) and written informed consent 
were obtained and the study complied with the Declaration of Helsinki. 
All assessments were undertaken between the two centres listed in the 
methods section over a period of two days. This was necessary due to the 
distance required to travel to the centres by some of the participants with 
mitochondrial disease. Over the two days both disease and control groups 
underwent assessment of resting metabolism, peak exercise capacity, proximal 
muscle strength (hip flexors, hip extensors) and lower limb function and were 
provided with a Sensewear activity monitor to assess physical activity.  
In addition the disease burden and cognition of participants with mitochondrial 
disease was assessed, whilst sedentary control volunteers underwent a review 
of their medical history with a physical examination and completed the Physical 
Activity Readiness Questionnaire prior to exercise testing (Appendix C). 
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Figure 3-1: Consort diagram for the study of physiological and functional measures 
in mitochondrial disease. 
 
 
81 
3.3.1 Disease Burden  
All Subjects underwent a physical examination by an experienced clinician, 
disease severity was assessed and disease burden was established using the 
Newcastle Mitochondrial Disease Adult Scale (Schaefer et al., 2006). Mutation 
load, an established marker of clinical outcome was derived from urinary 
epithelial cells (McDonnell et al., 2004; Shanske et al., 2004; Whittaker et al., 
2009). 
3.3.2 Physical Activity Levels  
Physical activity and energy expenditure were assessed objectively for seven 
days using a validated multi-sensor array (SenseWear Pro3, Bodymedia Inc, 
Pennsylvania, USA 2.5) (St-Onge et al., 2007).  
Participants also completed the International Physical Activity Questionnaire 
(IPAQ) (Hagströmer et al., 2006) (Appendix D) for the same seven days that the 
SenseWear armband was worn.  
3.3.3 Anthropometry 
Body weight (kg) and standing height (m) were measured. Whole body 
composition was determined using air displacement plethysmography using a 
BodPod (Life Measurement Inc., Concord, CA, USA). 
3.3.4 Resting Substrate metabolism  
Following an overnight fast, resting substrate oxidation was determined by 
expired gas analysis (CORTEX Biophysik, Leipzig, Germany) using a Hans 
Rudolf breathing mask while participants lay supine for 30 minutes in a quiet 
room. 
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3.3.5 Progressive Exercise testing  
A peak exercise test was performed; a number of parameters including peak 
exercise capacity (VO2PEAK), anaerobic threshold, peak workload and systemic 
arteriovenous oxygen difference (a-vO2 diff) were measured. 
3.3.6 Muscle Strength 
Proximal muscle power was measured using isokinetic dynamometry of the hip 
flexor and extensor muscles. Average peak torque was calculated for each 
muscle group (Julia et al., 2010).  
3.3.7 Functional outcome measures 
Four functional outcome measures were performed to assess functional ability: 
Six-minute walk distance (6MWD) (American Thoracic Society Statement, 
2002); 10 metre timed walk (10MTW) (Wade, 1992 ), Timed up and go (TUG) 
(Podsiadlo D et al., 1991 ) and the 5 times sit to stand tests (5XSTS) (Lord et al., 
2002).  
3.3.8 Cognitive Ability  
Cognitive function was tested using the revised Addenbrookes Cognitive 
Examination (ACE-R) (Appendix F). A score below 88 was used as an 
indication of mild cognitive impairment (Eneida et al., 2006). 
3.3.9 Quality of Life  
Quality of life was assessed using the short form (SF12) health survey, which 
already forms part of the Newcastle Mitochondrial Disease Adult Scale 
(Schaefer et al., 2006).
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 Statistical Analysis 
Differences between groups were calculated by an unpaired student t test or the 
Mann-Whitney U test as deemed appropriate. Significant statistical differences 
were assumed for p values < .05 and are labelled *, p values < .01 are 
labelled**. Associations between parameters were analysed by Spearman or 
Pearson’s correlation dependant on assessment for normality. To allow for 
multiple comparisons statistical significance was assumed for p values <. 01 
and are labelled**. Data is presented as means ± SD for continuous data and 
as numbers or percentages for categorical data unless otherwise stated. 
All statistical analysis was carried out using SPSS version 20 (SPSS Inc. 
Chicago, IL, USA).
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 Results  
All participants attended for all assessments. Three mitochondrial patients were 
unable to complete dynamometry testing due to ill health at time of testing 
(diarrhoea, migraine and a negative response to an exercise test earlier in day).  
The following sections will report the clinical characteristics of the mitochondrial 
group followed by the physical activity levels, exercise capacity and functional 
ability of both mitochondrial and control groups. Finally relationships between 
disease severity, mutation load and the physiological and functional measures 
used in the study are reported. 
3.5.1 Characteristics of participants 
No significant differences are seen between the groups for age (years) 
(Mitochondrial Disease (MD) group 41 ± 13, Control group 37 ± 12, p= .407), 
height (cm) (MD group 169 ± 10, Control group 172 ± 10, p= .392) and gender 
(MD group 14 male, 10 female, Control group 7 male, 5 female). Body mass (kg) 
and BMI (kg/m2) were significantly lower in participants with mitochondrial 
disease than controls (MD 63.9 ±15, Control 80.2±15, p= .005**; MD 22 ± 5, 
Control 27 ± 5, p= .009**).Mitochondrial participant’s clinical features, NMDAS 
scores and mutation load are also shown in Table 3-1. 
 Participants with the m.3243A<G mutation had a lower disease burden than 
the m.8344A<G group (NMDAS 16 ± 8 vs. 39 ± 17, p= .023*; mutation load (%) 
65 ± 18 vs. 88 ± 9, p= .001**). Clinical presentations within the mitochondrial 
disease group varied considerably with a wide range of symptoms being 
reported. Six mitochondrial patients showed cognitive impairment when 
measured using the ACE-R (scored <88).
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Table 3-1: Demographic and clinical details of participants with mitochondrial disease.  
Age Sex 
Height 
(cm) 
Mass 
(kg) 
BMI 
(kg/m2) 
Heteroplasmy 
(%) 
FVC 
(l) 
Cognitive score 
(ACE-R) 
Principle clinical features 
m.3243A>G          
58 F 173 52.1 17.4 59 2.6 98 Hearing loss, ataxia, constipation, underweight, myopathy, myalgia, exercise intolerance 
39 M 172 74.6 25.2 80 5.0 93 Hearing loss, diabetes, migraine, fatigue, hypothyroidism, ataxia, constipation, exercise intolerance 
37 F 164 50.7 18.9 48 2.8 91 Hearing loss, diabetes, exercise intolerance, ataxia, dysarthria, asthma 
42 M 176 83.7 27.0 82 4.0 90 Hearing loss, diabetes, migraine, ataxia, depression, exercise intolerance 
47 M 182 64.0 19.3 63 3.1 94 Hearing loss, diabetes, fatigue, ataxia, myalgia, depression, myopathy, neuropathy, ptosis, PEO 
38 F 164 54.2 20.1 53 2.6 97 Hearing loss, migraine, constipation, myopathy, fatigue, exercise intolerance, asthma 
22 M 183 59.2 17.7 89 4.2 94 Hearing loss, migraine, epilepsy, ataxia, constipation, underweight, exercise intolerance, fatigue 
36 M 179 72.4 22.6 80 4.8 95 Migraine, exercise intolerance 
50 M 162 64.6 24.6 87 3.3 66 
Hearing Loss, exercise intolerance, ataxia, myopathy, fatigue, depression, retinopathy, epilepsy, 
encephalopathy, cognitive decline, stroke-like episodes  
55 F 153 45.8 19.5 68 2.5 97 
Hearing loss, diabetes, myopathy, exercise intolerance, ataxia, constipation, depression, retinopathy, PEO, 
ptosis, short stature, mild dysphagia, hypertension 
42 F 154 49.0 20.7 43 2.6 90 Hearing loss, diabetes, ataxia, constipation, depression, exercise intolerance, short stature 
50 F 169 63.4 22.2 34 4.0 96 Migraine, fatigue, hypothyroidism, myalgia, constipation, hypertension, dyslipidemia, coeliac disease 
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58 M 186 89.8 25.9 66 2.6 87 
Hearing loss, diabetes, ataxia, retinopathy, constipation, hypertension, dysarthria, myopathy, neuropathy, 
exercise intolerance 
53 F 164 59.1 22.0 22 3.6 92 Hearing loss, ataxia, retinopathy, constipation, myopathy, exercise intolerance 
25 M 174 49.8 16.5 90 3.4 89 
Hearing loss, migraine, ataxia, retinopathy, constipation, depression, dysarthria, myopathy, exercise intolerance, 
short stature, asthma 
18 F 154 39.5 16.7 59 2.6 86 Hearing loss, retinopathy, underweight, myopathy, exercise intolerance, short stature  
24 F 155 64.0 26.7 72 3.3 89 
Hearing loss, migraine, ataxia, retinopathy, constipation, depression, dysarthria, myopathy, exercise intolerance, 
short stature 
55 M 179 104.5 32.6 76 2.5 97 Hearing loss, diabetes, depression  
m.8344A>G          
28 M 173 51.7 17.3 95 4.2 71 
Hearing loss, fatigue, epilepsy, ataxia, retinopathy, constipation, dysarthria, myopathy, myoclonus, neuropathy, 
exercise intolerance, underweight 
25 M 176 68.0 22.0 94 4.6 n/a Epilepsy, ataxia, retinopathy, depression, dysarthria, exercise intolerance, myopathy, myoclonus  
46 M 163 70.9 26.7 77 3.6 88 
Mild concentric LVH, lipomata, exercise intolerance, dysphagia, myoclonic jerks, ataxia, seizures, neuropathy, 
fasciculation’s, constipation, hearing loss, myopathy, parenchymal lung disease 
59 F 162 69.8 26.6 75 3.0 98 Myoclonus, deaf, diabetes, lipomata, myopathy, mild concentric LVH 
28 M 180 56.2 17.3 93 4.9 85 
Hearing loss, migraine, epilepsy, ataxia, constipation, underweight, depression, dysarthria, myopathy, 
neuropathy, exercise intolerance 
38 M 160 76.5 29.9 94 1.6 67 
Lipomata, hearing loss, migraine, epilepsy, ataxia, retinopathy, depression, dysarthria, myopathy, myoclonus, 
neuropathy, exercise intolerance, short stature 
FVC -Forced vital capacity
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Quality of life scores were lower in the mitochondrial sample compared with the 
control group when measured using the SF12 questionnaire, physical 
composite score (PCS) (MD group 38 ± 5 vs. control 55 ± 12, p< .001**), mental 
composite score (MCS) (MD group 42 ± 12 vs. control 47 ± 12, p= .186)  
Activity levels were significantly different between the groups when measured 
using Sensewear activity monitors despite attempts to match activity levels, 
participants with mitochondrial disease expending less energy and performing 
less steps daily. Whereas this difference was not replicated using the self-report 
physical activity questionnaire (IPAQ), participants with mitochondrial disease 
reporting that they performed a similar level of activity when compared to the 
sedentary control group, but both being classed as minimally active Table 3-2. 
Table 3-2: Activity levels of control and mitochondrial disease participants. 
Data is reported as median (quartiles), statistically significant results are shown in 
bold. ** p<.01 
Variable Control Group  Mitochondrial Group  p value  
Energy expenditure (calories) 2584 (2194, 2948) 2007 (1770, 2183) .001** 
Activity level (steps per day) 9296 (7455, 12123) 5924 (2979, 7533) .005** 
International Physical Activity 
Questionnaire  
(Metabolic equivalents/min/week) 
2504 (901, 4933) 1822 (969, 10413) .880 
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3.5.2 Resting metabolism 
Resting substrate oxidation showed no significant difference between the two 
groups (Table 3-3). 
Table 3-3: Resting substrate oxidation of both participants with mitochondrial 
disease and controls. 
Variable  MD group  Control group p value 
Ventilation (l)  7.7 (2.4) 7.5 (1.7) .771 
Oxygen consumption (?̇?O2) (l.min) 0.27 (0.07) 0.28 (0.06) .286 
Carbon Dioxide consumption (?̇?CO2) (l.min) 0.23 (0.07) 0.26 (0.05) .438 
Carbohydrate oxidation (mg.kg.min)  2.8 (1.5) 2.9 (0.9) .875 
Lipid oxidation (mg.kg.min)  1.1 (0.6) 0.8 (0.3) .057 
Respiratory Quotient  0.87 (0.08) 0.86 (0.19) .745 
3.5.3 Exercise capacity  
Exercise parameters measured during a peak exercise test for both groups are 
shown in Table 3-4 and Figure 3-2. Arteriovenous oxygen difference was only 
calculated in twenty-two mitochondrial patients due to a failure to capture 
cardiac output (NICOM) data on two participants. 
All exercise parameters demonstrated significant differences between the two 
groups (p< .05), with peak exercise capacity (?̇?O2PEAK) and the anaerobic 
threshold (AT) in mitochondrial participants being 31% and 26% lower than in 
sedentary controls and peak workload being 42% lower. 
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Table 3-4: Exercise variables of mitochondrial patients and controls from a peak 
exercise test.  
Data is reported as means (standard deviations). ** p<.01, * p<.05  
Variable Control group  
Mitochondrial 
group 
p value  
Peak Heart rate  186 (16) 155 (23) < .001** 
?̇?O2 (l/min) 2.2 (0.7) 1.2 (0.5) < .001** 
Peak exercise capacity 
(?̇?O2PEAK) (ml.kg.min.) 
27.9 (6.6) 19.3 (5.7) < .001** 
% predicted ?̇?O2 achieved 92% (20) 58% (21) 
 
Anaerobic Threshold (AT) 
(ml.kg.min) 
16.3 (4.62) 12.1 (4.0)) .006** 
AT as % of predicted 
?̇?O2MAX 
54% (13) 36% (15) 
 
Peak workload (watts) 176 (41) 83 (41) < .001** 
Peak workload (watts/kg) 2.2 (0.5) 1.3 (0.5) < .001** 
Arteriovenous difference 
(mlO2/dl) 
11.2 (4.8) 8.8 (2.7) .01* 
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Figure 3-2: Scatterplots of individual exercise variables of all participants.  
(Error bars denote means and standard deviations). 
 
91 
3.5.4 Muscle strength  
Proximal muscle strength was different between the groups in both hip flexor 
and extensor muscle groups with hip flexor strength (nm/kg) in mitochondrial 
participants reported as 45% lower than the sedentary control group (Table 3-5, 
Figure 3-3). Proximal muscle power followed the expected hierarchy with hip 
extensor strength being greater than hip flexor strength (Cahalan et al., 1989).  
Table 3-5: Table comparing muscle strength in patients with mitochondrial disease 
and sedentary controls. 
Data reported as medians and quartile ranges. ** p<.01 
Variable 
Control group 
(n = 12) 
MD Group 
(n = 21) 
p value 
Hip flexor strength (nm) 106 (51, 119) 28 (22,45) < .001** 
Hip extensor strength (nm) 175 (148, 225) 64 (52, 106) < .001** 
Hip flexor strength (nm/kg) 1.3 (0.7, 1.5)  0.5 (0.4, 0.8) .002** 
Hip extensor strength (nm/kg) 2.1 (1.6, 2.8) 1.1 (0.9, 1.8) .003** 
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Figure 3-3: Graphs of individual participants proximal muscle strength. 
(Error bars denote means and standard deviations). 
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3.5.5 Functional Ability 
The functional outcome measures used were able to detect significant 
differences between the two groups (p< .05). The outcome measures 
demonstrated that mitochondrial patients performed the functional tasks slower 
than the control group and walked a shorter distance over 6 minutes (Table 3-6, 
Figure 3-4). 
Table 3-6: Functional outcome measure results of control and mitochondrial 
patients. 
(MD, Mitochondrial Disease).Data is reported as medians (quartiles). ** p<.01, 
*p<.05 
Variable 
Median (Quartiles) p-values 
Control  MD 
MD-
control  
5 times Sit to Stand  
(secs) 
7 (6, 8) 12 (9, 13) < .001** 
Timed up and Go 
 (secs) 
7 (6, 7) 8 (7, 10) .001** 
10m timed walk  
(secs) 
7 (6, 7) 8 (7, 8) .006** 
6 minute walk 
distance (metres) 
500 (476, 535) 430 (361, 508) .013* 
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Figure 3-4: Graphs of individual performances of functional outcome measures.  
(Error bars denote means and standard deviations). 
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3.5.6 The relationships between biological, clinical and functional 
measures in patients with mitochondrial disease 
Correlations were performed between the three types of measures chosen 
(disease burden, exercise capacity and functional ability) to identify 
relationships between measures. First to be explored were the relationships 
between disease severity and the exercise and functional measures. The 
results of these initial correlations demonstrated that functional measures 
produced moderate correlations with disease severity; therefore further 
correlations were performed between the functional measures to assess if the 
functional measures used showed relationships with each other. The same 
procedures were repeated with the exercise measures. As multiple 
comparisons were performed statistical significance was assumed when the p 
value < .01. 
 Associations between disease severity, physical activity, functional capacity and 
exercise performance 
A direct relationship was seen between the two measures of disease severity 
(mitochondrial mutation load and disease severity measured using the NMDAS), 
demonstrating that an increase in disease burden was shown with an increased 
mutation load (r=0.6, p= .001). 
Disease severity using both the clinical disease scale (NMDAS) and mutation 
load showed moderate correlations with number of steps taken in a day, with 
increased disease severity showing a reduction in daily steps (NMDAS vs. daily 
step count; r =-0.6, p= .003**, mutation load vs. daily step count r =-0.5, 
p= .017*). Although, no relationship was demonstrated between disease 
severity and physical activity when energy expenditure is used as a variable 
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(NMDAS; r = 0.04, p= .854, mutation load r = 0.2, p= .352). Due to the 
discrepancy in the relationships between the two measures of physical activity 
and disease severity, further correlations were performed showing only a 
moderate relationship between the two measures of physical activity (step count 
vs. energy expenditure; r = 0.6, p= < .001).  
When investigating the two measures of disease severity and exercise and 
functional measures no relationships were evident between mutation load and 
any of the exercise and functional parameters measured, except the TUG 
(r=0.5)(Table 3-7) 
Table 3-7: Relationships between mutation load (heteroplasmy) and measures of 
physical activity, exercise capacity and functional outcome measures.  
Significant results are denoted in bold. 
Domain  Parameter Correlation coefficient  
(p value) 
Physical Activity 
Energy expenditure  0.2 (.352) 
Steps taken per day  -0.5 (.017)* 
   
Exercise capacity 
vO2PEAK (ml.kg.min) -0.2 (.430) 
Anaerobic threshold 
(ml.kg.min) 
-0.1 (.713) 
Peak workload (W/kg) -0.3 (.146) 
Arteriovenous difference  
(ml O2/dl) 
-0.2 (.317) 
   
Muscle Strength 
Hip flexor strength (nm/kg) -0.3 (.905) 
Hip extensor (nm/kg) -0.1 (.525) 
   
Functional Measures 
10m timed walk (secs) 0.3 (.172) 
Timed up and Go (secs) 0.5 (.020)* 
5 times sit to stand (secs) 0.3 (.162) 
6 minute walk distance (secs) -0.2 (.329) 
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Disease severity when measured using the Newcastle Mitochondrial Disease 
Adult Scale (NMDAS) showed relationships with all exercise parameters 
investigated, with peak workload (nm/kg) showing the strongest correlation (r = -
0.6, p = .001). These associations demonstrated that exercise capacity reduced 
with increased disease severity. Moderate relationships were also evident 
between clinically measured disease severity (NMDAS) and all functional 
outcomes except the 5 times sit to stand (5XSTS). Whereas hip muscle 
strength correlated poorly with disease severity (NMDAS) (r=0.3). 
These correlations are represented graphically in Figure 3-5 and are 
summarised in Table 3-8.  
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Figure 3-5: Scatterplots of the relationships between disease severity and exercise parameters. 
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Table 3-8: The relationships between disease severity, physical activity, exercise 
capacity and functional outcome measures. 
*p< .05, ** p< .01. Statistical significant results are shown in bold type.  
Domain Parameter 
NMDAS vs domain 
Correlation coefficient            
(p value) 
Physical Activity 
Energy Expenditure 0.04 (.854) 
Steps taken per day -0.6 (.003)** 
   
Exercise capacity 
?̇?O2PEAK (ml.min.kg) -0.5 (.015)* 
Anaerobic Threshold (ml.min.kg) -0.4 (.035)* 
Peak workload (Watts) -0.5 (.013)* 
Peak workload (W/kg) -0.6 (.001)** 
Arteriovenous difference (ml O2/dl) -0.5 (.019)* 
   
Muscle strength 
Proximal hip muscle strength 
(nm/kg) 
-0.3 (.136) 
   
Functional measures 
5 times sit to stand (secs) 0.3 (.266) 
Timed up and go (secs) 0.6 (.001)** 
10m timed walk (secs) 0.6 (.001)** 
6 minute walk distance (m) -0.5 (.018)* 
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 Associations between exercise parameters and physical activity  
Peak exercise capacity showed a direct relationship with both step count and 
energy expenditure as measures of physical activity (steps r = 0.7, p < .001**, 
energy expenditure r = 0.6, p = .006**). Demonstrating mitochondrial patients 
with higher physical activity levels had a greater exercise capacity. 
As all exercise parameters had demonstrated similar correlations to disease 
severity and physical activity, further investigations were undertaken to assess 
the relationships between these exercise parameters. The results demonstrated 
that all exercise parameters correlated strongly with each other (r ≥ 0.7) (Table 
3-9). 
Table 3-9: Relationships between measures of exercise performance.  
Correlation coefficients (p values) ** p< .01.Statistically significant results are 
shown in bold type. 
Exercise parameter 
 
?̇?O2PEAK 
(ml.min.kg) 
Anaerobic 
Threshold 
(ml.min.kg) 
Peak workload 
(w/kg) 
Arteriovenous 
difference 
(ml O2/dl) 
?̇?O2PEAK (ml.min.kg)  0.9 (< .001)** 0.9 (< .001)** 0.8 (< .001)** 
Anaerobic Threshold 
(ml.min.kg) 
  
0.8 (< .001)** 0.8 (< .001)** 
Peak workload (w/kg)    0.7 (< .001)** 
 Associations between Functional outcome measures and physical activity 
Functional outcome measures also demonstrated relationships with the daily 
step count (Timed up and go, r =-0.5, p = .009**, 10 m timed walk r =-0.5, p 
= .019*), although this relationship was not replicated when considering energy 
expended (r< 0.4). As all but one of the functional measures had demonstrated 
similar relationships between disease severity and physical activity, further 
correlations between the functional measures were also performed. 
Unsurprisingly all the walking tests showed strong relationships with each other. 
Whereas the 5 times sit to stand test only showed an association with the 
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Timed up and go test. This is also unremarkable as both measures include the 
sit to stand movement (Table 3-10). 
Table 3-10: Relationships between functional walking tests.  
Correlation coefficients (p values) *p< .05 ** p< .01. Statistically significant results 
are shown in bold type. 
Walking Test 
Timed up 
and go 
10m timed walk 
(single) 
6 minute walk 
distance 
5 times sit to 
stand 
Timed up and go  0.8 (<.001)** -0.6 (.001)** 0.6 (.003)** 
10m timed walk    -0.9 (<.001)** 0.4 (.038)* 
6 minute walk 
distance  
   -0.3 (.142) 
 Associations between physiological and functional measures 
To investigate the relationships between the exercise and functional measures 
further correlations were performed and are summarised in Table 3-11. Strong 
relationships were seen between proximal muscle strength and all exercise 
parameters (r ≥ 0.7). The only significant relationship between proximal muscle 
strength and functional measures was demonstrated with the 6-minute walk 
distance (r = 0.6). These results demonstrate that the mitochondrial participants 
with stronger proximal muscles or lower levels of myopathy had better exercise 
capacity and were able to walk further over 6 minutes. The remaining walking 
measures also showed significant relationships with the exercise measure of 
peak workload (Timed up and go; r = -0.5, 10 metre timed walk; r =-0.6, 6 
minute walk distance; r = 0.6).
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Table 3-11: Relationships between functional and exercise test parameters. 
(*p< .05, **p< .01). Statistically significant results (p< .01) are shown in bold type. 
 
Correlation coefficient (p value) 
Parameter ?̇?O2 PEAK 
(ml.min.kg) 
Arteriovenous difference 
(mlO2/dl) 
Peak workload 
(w/kg) 
Anaerobic threshold 
(ml.min.kg) 
Hip flexor strength 
(nm/kg) 
5 times sit to stand (secs)  -0.2 (.305) 0.1 (.811) -0.3 (.191) -0.1 (.597) -0.4 (.086) 
Timed up and go test (secs)  -0.4 (.049*) -0.1 (.524) -0.5 (.009**) -0.4 (.71) -0.4 (.099) 
10m timed walk (single) (secs) -0.4 (.037*) -0.3 (.232) -0.6 (.002**) -0.4 (.035*) -0.5 (.014*) 
6 minute timed distance (m) 0.4 (.030*) 0.4 (.074) 0.6 (.002**) 0.5 (.026*) 0.6 (.003**) 
Hip flexor strength (nm/kg) 0.8 (< .001**) 0.7 (.001**) 0.7 (< .001**) 0.8 (< .001**)  
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 Exploration of individual items of the Newcastle Mitochondrial Disease Adult Scale 
(NMDAS) relationships with exercise and functional measures 
As the NMDAS investigates many aspects of mitochondrial disease correlations 
for each sub section of the NMDAS were performed. This enabled investigation 
of the relationships between different aspects of mitochondrial disease and the 
measures performed in the study.  
The NMDAS scale consists of 29 questions, which represent different aspects 
of mitochondrial disease. These aspects are listed in the first column of Table 
3-12. Table 3-12 reports the highly significant correlations highlighted in bold 
text. From these correlations it can be seen that self-reported exercise tolerance 
showed a strong relationship with measured exercise capacity (peak workload; 
r=-0.8, p < .001, peak exercise capacity; r =-0.7, p < .001) and proximal muscle 
strength (r= -0.6, p = .002). With those mitochondrial patients reporting 
subjectively reduced exercise tolerance having reduced measured exercise 
capacity and proximal muscle strength. Reported exercise intolerance also 
showed a relationship with two functional measures; the 10m timed walk and 
the Timed up and go (r= 0.6, r = 0.5, p< .01). With those mitochondrial patients 
reporting impaired exercise tolerance taking longer to perform walking tasks.  
All the functional components of the scale (such as dressing and hygiene) 
showed associations with the walking outcome measures (r values from 0.5 - 
0.6). In addition the Timed up and Go demonstrated a relationship with 
cerebellar signs (r= 0.5, p < .01) and cognition (r= 0.5, p < .01). 
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Table 3-12: Correlations of individual sections of the Newcastle Mitochondrial Disease Adult Scale (NMDAS) with physiological and functional 
measures.  
(** p =0.01,*p=0.05). Statistically significant results are shown in bold text. (CPEO-Chronic Progressive External Opthalmoplegia).  
Spearman correlations (p value) 
NMDAS 
component 
Peak exercise 
capacity 
(ml.kg.min) 
Peak Workload 
(w/kg) 
Timed up and 
go (secs) 
10m timed walk 
(secs) 
6 minute walk 
distance (m) 
Hip flex 
strength 
(nm/kg) 
Five times sit to 
stand (secs) 
Total NMDAS -0.5*(.015) -0.6**(.001) 0.6**(.001) 0.6**(.001) -0.5*(.018) -0.3 (.136) 0.3 (.266) 
Vision -0.1 (.622) -0.1 (.447) 0.2 (.286) 0.4*(.044) -0.4 (.090) -0.1 (.561) 0.01 (.968) 
Hearing  0.1 (.770) 0.03(.860) 0.1 (.589) 0.1 (.605) 0.04 (.843) 0.1 (.662) -0.1 (.697) 
Speech -0.3 (.970) -0.5*(.015) 0.5*(.026) 0.5*(.022) -0.4 (.080) -0.3 (.241) 0.2 (.375) 
Swallowing 0.3 (.222) -0.2 (.435) 0.2 (.338) 0.3 (.210) -0.3 (.175) -0.3 (.215) 0.2 (.251) 
Handwriting -0.2 (.248) -0.5*(.026) 0.5*(.012) 0.6**(.003) -0.5*(.011) -0.3 (.223) 0.2 (.331) 
Cutting  -0.4 (.053) -0.5*(.024) 0.5*(.025) 0.5**(.008) -0.6**(.002) -0.5*(.012) 0.2 (.282) 
Dressing  -0.4 (.065) -0.5*(.026) 0.5**(.010) 0.5*(.010) -0.6**(.005) -0.5*(.027) 0.3 (.092) 
Hygiene -0.4 (.066) -0.5*(.029) 0.5**(.010) 0.5**(.010) -0.6**(.005) -0.5*(.030) 0.3 (.095) 
Exercise  -0.7**(<.001) -0.8**(<.001) 0.5**(.009) 0.6**(.001) -0.5*(.005) -0.6**(.002) 0.2 (.358) 
Gait -0.4*(.038) -0.5*(.013) 0.6** (.003) 0.5**(.009) -0.5*(.020) -0.4 (.099) 0.2 (.331) 
Psychiatric -0.3 (.103) -0.5*(.017) 0.3 (.164) 0.4 (.069) -0.2 (.322) -0.1 (.597) -0.02 (.941) 
Migraine -0.1 (.590) -0.1 (.627) -0.01 (.979) -0.2 (.320) 0.3 (.157) 0.3 (.161) -0.1 (.520) 
Seizures -0.4 (.071) -0.5*(.017) 0.5*(.012) -0.4*(.032) -0.4*(.047) -0.3 (.274) 0.3 (.169) 
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Spearman correlations (p value) 
NMDAS 
component 
Peak exercise 
capacity 
(ml.kg.min) 
Peak Workload 
(w/kg) 
Timed up and 
go (secs) 
10m timed walk 
(secs) 
6 minute walk 
distance (m) 
Hip flex 
strength 
(nm/kg) 
Five times sit to 
stand (secs) 
Stroke like episodes 0.1 (.595) 0.2 (.413) -0.1 (.692) -0.01 (.966) 0.1 (.486) -0.2 (.466) 0.1 (.513) 
Encephalopathic 0.1 (.613) 0.2 (.416) -0.1 (.686) -0.02 (.920) 0.2 (.445) 0.2 (.450) 0.1 (.543) 
Gastro-intestinal -0.2 (.368) 0.1 (.501) -0.3 (.192) -0.4 (.053) 0.4 (.090) 0.02 (.926) -0.2 (.360) 
Diabetes 0.3 (.173) 0.2 (.389) -0.01 (.942) 0.03 (.906) -0.01 (.972) 0.1 (.525) -0.03 (.883) 
Respiratory 0.1 (691). 0.1 (.763) -0.3 (.175) -0.1 (.643) -0.03 (.907) -0.1 (.687) 0.1 (.799) 
Cardiovascular -0.2 (.389) -0.2 (.264) 0.4*(.029) 0.4*(.028) -0.5*(.013) -0.3 (.137) -0.3 (.103) 
Visuals -0.3 (.129) -0.4 (.069) 0.3 (.215) 0.4 (.058) -0.4*(.083) -0.3 (.173) -0.1 (.812) 
Ptosis 0.2 (.289) -0.1 (.810) -0.1 (.695) -0.2 (.402) 0.2 (.259) -0.1 (.809) -0.1 (.540) 
CPEO -0.4*(.047) -0.3 (.108) 0.4 (.089) 0.4 (.080) -0.4 (.052) -0.4 (.053) 0.1 (.525) 
Dysphonia/Dysarthria -0.3 (.152) -0.5*(.020) 0.3 (.096) 0.4*(.046) -0.4*(.035) -0.3 (.212) 0.1 (.592) 
Myopathy -0.5*(.019) -0.5*(.023) 0.2 (.247) 0.4 (.056) -0.3 (.223) -0.5*(.038) 0.1 (.623) 
Cerebellar -0.3 (.123) -0.4 (.060) 0.5**(.008) 0.4*(.047) -0.4 (.072) -0.3 (.224) 0.1 (.572) 
Neuropathy -0.4 (.052) 0.5 (.011) 0.5*(.002) 0.5*(.014) -0.4 (.072) -0.4 (.073) 0.5**(.008) 
Pyramidal -0.1 (.762) -0.02 (.920) 0.2 (.477) 0.1 (.686) 0.01 (.960) 0.04 (.863) -0.1 (.762) 
Extrapyramidal -0.1 (.727) -0.1(.522) 0.3 (.132) 0.3 (.097) -0.3 (.113) -0.1 (.522) -0.02 (.922) 
Cognition -0.4*(.04) -0.5**(.008) 0.5**(.007) 0.5*(.016) -0.3 (.103) -0.2 (.418) 0.3 (.114) 
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 Discussion  
The key findings of the study were that both exercise and functional measures 
were able to differentiate between participants with mitochondrial disease and 
sedentary controls; with disease severity demonstrating strong relationships 
with both exercise and functional measures. In addition this study demonstrated 
that dynamometry was able to detect impaired proximal muscle strength and 
this reduction in strength had a strong relationship with the peak exercise 
performance of participants with mitochondrial disease. Finally the study 
confirmed previous findings that the level of mitochondrial mutation load related 
to disease severity, exercise capacity and daily activity levels (Chinnery et al., 
1997; Jeppesen et al., 2003; Taivassalo et al., 2003; Whittaker et al., 2009; 
Apabhai et al., 2011). 
3.6.1 Physical Activity  
Despite the level of physical activity not being a primary hypothesis of this study 
discussion of the differences demonstrated between the activity levels of the 
two groups is essential, as the low levels of physical activity are likely to impact 
on the levels of exercise capacity and potentially the functional ability of 
participants with mitochondrial disease.  
This study reported that patients with mitochondrial disease had low levels of 
day-to-day physical activity when measured objectively. This finding is in line 
with previous studies in people with mitochondrial and other neuromuscular 
conditions and is related to disease severity (Phillips et al., 2009; Tudor-Locke 
et al., 2009; Apabhai et al., 2011). Levels of physical activity reported in this 
study in the mitochondrial group also related to the level of peak exercise 
capacity. It is not possible to report that the lower activity levels in the 
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mitochondrial patients resulted in reduced exercise capacity, although previous 
exercise studies have indicated that the exercise capacity within a mitochondrial 
population can be improved with increased activity in the form of exercise 
(Taivassalo et al., 2001; Pilar et al., 2005; Jeppesen et al., 2006b). 
A study by Apabhai et al investigating physical activity in a larger cohort of 
patients with mitochondrial disease participants reported low levels of physical 
activity alongside increased obesity (Apabhai et al., 2011). This finding was not 
replicated in this study where the group with mitochondrial disease did not show 
signs of obesity and in fact had significantly lower BMI’s than the control group. 
The difference in weight between the two studies of patients with mitochondrial 
disease is probably due to the restriction in this study to two specific genotypes, 
level of disease burden and sample size. The population used in this study was 
smaller than in the study by Apabhai et al and hence may not be representative 
of the total population of mitochondrial disease patients. Gastro intestinal 
symptoms are a common feature of patients with the m.3243A>G genotype 
(Chinnery et al., 1997) and were noted in ten of our participants with this 
genotype, which also may have contributed to a lower weight in this study’s 
population. In addition the mitochondrial population used in this study were all 
independently ambulant which may have resulted in lower body mass. From the 
results of this study it is impossible to ascertain whether the lower weight of 
participants reported in this study was due to the higher disease burden, or type 
of mitochondrial genotype.  
It is already known that low levels of physical activity are detrimental in people 
with neuromuscular disease who are at increased risk of coronary heart disease, 
obesity, osteoporosis and depression (McDonald, 2002 ; Abresch et al., 2009 ). 
Increased activity has specific disease benefits for patients with mitochondrial 
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disease over and above the known general health benefits. These benefits 
include increased to mitochondrial biogenesis in muscle (Taivassalo et al., 
2001), improved heart function (Bates et al., 2013) and improved quality of life 
(Taivassalo et al., 2006). The reasons for reduced physical activity in 
mitochondrial disease are likely to be multifactorial and require further 
investigation to fully understand the relationship between disease burden and 
daily physical activity. Understanding this relationship may enable more 
appropriate interventions to be developed to increase physical activity in this 
group and ameliorate the effects of reduced levels of physical activity. 
3.6.2 Disease severity and exercise capacity  
Disease severity in this study was reported in two ways; by use of Newcastle 
Mitochondrial Disease Adult Scale (NMDAS) (Schaefer et al., 2006) and % 
mitochondrial mutation load in epithelial cells of urine (Whittaker et al., 2009). 
The relationship between disease severity and mutation load is in agreement 
with previous work that reported an increased mutation load associated with 
increased disease severity, reduced oxidative capacity (Jeppesen et al., 2003; 
Jeppesen et al., 2006a) and increased clinical features in mitochondrial disease 
(Chinnery et al., 1997). However the relationship is only moderate and therefore 
does not tell the full story. This is highlighted in two participants from this study 
who had the lowest disease severity scores (NMDAS) despite having very 
different mutation loads, one being 34% and the other 80%. The presence of 
clinical features in this study group at low mutation levels also supports previous 
findings that reported symptoms at mutation loads as low as 40% in the 
m.3243A>G mutation (Jeppesen et al., 2006a). These findings support the 
adoption of a cautious approach when trying to predict clinical severity by 
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mutation load alone, as mutation levels vary from tissue to tissue and genotype 
to genotype (DiMauro and Schon, 2003). 
Comparing disease severity and exercise capacity in this study to previous 
exercise studies is difficult. This is because previous studies included either 
multiple genotypes with a wide variety of mutation loads and clinical features, or 
very small numbers of patients with one genotype (large-scale single deletion) 
(Jeppesen et al., 2003; Taivassalo et al., 2003; Trenell et al., 2006). Our 
participants despite being recruited to take part in an exercise study had 
relatively high mutation levels ranging from 22 to 94%. These mutation levels 
are similar to previous studies that report mutation loads (Taivassalo et al., 
2003; Jeppesen et al., 2006a) and are more reflective of the clinical caseload 
seen in our clinics than some previous studies, as none of the participants had 
extremely low mutation loads and non were asymptomatic (Jeppesen et al., 
2006b).  
The restriction to two genotypes follows recommendations made in the recent 
Cochrane review to reduce the number of genotypes within studies in 
mitochondrial disease (Pfeffer et al., 2012). Despite restricting the study to two 
genotypes the variability in symptoms and exercise performance reported 
remained as high as previous exercise studies with a wider range of genotypes. 
The wide variety of performance was disappointing but highlights the variability 
of disease burden and clinical features within genotypes and confirms the 
previously reported differences between genotypes (Taivassalo et al., 2003; 
Cejudo et al., 2005).  
The lower peak exercise capacity (58% vs. 92%), anaerobic threshold (36% vs. 
54%) and arteriovenous oxygen difference reported in this study’s patient group 
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support the findings of previous studies and indicate a reduction in 
mitochondrial function in the muscles of patients with mitochondrial disease 
(Taivassalo et al., 2003). These lower results are due to muscles reverting to 
non-aerobic methods of energy production earlier in exercise testing as the 
mitochondrial respiratory chain fails to keep up with the energy requirements of 
the cell placed upon it by exercise. The exercise response seen in patients 
replicated previously reported linear responses of increased oxygen 
consumption with increasing workload with the limiting factor being oxygen 
extraction (Taivassalo et al., 2003). It is difficult to ascertain how much of the 
reduction in exercise performance can be attributed to the primary biological 
deficit as the mitochondrial group also reported lower levels of physical activity. 
Therefore some impairment in exercise capacity is likely to be due to 
deconditioning. 
This study demonstrated that objectively measured exercise capacity had a 
moderate relationship with self-reported exercise capacity, myopathy, chronic 
progressive external ophthalmoplegia and gait, within the disease severity scale. 
This is unsurprising as all are muscle related symptoms. These findings support 
the continued use of exercise testing as a non-invasive measure of 
mitochondrial function within muscle in the mitochondrial disease population. 
Widespread adoption of exercise testing is however hampered, as facilities and 
expertise are limited to specialist centres. 
In summary the exercise capacity of subjects with mitochondrial disease in this 
study was similar to previous studies. Despite the cohort not including 
candidates with low mutation loads and only including patients with two 
genotypes with demonstrable clinical signs of disease, no reduction in the 
variability of exercise response was reported. Lower activity levels in the 
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mitochondrial group may have also further attenuated the exercise performance 
within the patient group compared to controls. Therefore the current treatment 
advice given to mitochondrial patients to participate in regular exercise should 
continue, as physical activity has been shown to improve exercise capacity and 
reduce exacerbation of muscle symptoms due to de-conditioning. 
3.6.3 Disease severity and functional ability  
Alongside exercise capacity this study investigated the use of clinically based 
functional outcome measures in participants with mitochondrial disease. 
Functional outcome measures are frequently used to evaluate therapy by 
physiotherapists (Yoward et al., 2008). Functional outcome measures have 
been used in numerous studies involving neurological, neuromuscular and 
elderly populations, to measure a variety of parameters from motor impairment 
and functional mobility to disease severity and also to predict future disability 
(Takeuchi et al., 2008; Ries et al., 2009; McDonald et al., 2010). Functional 
outcome measures are being shown to be reliable in an increasing number of 
neurological and neuromuscular conditions (Steffen et al., 2002; Flansbjer et al., 
2005; Andersson et al., 2006; Katz-Leurer et al., 2008; McDonald et al., 2010) 
and their ease of use (Whitney et al., 2005) in both the clinical and research 
setting make investigation of their possible use in mitochondrial disease 
imperative. 
Many outcome measures are available for use in the clinical and research areas 
in neurological conditions. The measures used in this study were chosen 
because they were clinically relevant to this population and are commonly used 
by physiotherapists working in Neurology (Yoward et al., 2008). In this study all 
the Functional Outcome Measures (FOM) used were able to detect differences 
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between the participants with mitochondrial disease and controls. Three of the 
FOMs used in this study involved walking and therefore unsurprisingly 
demonstrate strong relationships with each other. Strong relationships were 
also demonstrated between the sit to stand measure and the Timed up and go, 
which both contain the movement of sit to stand. The 10m timed walk and the 
Timed up and go test in this study demonstrated very strong correlations with 
the total disease severity score, exercise capacity (measured and reported) and 
functional tasks within the Newcastle Mitochondrial Disease Adult Scale. In 
addition the Timed up and go showed an association with Cerebellar symptoms 
in the scale. For each outcome measure the following paragraphs will discuss 
their previous use and the results of this study. 
The Timed up and go was originally used to test functional mobility in the elderly 
frail population (Podsiadlo D et al., 1991 ) and provided timed cut-offs for 
independent living. As the measure included a move from sitting to standing 
and a change of direction it was thought to also test elements of balance ability 
and has been used to assess patients risk of falling (Shumway-Cook et al., 
2000). These attributes support the finding in this study of a relationship 
between cerebellar signs and the Timed up and go. Unfortunately no other 
balance tests were performed in the study due to time constraints so this 
observation cannot be confirmed. The TUG has been shown in other 
populations to assess balance (Brusse et al., 2005; Katz-Leurer et al., 2008; 
Schepens et al., 2010), but further studies are required comparing this measure 
with other methods of assessing balance to confirm this in a mitochondrial 
population.  
The 10m Timed Walk has been used previously to calculate gait speed and has 
been described as an almost perfect measure (Wade, 1992 ). Many 
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neurological and neuromuscular populations have used this measure and have 
reported relationships to lower limb strength (Scott et al., 1982) community 
ambulation (Busse et al., 2006; Vandervelde et al., 2009) and subsequent 
disability (Guralnik et al., 2000; Studenski et al., 2003). Despite the strong 
correlations with disease severity and exercise capacity this study failed to 
demonstrate any relationship between gait speed and muscle strength when 
measured by dynamometry or reported muscle strength in the disease scale. 
This conflicting finding may be due to the multitude of symptoms seen in this 
cohort of mitochondrial patients (Table 3-1). It may also be that muscle 
weakness is not such a prominent symptom as reported in other neuromuscular 
conditions such as Spinal muscle atrophy and the muscular dystrophies and 
also not the primary cause for reduced function (Scott et al., 1982; Merlini et al., 
2004). 
The 6-minute walk distance was able to discriminate between the two groups 
but showed weaker relationships with disease severity and only correlated 
significantly with peak exercise workload and proximal muscle strength. The 6-
minute walk distance was originally devised as a field test for exercise capacity 
(Society, 2002) and is described as a non-specific and non-diagnostic test 
which can be used in a multitude of conditions. The 6-minute walk distance 
(6MWD) has been used in numerous neuromuscular trials to measure a variety 
of parameters including disease progression, exercise capacity, functional 
mobility and fatigue (Takeuchi et al., 2008; Montes et al., 2010; Hashizume et 
al., 2012). It has been  reported to evaluate the global and integrated response 
of all body systems involved in walking, including neuromuscular, pulmonary, 
and cardiovascular systems and is therefore considered to be a valid clinical 
endpoint in neuromuscular studies (Florence et al., 2008; Montes et al., 2010; 
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McDonald et al., 2013; Willis et al., 2013). The lack of strong relationships 
between the 6MWD and exercise parameters in this study was unexpected 
given the original use of the measure. Possible explanations for this result may 
have been: that only one attempt at the 6 minute walk test was completed, this 
was despite knowing that an increased distance is usually covered on a second 
attempt (2002). Also the mitochondrial group may have performed the walk at a 
lower self-selected speed to prevent any negative effects they may have 
previously experienced when walking long distances. Only one test was 
performed in this study to reduce the risk of fatigue affecting subsequent trials in 
the MD group. The performance of one attempt of the 6-minute walk was 
justified, as it is in line with previous studies in neuromuscular conditions where 
fatigue is perceived as a limiting factor (Andersson et al., 2006; Montes et al., 
2010). To ensure a maximal performance of a 6-minute walk in this disease 
group with only one attempt future studies may require additional 
encouragement to obtain an accurate result (McDonald et al., 2010; Lerario et 
al., 2012).  
Despite the 6-minute walk test taking more time, requiring more space to 
perform and producing similar results to the other walking tests it is not 
superfluous. The 6-minute walk test did show a stronger relationship to muscle 
strength than the other functional tests, which is in line with previously reported 
studies in other neuromuscular diseases (Lerario et al., 2012).  
As proximal myopathy is a common symptom reported in studies of these two 
genotypes (Chinnery et al., 1997) a functional activity was chosen that 
measured lower limb strength. This was a measure of the movement from sit to 
stand, which requires greater lower limb strength than walking and stair 
climbing (Berger et al., 1988). This study demonstrated that participants with 
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mitochondrial disease had weaker hip muscles and were significantly slower to 
get in and out of a chair. Despite these findings the two measures only 
demonstrated a weak relationship to each other and reported muscle strength 
within the NMDAS. The failure of the 5 times sit to stand test to demonstrate a 
relationship with any aerobic exercise measures is unremarkable as this test is 
reported to measure lower limb strength. However it was surprising that only a 
weak relationship was demonstrated to proximal muscle strength, which 
conflicts with previous work investigating the sit to stand movement (Nitz et al., 
1997; Inkster et al., 2003). A possible explanation for this lack of a relationship 
may be due to the sit to stand motion being more than just a measure of lower 
limb strength, but also a measure of the efficiency of other systems such as 
balance and sensation in providing constant feedback throughout the sit to 
stand movement (Lord et al., 2002). All of these systems can be affected in this 
disease group and may have had a bearing on the results.  
In summary functional outcome measures were able to discriminate between 
the mitochondrial disease and control groups. They were quick and easy to 
perform and showed good relationships to disease severity in mitochondrial 
patients. The variety of relationships reported between functional and exercise 
measures used in this study highlight that these outcomes appear to measure 
different aspects of mitochondrial disease. With functional measures allowing 
measurement of impairment in multiple systems simultaneously whereas 
physiological measures likely to be limited to measuring one specific system. 
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3.6.4 Proximal muscle strength 
Although proximal myopathy is a common symptom of mitochondrial disease 
this is the first study to show that the muscle strength was nearly 50% lower 
within the mitochondrial group compared to a disease free control group. 
The use of dynamometry to measure muscle strength was developed in 
orthopaedic conditions and is seen as the gold standard for measuring muscle 
strength. Normative values of dynamometry values for hip muscle strength are 
limited and previous work has reported variable reproducibility (Burnett et al., 
1990; Boling et al., 2009; Julia et al., 2010). Although no previous studies to our 
knowledge report measuring hip muscle strength in mitochondrial disease, 
dynamometry has been used in other neuromuscular (Burnett et al., 1990; 
Tiffreau et al., 2007) and elderly populations (Bohannon, 1998). The use of 
dynamometry in other neuromuscular diseases has demonstrated that it is 
capable of; i) measuring the extremely low torques produced by participants 
with severe muscle disease, ii) disease progression and, iii) relate to functional 
abilities (Tiffreau et al., 2007; Lerario et al., 2012; El Mhandi and Bethoux, 
2013). To overcome the lack of comparable data this study included a control 
group of comparable age. Both disease and control groups performed the same 
protocol in a lying as opposed to standing and were assessed by the same 
tester at a similar time of day (Julia et al., 2010; Maffiuletti, 2010). 
The strong relationship between exercise capacity and strength reported in this 
study has been seen previously in mitochondrial patients where improvements 
in muscle strength were reflected in improvements in peak exercise capacity 
(Murphy et al., 2008). Results from this study demonstrate that limitations in 
peak exercise capacity in mitochondrial patients may not be solely due to 
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aerobic capacity and impaired mitochondrial function but also reduced muscle 
strength. It should be noted that the strong relationship between proximal 
muscle strength and peak exercise capacity may have been heightened by the 
use of a recumbent bike, which required increased muscle strength when 
reaching higher wattages (Walsh Riddle and Blumenthal, 1989 ). These results 
highlight that the relationship between aerobic and strength performance of 
muscles in MD patients requires further investigation. 
Unfortunately the study was unable to demonstrate a relationship between 
measured muscle strength using dynamometry and clinical testing of muscle 
strength recorded within the NMDAS. Muscle strength in the disease severity 
scale was measured using manual muscle testing (Frese et al., 1987). 
Differences in accuracy between the two methods of muscle testing may 
explain why no relationship was demonstrated. Previous studies have reported 
that patients can lose up to 50% of muscle power and still be reported as having 
normal muscle strength on clinical testing (Watkins et al., 1984; Sapega, 1990). 
These findings are in agreement with the results, of this study where a great 
variability in proximal muscle strength was seen using dynamometry, yet all MD 
participants reported muscle strength of grade 4 or above on manual muscle 
testing, where a score of 5 is normal. 
As reported in the previous section a moderate relationship was seen between 
muscle strength and only one functional measure(6MWD), despite two 
functional tests (TUG and 5XSTS) including a movement of sit to stand which 
requires an increased lower limb strength (Berger et al., 1988). Reasons for the 
poor correlations between tests with a sit to stand component and hip strength 
are likely due to the Timed up and go test allowing the use of upper limbs which 
will compensate for lower limb weakness and, considerable loss of power being 
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required prior to a loss of function being observed (Lexell, 2000). Also as 
discussed in the previous section, although the sit to stand test has been 
reported to be a functional marker of lower limb strength in the elderly, or 
people with proximal myopathy (Bohannon, 1995; Jones et al., 1999; Merlini et 
al., 2004; Busse et al., 2006) the sit to stand movement is more complicated 
than originally thought and requires the integration of balance systems, muscle 
power and sensory feedback to perform efficiently (Lord et al., 2002). These 
systems are likely to be affected in patients with mitochondrial disease and 
impact on the sit to stand movement. Therefore the poor relationship with lower 
limb strength and functional tests is unsurprising. The poor correlation 
demonstrates that reduced muscle power is not the primary contributor to 
difficulties in performing the sit to stand movement and it is likely that patients 
adopt compensatory mechanisms to allow them to continue to perform the 
functional task of sit to stand.  
In summary, although the measurement of muscle strength by dynamometry is 
considered a gold standard, further work is required to establish robust 
normative values and verify its reproducibility in the testing of hip muscles. The 
use of dynamometry in research investigating the muscle strength of 
neuromuscular conditions should be continued due its high levels of precision 
(Boling et al., 2009), reliability (Julia et al., 2010) and its ability to measure 
muscle strength over a wide range of ability (Tiffreau et al., 2007). It should be 
borne in mind that measurement of muscle strength provides limited information 
on the functional consequences of muscle weakness. Finally the use of 
dynamometry in a clinical setting is limited due to expense and limitations in 
space. Consequently other methods of measuring muscle strength, such as 
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hand held dynamometry may need to be considered for more inclusive trials 
(Reed et al., 1993).
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 Limitations 
Although this study is one of the largest studies into the exercise capacity of a 
clinically affected group of mitochondrial patients with to two specific genotypes, 
the sample size remains small. The sample size was chosen to detect a change 
in exercise capacity in a population with mitochondrial disease following an 
exercise study, not to detect between group differences, which may have 
required a larger sample size. The restriction to only two genotypes 
unfortunately did not reduce the heterogeneity in the mitochondrial patient’s 
performance of both exercise and functional tests. Despite the levels of 
heterogeneity reported, this study was still able to demonstrate differences 
between the two groups. The variety of responses reported in the study is 
unavoidable in such a heterogeneous disease and is acceptable as it reflects 
the true nature of the disease presentation in these two genotypes. 
Mitochondrial disease remains a rare condition and therefore an increase in 
numbers would only have been possible with the inclusion of multiple sites, 
which was beyond the scope and funding of this study.  
A potential bias in the mitochondrial population studied may have occurred as 
the participants were recruited as part of a study investigating cardiac 
adaptations to an aerobic training programme and therefore participants had to 
be capable of completing a 4 month training programme independently. These 
inclusion requirements may have resulted in a high functioning sub-set of 
patients being included, although this is not reflected in the high mutation levels 
and low levels of daily activity reported in this study’s population.  
The low levels of physical activity in the mitochondrial population resulted in the 
two groups having very different levels of daily physical activity. The difference 
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between the group’s activity levels was difficult to overcome due to the severely 
low levels of activity in some of the mitochondrial population, which is typical of 
this disease. Controlling for the low levels of activity would have been 
inappropriate due to the small numbers included in the study.  
The number of correlations performed on the sub sections of the disease 
severity scale resulted in multiple comparisons being performed, which may 
have resulted in some spurious results due to type 1 error. The number of 
comparisons could have been reduced by choosing only the subsections 
thought to relate to functional and exercise data, but for completeness it was felt 
that inclusion of all comparisons was more transparent. To overcome spurious 
results the significance value was increased to a p value of <.01.  
The extensive protocol and high participant burden meant that it was not 
possible to assess the reliability of functional measures in this population, 
although they have all been shown to be reliable in other populations (Tyson 
and Connell, 2009). To ensure maximum reproducibility of tests in this study the 
same practitioners performed all the tests, they were performed at a similar time 
of day and all exercise tests were analysed by one exercise physiologist.  
This study tested lower limb functional tests and no testing of upper limb 
function was possible due to time constraints. It was, however, interesting to 
note that functional tasks using upper limbs in the disease severity scale 
(handwriting, dressing) related to the walking tests. This is likely to be due to the 
global nature of functional tests and mitochondrial disease.
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 Conclusions  
In summary this data shows that exercise and functional measures are able to 
detect impaired performance of exercise and functional tasks in mitochondrial 
patients with these two specific genotypes. The functional measures showed 
relationships with exercise capacity and disease severity. Further investigation 
into these measures is required to assess their reliability, sensitivity and 
reproducibility over time. The use of functional measures within a clinical 
situation is possible due to the lack of specialist equipment required and the 
speed of execution. Future use of functional measures in clinical settings will 
provide additional information concerning disease severity and the impact of 
mitochondrial disease on our patient’s daily lives.  
Taken in combination, these data suggest that clinical care teams should 
explore the utility of functional outcome measures in routine clinical assessment 
as a means to better understand the functional impact of mitochondrial disease.
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Chapter 4 Gait characteristics in mitochondrial 
disease. A cross sectional study of two 
mitochondrial genotypes
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 Introduction  
Mitochondrial disease as described previously is a disease that has multisystem 
involvement which results in symptoms such as muscle weakness, pain, cardiac 
impairment, fatigue, ataxia, and visual disturbance. The varied presentations of 
symptoms have made study of disease progression and the effect of 
interventions difficult. The multitude of symptoms seen in mitochondrial 
diseases has led to characterisation of different phenotypes into syndromes 
such as MELAS (mitochondrial encephalopathy lactic acidosis and stroke-like 
episodes syndrome) and MERRF (myoclonic epilepsy with ragged red fibres) or 
by genetic mutation (m.3243A>G and m.8344A>G). These characteristics 
however are of little benefit to the patient or clinician in predicting the course of 
the disease due to the heterogeneity between genotype and phenotype.  
Clinical measures used currently are unable to accurately discriminate between 
levels of heteroplasmy and genotype and therefore are of limited use in 
understanding disease progression, underlying pathology and the benefits of 
interventions. A recent Cochrane review concurred with this opinion reporting 
that the wide variety of outcomes used in clinical trials limited the comparability 
of trials and that the outcomes used provided no evidence to support the use of 
any intervention in mitochondrial disease (Pfeffer et al., 2012). 
Symptoms such as myopathy and exercise intolerance have  previously been 
measured in studies in mitochondrial disease (Jeppesen et al., 2003; 
Taivassalo et al., 2003), whereas fatigue, although a prominent feature of 
mitochondrial disease affecting between 20-60% of patients has had limited 
research (Mancuso et al., 2012; Gorman et al., 2015). The definition of fatigue 
encompasses concepts such as tiredness and clinically relevant symptoms 
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such as exercise intolerance and muscle fatigue. Fatigue is a complex, multi-
faceted symptom that encompasses physical, central, and general fatigue. Due 
to its complex and subjective nature fatigue remains difficult to evaluate. 
Gait is becoming a useful tool in identifying markers of pathology, disease 
progression and in measuring the efficacy of interventions (Lord et al., 2013a). 
Discrete features of gait, such as stride-to-stride variability, are highly sensitive 
to aging, pathology and early (pre-clinical) symptoms (Baltadjieva et al., 2006; 
Verghese et al., 2007; Rochester et al., 2012; Rochester et al., 2014b). To date, 
however, no detailed investigation of gait in patients with mitochondrial disease 
has been performed. Therefore this study provides a preliminary investigation 
into the use of gait measures in two mitochondrial genotypes. The study 
investigates whether gait characteristics relate to genotypes, heteroplasmy and 
disease burden, and then assesses whether gait characteristics are altered with 
the addition of a secondary task or fatigue. The results may provide a robust 
and sensitive measure of pathology, disease burden and treatment efficacy in 
this disease that will be useful to researchers and clinicians alike.
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 Study aims and hypotheses  
 Aims  
1. To describe the pattern of gait impairments within two genetic types of 
mitochondrial disease (m.3243A>G and m.8344A>G). 
2. To explore the relationships between gait characteristics, disease 
severity and other measures of physical performance such as exercise 
capacity and strength. 
 Primary Hypothesis  
Gait characteristics will differ between mitochondrial and control groups. 
 Secondary hypotheses 
1. The pattern of gait impairments will differ between the two genotypes. 
2. Gait characteristics will be associated with underlying markers of disease 
severity (e.g. heteroplasmy) and its pathological consequences (e.g. 
proximal myopathy and ataxia). 
3. Gait characteristics will be able to indicate fatigue within mitochondrial 
participants.
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 Subject and Methods 
4.3.1 Subjects and study design 
Patients with mitochondrial disease due to two genotypes (m.3243A>G and 
m.8344A>G) were recruited from the Newcastle Mitochondrial Disease 
database (Figure 4-1).  
All eligible patients were invited to participate based on the following clinical 
inclusion criteria: (i) clinical stability for >6 months; (ii) ability to use an upright 
stationary bicycle ergometer; (iii) no current participation in regular physical 
activity (≤1 weekly session); (iii) reported exercise intolerance and fatigue, and 
(iv) ability to perform the walking assessment safely. 
Exclusion criteria were the presence of known cardiac involvement, co-
morbidities precluding exercise training, and contra-indications to Magnetic 
Resonance Imaging. 
Twenty-four mitochondrial participants with the two genotypes (m.3243A>G, 
n=18; m.8344A>G, n=6) were recruited to participate from consecutive 
attendees at a mitochondrial clinic as part of an exercise intervention study 
(Bates et al., 2013). A sample of age and sex matched control participants with 
normal ECG and no history of cardiovascular or metabolic disease were also 
recruited from local advertisement and the gait laboratory database (Rochester 
et al., 2014b). 
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Figure 4-1: Consort Diagram for the cross sectional study of gait characteristics in 
mitochondrial disease.  
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The following sections include brief explanations of the methods used in the 
study. Full details of the investigations performed can be found within Chapter 2. 
All assessments were undertaken between the two centres listed in the 
methods section over a period of two days. This was necessary due to the 
distance required to travel to the centres by some of the mitochondrial 
participants. 
4.3.2 Disease Burden  
All subjects underwent a physical examination by an experienced clinician, 
disease severity was assessed and disease burden was established using the 
Newcastle Mitochondrial Disease Adult Scale (Schaefer et al., 2006) and 
mutation load.  
4.3.3 Physical Activity  
Physical activity and energy expenditure were assessed objectively using a 
validated multi-sensor array (SenseWear Pro3, Bodymedia Inc, Pennsylvania, 
USA 2.5)(St-Onge et al., 2007).  
4.3.4 Anthropometry 
Body weight (kg) and standing height (m) were measured. Whole body 
composition was determined using air displacement plethysmography using a 
BodPod (Life Measurement Inc., Concord, CA, USA). 
4.3.5 Progressive Exercise testing  
A stepped incremental workload test was performed using analysis of expired 
air gases and non-invasive bio reactance cardiac output. The test was 
performed on an electronically braked stationary bike at a steady cadence 
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between 60 and 80 rpm to elicit a symptom limited maximum oxygen uptake 
and heart rate response.  
4.3.6 Muscle Strength 
Proximal muscle power of the hip flexor and extensor muscles was measured 
using an isokinetic dynamometer (CSMI HUMAC®/NORM testing and 
rehabilitation system). Average peak torque was calculated for each muscle 
group from averaging the middle four repetitions.  
4.3.7 Quantitative gait assessment 
Gait was assessed in a gait laboratory setting along with other functional 
outcome measures (reported in Chapter 3). Gait was assessed using a 7m long 
× 0.6m wide instrumented mat (Platinum model Gaitrite, software version 4.5, 
CIR systems, USA). The mat was placed in the centre of the 12 m walkway to 
ensure that steady gait speed was measured (Figure 2-4). 
Figure 4-2: Gait laboratory set up for testing single and dual walks. 
 
Participants were asked to perform 3 different walking tasks (single task, dual 
task and a continuous walk over 6 minutes). During the single task walks 
participants were instructed to perform three 12m walks at their “comfortable 
pace”. The concurrent task for the dual task walks consisted of a digit span task.  
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The 6 minute walk involved participants walking continuously around a 25m 
oval circuit. Instructions provided were as stated for the 6 minute timed walk, 
where participants were encouraged to walk as far as possible in 6 minutes 
(Society, 2002). Gait was repeatedly recorded as they walked over the mat 
placed on one side of circuit (Figure 4-3). 
Figure 4-3: Gait laboratory set up for continuous 6-minute walk. 
 
  
Gait was quantified using a predefined model hypothesized to reflect 
independent features of neural control and characterise the features of gait 
associated with mitochondrial disease and its genotypes (Lord et al., 2013b). 
This model included: pace (step velocity and step length); rhythm (cadence); 
variability (step time and step length variability); asymmetry (step time 
asymmetry); and postural control (step width, step width variability, step length 
asymmetry). Gait variability, otherwise known as gait dynamics, was measured 
to characterise the step–to step fluctuations over the walking task. Gait 
variability was calculated for step length, step time and step width. 
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 Statistical analysis  
Due to the small numbers and variability in some parameters a conservative 
approach to statistical analysis was undertaken. Non-parametric Kruskal-
Wallace tests were used to test for group differences in gait characteristics. 
Post-hoc Mann-Whitney U tests are recorded as significant post Holm-
Bonferroni corrections (Rice, 1989). 
Within group comparisons were performed using Wilcoxon Signed rank tests to 
assess the effect of performing a dual task on gait characteristics.  
Associations between gait and disease severity, mutation load and 
pathophysiological variables were assessed using Spearmen Rho correlations. 
To avoid misleading findings we limited the correlation analysis between gait 
and NMDAS (total NMDAS score and subsections concerning, exercise 
tolerance, gait stability, cerebellar ataxia and myopathy). To accommodate for 
multiple correlations, only correlations with a p < 0.01 were considered to be 
statistically significant.  
For completeness comparisons of all sections of the NMDAS are included in 
Appendix G. 
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 Results  
All consented participants attended for all gait assessments. Two mitochondrial 
participants were unable to complete the walks with the addition of a dual task 
due to an increased risk of falling. The same participants stopped walking prior 
to the end of the continuous 6-minute walk; therefore their data was excluded 
from continuous walk data. Three mitochondrial participants were unable to 
complete dynamometry testing due to ill health (diarrhoea, migraine and a 
negative response to exercise test earlier in the day). Data was available only 
for 12 control participants performing the 6 minute continuous walk as the 12 
control participants obtained from the gait laboratory database had only 
completed single and dual task walks. 
Of the 24 mitochondrial participants, 18 presented with the m.3243A>G 
mutation and 6 with the m.8344A>G mutation (as reported in chapter 3). 
Participant demographic and clinical symptoms are presented in Table 4-1. 
Both the NMDAS score and urinary mutation load were significantly lower in the 
m.3243A>G genotype than the m.8344A>G genotype (NMDAS, p = .023*, 
mutation load p = .001**).  
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Table 4-1: Individual and group demographic characteristics of patients with mitochondrial disease and control subjects.  
Data presented as median and (quartiles). 
Group Age Sex Height (cm) Body mass (kg) BMI (kg.m-2) Mutation load (%) NMDAS Phenotype 
m.3243A>G 50 f 169 63.4 22.2 34 3 
Migraine, fatigue, hypothyroidism, myalgia, constipation, hypertension, dyslipidaemia, coeliac 
disease 
 
58 f 173 52.1 17.4 59 12 Hearing loss, ataxia, constipation, underweight, myopathy, myalgia, exercise intolerance 
 
58 m 186 89.8 25.9 66 30 
Hearing loss, diabetes, ataxia, retinopathy, constipation, hypertension, dysarthria, myopathy, 
neuropathy, exercise intolerance 
 
39 m 172 74.6 25.2 80 17 
Hearing loss, diabetes, migraine, fatigue, hypothyroidism, ataxia, constipation, exercise 
intolerance 
 
37 f 164 50.7 18.9 48 10 Hearing loss, diabetes, exercise intolerance, ataxia, dysarthria, asthma 
 
42 m 176 83.7 27.0 82 12 Hearing loss, diabetes, migraine, ataxia, depression, exercise intolerance 
 
42 f 154 49.0 20.7 43 15 Hearing loss, diabetes, ataxia, constipation, depression, exercise intolerance, short stature 
 
47 m 182 64.0 19.3 63 28 Hearing loss, diabetes, fatigue, ataxia, myalgia, depression, myopathy, neuropathy, ptosis, PEO 
 
38 f 164 54.2 20.1 53 11 Hearing loss, migraine, constipation, myopathy, fatigue, exercise intolerance, asthma 
 
22 m 183 59.2 17.7 89 17 Hearing loss, migraine, epilepsy, ataxia, constipation, underweight, exercise intolerance, fatigue 
 
53 f 164 59.1 22.0 22 10 Hearing loss, ataxia, retinopathy, constipation, myopathy, exercise intolerance 
 
25 m 174 49.8 16.5 90 26 
Hearing loss, migraine, ataxia, retinopathy, constipation, depression, dysarthria, myopathy, 
exercise intolerance, short stature, asthma 
 
18 f 154 39.5 16.7 59 9 Hearing loss, retinopathy, underweight, myopathy, exercise intolerance, short stature  
 
24 f 155 64.0 26.7 72 27 
Hearing loss, migraine, ataxia, retinopathy, constipation, depression, dysarthria, myopathy, 
exercise intolerance, short stature 
 
55 m 179 104.5 32.6 76 14 Hearing loss, diabetes, depression  
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36 m 179 72.4 22.6 80 4 Migraine, exercise intolerance 
 
50 m 162 64.6 24.6 87 23 
Hearing Loss, exercise intolerance, ataxia, myopathy, fatigue, depression, retinopathy, epilepsy, 
encephalopathy, cognitive decline, stroke-like episodes  
 
55 f 153 45.8 19.5 68 25 
Hearing loss, diabetes, myopathy, exercise intolerance, ataxia, constipation, depression, 
retinopathy, PEO, ptosis, short stature, mild dysphagia, hypertension 
         
m.8344A>G 46 m 163 70.9 26.7 77 19 
Mild concentric LVH, lipomata, exercise intolerance, dysphagia, myoclonic jerks, ataxia, seizures, 
neuropathy, fasciculation’s, constipation, hearing loss, myopathy, parenchymal lung disease 
 
28 m 173 51.7 17.3 95 55 
Hearing loss, fatigue, epilepsy, ataxia, retinopathy, constipation, dysarthria, myopathy, 
myoclonus, neuropathy, exercise intolerance, underweight 
 
59 f 162 69.8 26.6 75 19 Myoclonus, deaf, diabetes, lipomata , myopathy, mild concentric LVH 
 
25 m 176 68.0 22.0 94 48 Epilepsy, ataxia, retinopathy, depression, dysarthria, exercise intolerance, myopathy, myoclonus  
 
28 m 180 56.2 17.3 93 35 
Hearing loss, migraine, epilepsy, ataxia, constipation, underweight, depression, dysarthria, 
myopathy, neuropathy, exercise intolerance 
 
38 m 160 76.5 29.9 94 58 
Lipomata, hearing loss, migraine, epilepsy, ataxia, retinopathy, depression, dysarthria, 
myopathy, myoclonus, neuropathy, exercise intolerance, short stature 
         m.3243A>G   42 (36 ,52) f9  m9 170 (162 ,178) 61.3 (51.0 ,70.4) 21.3 (18.9 ,25.1) 67.0 (51.8 ,80.5) 15 (10, 25) 
 m.8344A>G   33 (28 ,44) f1  m5 168 (162 ,175) 68.9 (59.1 ,70.6) 24.3 (18.5 ,26.7) 93.5 (76.5 ,94.3) 42 (19 ,56) 
 Control 41 (32 ,51) f10  m14 170 (163 ,178) 75.4 (69.7 ,84.4) 25.2 (24.1 ,28.9)       
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4.5.1 Gait impairments associated with mitochondrial disease 
Gait characteristics in single task walking. 
Participants with mitochondrial disease when compared to the control group 
demonstrated significantly reduced gait speed, step length and increased 
variability in step time, step length and step width when performing a single task 
walk (Table 4-2, Figure 4-4). However, when described by genotype, more 
selective gait impairments are seen, with the m.8344A>G participants 
demonstrating more globally impaired gait characteristics in all variables except 
cadence, step width and step length asymmetry when compared to both the 
control and the m.3243A>G group (Table 4-2, Figure 4-4). The m.3243A>G 
group demonstrated differences in only three gait variables when compared to 
controls, with a shorter step length and increased variability in step time and 
step width.  
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Table 4-2: Gait performance whilst performing a single task walk. 
(MD n=24, controls n=24). Data presented as group medians (quartiles), raw p values presented. Significant group differences after Holm-
Bonferroni correction are highlighted in bold type. 
Gait Domain Gait Variables Controls m.3243A>G m.8344A>G Kruskal- 
Wallis 
(p) 
Mann Whitney U tests (p) 
     
Controls & 
mtDNA disease 
Controls & 
m.3243A>G 
Controls & 
m.8344A>G 
m.3243A>G 
& 
m.8344A>G 
Pace 
Step velocity (m.s-1) 1.52 (1.43, 1.66) 1.40 (1.30, 1.60) 0.91 (0.56, 1.30) .002 .002 .042 <.001 .003 
Step length (m) 0.78 (0.75, 0.82) 0.71 (0.68, 0.78) 0.57 (0.49, 0.65) .001 .001 .024 <.001 .001 
Rhythm Cadence (steps.min-1) 117 (112, 123) 116 (108, 123) 93 (62, 116) .046 .155 .525 .021 .040 
Asymmetry Step time asymmetry (ms) 7.3 (2.6, 11.9) 7.8 (3.5, 10.8) 39.4 (19.2, 202.6) .035 .149 .629 .006 .009 
Variability 
Step length variability (mm) 16.3 (13.5, 18.5) 20.3 (14.5, 23.9) 44.8 (29.6, 73.4) <.001 .004 .067 <.001 <.001 
Step time variability (ms) 11.1 (8.6, 14.6) 15.2 (11.9, 18.5) 61.5 (24.8, 368.1) .005 < .001 .004 <.001 .002 
Postural 
control 
Step width (m) 0.092 (0.076, 0.102) 0.100 (0.075, 0.112) 0.110 (0.090, 0.174) .220 .112 .297 .065 .251 
Step width variability (mm) 16.9 (15.6, 22.3) 24.2 (19.4, 31.2) 42.6 (24.9, 64.3) .016 <.001 .001 <.001 .022 
Step length asymmetry (mm) 15.5 (5.3, 25.6) 12.7 (7.4, 22.6) 21.7 (17.3, 43.8) .019 .536 .980 .116 .056 
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Figure 4-4: Individual and group gait performance of single task walking. 
The solid bar represents the median value with individual scores displayed around 
the median. * Indicates a significant difference compared to control participants. Ɨ 
Indicates a significant difference between m.3243A>G and m.8344A>G genotypes. 
A p value<.05 is considered as significant after Holm-Bonferroni corrections were 
performed. 
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 Gait characteristics performing a dual task walk  
Dual task walking was performed in 22 mitochondrial and 24 control participants 
(two mitochondrial participants with the m.8344A>G did not perform the dual 
task walk due to an undue risk of falling). No further gait characteristics were 
noted to be different between the groups than was reported performing single 
task walking. The m.8344A>G group continued to demonstrate a globally 
impaired gait pattern, with the m.3243A>G group demonstrating differences in 
step time and width variability when compared to controls (Table 4-3, Figure 
4-5). 
To investigate if performing another task whilst walking resulted in interference 
of gait, the study compared gait characteristics during single and dual task 
walking. Two gait characteristics, step velocity (p = 0.031) and step length (p = 
0.026) demonstrated differences between the two walking tasks, with a 
reduction in step velocity and step length being reported on the performance of 
a secondary task (Table 4-4). To investigate if this interference was unique to 
the mitochondrial group the dual task interference value was calculated for 
these two variables. Dual task interference was calculated using the equation 
shown below (Rochester et al., 2014a): 
𝐷𝑢𝑎𝑙 𝑡𝑎𝑠𝑘 𝑖𝑛𝑡𝑒𝑟𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
𝑑𝑢𝑎𝑙 𝑡𝑎𝑠𝑘 − 𝑠𝑖𝑛𝑔𝑙𝑒 𝑡𝑎𝑠𝑘 
𝑠𝑖𝑛𝑔𝑙𝑒 𝑡𝑎𝑠𝑘 
   
No differences were demonstrated between the mitochondrial and control 
groups dual task interference scores (Step velocity: MD; median value, -0.06, 
IQR (-0.13, 0.05), Control; -0.06 (-0.12, 0.04), (p= .809). Step length: MD; -0.04 
(-0.1, 0.02), Control; -0.03 (-0.12, 0.04), (p= .930).
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Table 4-3: Gait performance whilst performing a dual task walk. 
(MD n=22, Controls n=24). Data presented as group medians (quartiles) raw p values presented. Significant group differences after Holm-
Bonferroni correction are highlighted in bold type. 
 
Gait Domain Gait Variables Controls m.3243A>G m.8344A>G 
Kruskal- 
Wallis 
(p) 
Mann Whitney U tests (p) 
     
Controls & 
mtDNA 
disease 
Controls & 
m.3243A>G 
Controls & 
m.8344A>G 
m.3243A>G  
& 
 m.8344A>G 
Pace 
Step velocity (m.s-1) 1.46 (1.36, 1.53) 1.35 (1.18, 1.48) 1.12 (0.59, 1.33) .016 .021 .104 .004 .098 
Step length (m) 0.75 (0.69, 0.80) 0.71 (0.63, 0.75) 0.62 (0.52, 0.65) .005 .008 .057 <.001 .066 
Rhythm Cadence (steps.min-1) 115 (109, 121) 116 (107, 120) 107 (66, 124) .324 .218 .374 .186 .434 
Asymmetry Step time asymmetry (ms) 5.2 (2.6, 9.9) 8.1 (3.9, 16.1) 15.1(12.6, 29.16) .032 .062 .232 .013 .066 
Variability 
Step length variability (mm) 17.9 (14.6, 21.5) 21.7 (16.9, 26.5) 27.2 (23.7, 43.3) .022 .029 .127 .007 .098 
Step time variability (ms) 12.65 (10.15, 14.86) 15.3 (13.0, 21.7) 25.1 (18.7, 169.9) .002 .002 .013 .001 .042 
Postural 
control 
Step width (m) 0.091 (0.079, 0.105) 0.096 (0.075, 0.120) 0.092 (0.088, 0.106) .780 .482 .509 .728 .967 
Step width variability (mm) 17.2 (13.7, 21.2) 25.7 (19.2, 29.9) 27.9 (22.2, 33.6) .001 <.001 .001 .005 .652 
Step length asymmetry (mm) 16.3 (2.9, 26.9) 15.8 (4.5, 23.0) 23.1 (8.6, 50.1) .627 .598 .819 .355 .484 
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Figure 4-5: Individual and group gait performance of dual task walking. 
The solid bar represents the median value with individual scores displayed around 
the median. * Indicates a significant difference compared to control participants. Ɨ 
Indicates a significant difference between m.3243A>G and m.8344A>G genotypes. 
A p value<.05 is considered as significant after Holm-Bonferroni corrections were 
performed. 
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Table 4-4: Comparisons of single and dual task walking on gait characteristics of 
mitochondrial participants.  
A p value<.05 is considered significant and is shown in bold type. 
Gait variables  Median (Quartiles) Wilcoxon rank test 
 Single task walking Dual task walking P value 
Step Velocity (m.s-1) 1.33 (1.27, 1.52) 1.26 (1.12, 1.48) .031 
Step length (m) 0.70 (0.64, 0.76). 0.68 (0.62, 0.75) .026 
Cadence (steps min-1) 115 (108, 123) 112 (107, 121) .131 
Step time asymmetry (ms) 8.1 (3.5, 17.3) 9.0 (5.3, 17.9) .733 
Step length variability (mm) 22.8(15.9, 26.5) 22.7(18.0, 28.5) .485 
Step time variability (ms) 15.4 (13.0, 20.9) 16.5 (13.0, 24.0) .758 
Step width (m) 0.099 (0.079, 0.112) 0.095 (0.077, 0.119) .987 
Step width variability (mm) 24.9 (20.4, 33.6) 25.7 (21.1, 31.4) .506 
Step length asymmetry (mm) 15.4 (7.9, 23.8) 15.8 (6.2, 28.9) .758 
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 Gait characteristics during a continuous 6 minute walk. 
Twelve control and 22 mitochondrial participants performed the continual walk 
over 6 minutes. Step time variability remained as a gait characteristic 
demonstrating differences between the control and m.3243A>G group. Other 
variables such as step length and velocity remained different but failed to reach 
statistical significance due to multiple comparisons. The m.8344A>G group 
continued to demonstrate differences in step time variability, step velocity and 
step length (Table 4-5, Figure 4-6).
  
144 
Table 4-5: Differences in gait performance when performing a 6-minute walk. 
(MD n=22, controls n=12). Data presented as group medians (quartiles) raw p values presented. Significant group differences after Holm-
Bonferroni correction are highlighted in bold type. 
Gait Domain Gait Variables 
Controls 
(n=12) 
m.3243A>G 
(n=18) 
m.8344A>G 
(n=4) 
Kruskal- 
Wallis 
(p) 
Mann Whitney U tests (p) 
     
Controls & 
mtDNA 
disease 
Controls & 
m.3243A>G 
Controls & 
m.8344A>G 
m.3243A>G 
 & 
m.8344A>G 
Pace 
Step velocity (m.s-1) 1.46 (1.34, 1.53) 1.31 (1.19, 1.48) 1.05 (0.64, 1.32) .011 .011 .035 .013 .066 
Step length (m) 0.75 (0.72, 0.79) 0.69 (0.65, 0.75) 0.58 (0.52, 0.68) .009 .010 .043 .002 .081 
Rhythm Cadence (steps.min-1) 114 (111, 118) 116 (108, 119) 108 (74, 116) .340 .534 .787 .212 .195 
Asymmetry Step time asymmetry (ms) 9.4 (4.9, 13.6) 7.8 (4.8, 9.9) 25.6(7.5, 38.0) .269 1.000 .602 .170 .166 
Variability 
Step length variability (mm) 17.1 (14.7, 22.0) 20.2 (16.2, 22.7) 29.6 (21.5, 45.2) .042 .094 .232 .030 .042 
Step time variability (ms) 10.61 (9.95, 12.56) 14.52 (12.39, 16.48) 25.44 (17.47, 90.67) <.001 <.001 <.001 .001 .014 
Postural 
control 
Step width (m) 0.109 (0.088, 0.122) 0.107 (0.082, 0.125) 0.111 (0.106, 0.123) .753 .790 .917 .599 .484 
Step width variability (mm) 21.6 (19.2, 25.9) 25.9 (21.1, 29.8) 31.1 (23.6, 32.9) .115 .102 .215 .058 .227 
Step length asymmetry (mm) 12.1 (5.5, 22.0) 10.7 (7.4, 14.4) 26.7 (20.1, 46.2) .033 .845 .642 .058 .003 
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Figure 4-6: Individual and group gait performance of a long continuous walking 
task.  
The solid bar represents the median value with individual scores displayed around 
the median. *Indicates a significant difference compared to control participants.     
Ɨ Indicates a significant difference between m3243A>G and m.8344A>G genotypes. 
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4.5.2 Changes in gait characteristics over a 6-minute continuous walk. 
To investigate whether gait characteristics in the mitochondrial group altered 
over a prolonged walk (6 minutes) due to muscle fatigue, comparisons were 
made between gait characteristics during the first and last two minutes of a six-
minute walk. The gait characteristic of cadence was the only characteristic to 
report a statistical difference between these two time points (p = .022) with a 
reduction in cadence seen over time (Table 4-6, Figure 4-7). 
Figure 4-7: Cadence change scores over a 6-minute walk.  
 
A change in cadence was also reported in the control group (p = .041). 
Comparison of the change in cadence between both groups was unable to 
demonstrate a difference between groups (p = .736). However four participants 
with mitochondrial disease demonstrate a decrease in cadence greater than 
seen in the control group.
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Table 4-6: Changes in gait characteristics in participants with mitochondrial disease over a six-minute walk.  
Data presented as group medians (quartiles), raw p values presented. 
Gait domain Gait variables Minute 1&2 Minute 5&6 p value 
Pace 
Step Velocity (ms-1) 1.31 (1.19, 1.39) 1.27 (1.15, 1.42) 0.223 
Step length (m) 0.68 (0.64, 0.72) 0.69 (0.62, 0.74) 0.685 
Rhythm Cadence (steps min-1) 115 (107, 119) 114 (106, 118) 0.022 
Asymmetry Step time asymmetry (ms) 10.56 (5.28, 17.16) 8.49 (1.35, 20.25) 0.884 
Variability 
Step length variability (mm) 21.1 (17.5, 28.1) 19.8 (15.2, 26.6) 0.223 
Step time variability (ms) 17.88 (14.33, 20.66) 16.85 (12.55, 20.23) 0.355 
Postural Control 
Step width (m) 0.107 (0.089, 0.120) 0.110 (0.086, 0.124) 0.189 
Step width variability (mm) 27.1 (21.3, 34.5) 24.4 (21.2, 30.0) 0.211 
Step length asymmetry (mm) 12.8 (5.8, 23.3) 11.7 (7.8, 22.13) 0.709 
  
148 
4.5.3 Relationships between gait characteristics and clinical disease 
burden 
To examine the relationship between gait characteristics of participants with 
mitochondrial disease and clinically measured disease burden the data from 
both genotypes were pooled (n = 24). The NMDAS scale has 29 questions 
investigating all aspects of mitochondrial disease. In this study relationships 
were investigated between gait characteristics, total disease burden and 
sections of the NMDAS that were hypothesised to affect gait characteristics. 
This limited the number of comparisons performed. Analyses on all sections of 
the NMDAS scale were performed for completeness and are shown as an 
appendix (Appendix G).  
Disease burden (total NMDAS score) showed a moderate indirect relationship 
with walking speed (r = -0.6) and step length (r = -0.6), both within the pace 
domain. This, therefore, demonstrated that mitochondrial subjects with a higher 
disease burden walked at a slower speed with a shorter step length. Direct 
relationships were also shown between disease burden and the postural control 
domain, with associations demonstrated with step width variability (r =0.6) and 
step length asymmetry (r = 0.6). These relationships demonstrated that gait 
became more variable and asymmetric with increased disease burden (Table 
4-7, Figure 4-8). 
Investigations of the sub sections within the NMDAS highlighted additional gait 
features in respect to variability and asymmetry (Table 4-7). In addition 
cerebellar ataxia and gait stability demonstrated moderate correlations with all 
but two gait variables. 
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Table 4-7: Relationships between gait characteristics, disease severity (total NMDAS score) and individual NMDAS subsections. 
Significant correlations are presented in bold type (p ≤ 0.01, two-tailed) 
 
Gait Domain Gait Variables NMDAS 
NMDAS Subscale 
Exercise tolerance Gait stability Myopathy Cerebellar ataxia 
Pace Step Velocity (ms-1) -0.6 (.001) -0.7 (<.001) -0.6 (.006) -0.4 (.054) -0.4 (.039) 
 Step length (m) -0.6 (.003) -0.7 (<.001) -0.6 (.004) -0.5 (.014) -0.4 (.068) 
Rhythm Cadence (steps min-1) -0.4 (.042) -0.3 (.096) -0.4 (.048) -0.1 (.937) -0.3 (.160) 
Asymmetry Step time asymmetry (ms) 0.5 (.024) 0.5 (.016) 0.4 (.029) 0.5 (.007) 0.4 (.034) 
Variability Step length variability (mm) 0.3 (.110) 0.5 (.010) 0.5 (.024) 0.2(.374) 0.5 (.009) 
 Step time variability (ms) 0.1 (.506) 0.5 (.012) 0.3 (.114) 0.1 (.626) 0.5 (.010) 
Postural control Step width (m) 0.4 (.081) 0.4 (.087) 0.4 (.033) 0.3(.214) 0.4 (.039) 
 Step width variability (mm) 0.6 (.002) 0.4 (.078) 0.6 (.002) 0.4 (.071) 0.6 (.001) 
 Step length asymmetry (mm) 0.6 (.001) 0.4 (.032) 0.3 (.174) 0.6 (.001) 0.4 (.029) 
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Figure 4-8: Scatter plots of the relationships between total disease severity score (NMDAS) and gait characteristics. 
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4.5.4  Relationships between gait characteristics and pathophysiological 
measures of disease burden. 
Explorations of a number of pathophysiological markers of mitochondrial 
disease with respect to gait characteristics were performed. Increased mutation 
load demonstrated a moderate relationship with increased step time asymmetry 
(r = 0.6) and step width variability (r = 0.6) (Table 4-8). The relationships 
between gait characteristics, energy expenditure, peak exercise capacity and 
muscle strength were less clear. Moderate relationships were seen between 
step length and velocity with impaired proximal muscle strength, peak exercise 
capacity and energy expenditure, denoting a relationship with the domain of 
pace (Table 4-8). However, these were not deemed to be significant due to 
multiple comparisons. No other gait variables demonstrated relationships with 
the pathophysiological characteristics of disease.
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Table 4-8: Relationships between mutation load, energy expenditure, peak exercise capacity muscle strength variables and gait outcomes in 
people with mitochondrial disease.  
Significant correlations are presented in bold type (p ≤ 0.01, two-tailed) 
 
Gait Domain Gait Variables Mutation load (%) 
Community energy 
expenditure 
(calories) 
Exercise capacity 
(peak oxygen 
consumption) 
(ml.kg.min) 
Hip flexor strength 
(nm/kg) 
Hip extensor strength 
(nm/kg) 
Pace Step velocity -0.3 (.164) 0.3 (.157) 0.5 (.019) 0.4 (.045) 0.5 (.039) 
 Step length -0.2 (.285) 0.4 (.039) 0.6 (.002) 0.5 (.017) 0.5 (.019) 
Rhythm Cadence -0.4 (.049) <-0.1 (.918) 0.2 (.405) 0.1 (.773) 0.2 (.404) 
Asymmetry Step time asymmetry 0.6 (.004) -0.1 (.673) -0.3 (.109) -0.3 (.128) -0.5 (.037) 
Variability Step length variability 0.4 (.064) -0.2 (.396) -0.2 (.328) -0.2 (.430) -0.2 (.454) 
 Step time variability 0.2 (.474) -0.3 (.239) -0.2 (.473) -0.3 (.159) -0.2 (.378) 
Postural control Step width 0.1 (.674) 0.2 (.359) <-0.1 (.990) -0.1 (.767) <-0.1 (.929) 
 Step width variability  0.6 (.002) 0.1 (.754) -0.2 (.440) -0.3 (.140) -0.3 (.205) 
 Step length asymmetry 0.4 (.058) 0.1 (.723) -0.3 (.129) -0.2 (.431) -0.2 (.369) 
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 Discussion  
Mitochondrial diseases result in a wide variety of symptoms that can lead to gait 
impairment; previous studies in this patient group have looked at the clinical 
manifestations of disease by assessing exercise capacity and muscle strength. 
This study is the first to attempt to quantify gait in a group with genetically 
confirmed mitochondrial disease. A previously reported model was used to 
capture the complexity of gait. The use of this model enabled the identification 
of patterns of gait deficits that reflect the underlying pathophysiology and 
differentiate between a group of participants with mitochondrial disease and 
disease free controls, and between different mitochondrial genotypes.  
The key findings of the study are that gait characteristics differed in a sensitive 
and selective manner between patients with mitochondrial disease and disease 
free participants. Gait characteristics were also able to discriminate between the 
two mitochondrial genotypes; those with the m.8344A>G demonstrating global 
gait impairment whereas, within a mildly affected m.3243A>G subgroup, this 
was reduced to a discreet number of gait variables. These variables did not 
change with the addition of another task whilst walking or when the length of the 
walk was extended. The relationships demonstrated between gait, disease 
severity, and pathophysiological markers, support the future use of gait analysis 
as a robust clinical measure of disease severity in mitochondrial patients.  
4.6.1 Gait deficits associated with mitochondrial disease and genotype. 
Differences in gait characteristics were demonstrated in both the mitochondrial 
disease group and the two genotypes when compared to controls. The 
m.8344A>G genotype group was globally impaired with differences evident in 
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all gait characteristics except cadence, step width and step length asymmetry. 
The global impairment in the m.8344A>G group is unremarkable given the high 
number of clinical symptoms and high level of disease burden reported in this 
group. The m.3243A>G group however demonstrated fewer gait characteristics 
that differed from the control group, reflecting their higher level of ability. 
Despite their high functioning, differences were highlighted in maintaining 
adequate pace (step length), low levels of variability (step time variability) and 
postural control (step width variability) (Galna et al., 2013a). These results 
suggest that different pathological processes may result in gait impairments 
even in a mildly affected group of the m.3243A>G genotype and these patients 
can be differentiated by their gait characteristics. 
When participants performed a secondary task whilst walking, no further gait 
characteristics were observed to be different between the groups. The addition 
of a dual task whilst walking unsurprisingly affected pace in the mitochondrial 
group, but a similar response was also reported in the control group and has 
been reported in other populations (Kelly et al., 2012a).  
The addition of another task whilst walking aims to provide further stress to the 
systems controlling locomotion. This added stress aims to reduce any cognitive 
compensation employed to maintain walking performance and hence dual task 
walking is able to reveal latent motor deficits (Yogev-Seligmann et al., 2008; 
Kelly et al., 2012b). The use of dual task testing during gait assessment and 
how it can be interpreted remains under debate, with the type of dual task and 
the emphasis given to the dual task during walking affecting results (Kelly et al., 
2010; Al-Yahya et al., 2011). Walking at a pace other than preferred speed has 
also been shown to be a more sensitive measure of pathology and reveal 
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deficits in motor ability (Mirelman et al., 2011; Verghese et al., 2012). Whilst the 
dual task testing appears to provide consistent results in conditions such as 
Parkinson Disease, with resultant increases in variability and reduced speed 
(Kelly et al., 2012a), dual task interference is also a feature of healthy ageing 
and its value in predicting clinical problems such as falls has been questioned 
(Smulders et al., 2012).  
An explanation for the lack of any further gait impairment becoming apparent 
with dual tasking in this study may be due to the type and difficulty of the dual 
task and the attention given to that task. The dual task performed may not 
provide enough stress to reduce any cognitive compensation in participants. 
This is unlikely in this study as the difficulty of the cognitive task was calculated 
for each participant, in a non-challenging sitting position, prior to walking. Also 
participants in this study were not instructed to give more attention to the 
cognitive task whilst walking. Despite this an error rate of only 23% was 
reported in recalling the digit span, which demonstrates that attention was given 
to the cognitive task whilst walking. Another possible reason for the lack of 
effect of a dual task was the removal of two of the most affected participants 
(both with the m.8344A>G mutation) from performing the dual task walk due to 
a risk of falling. Inclusion of these participants in the single task data may have 
increased the gait disturbances reported during single task walking, although 
this would not explain why no further changes in gait were observed when only 
the m.3243A>G group were considered. It should also be noted that the 
m.3243A>G group were a high functioning group and therefore cognitive 
compensation may not have been necessary to maintain gait performance.  
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In summary the performance of a dual task did not appear to provide any 
additional information concerning gait impairments in this cohort of patients. 
Further work may be warranted to investigate if this remains the case in all 
genotypes and also whether the type of dual task performed has an effect.  
The measurement of gait characteristics during a continuous walk were 
performed to reveal whether gait altered as walking became more automatic 
during a longer walk versus a short intermittent walk (Bilney et al., 2003; 
Lindemann et al., 2008; Paterson et al., 2009) and to investigate if the 
characteristics of gait changed with fatigue. Although fewer gait impairments 
were noted during a continuous walk, this was not due to changes in gait 
characteristics within the group of mitochondrial patients, but due to an 
increased variability in a smaller control group performing the continuous walk 
test (n = 12 vs. n = 24). The difference in the performance of the smaller control 
group makes comparisons between the three walking tasks more difficult, 
although gait characteristics across all walking tasks appear to be similar. 
The similarities in the gait deficits reported across the three walking tasks 
provide reassurance as to the robust nature of gait assessment under different 
situations. These similarities may allow us to reduce participant burden in future 
investigations by reducing the number of walks performed. In a patient group 
that has a high incidence of reported fatigue this may prove beneficial. 
4.6.2 Does gait reflect the burden of disease? 
The exploration of relationships between gait and clinical disease severity 
(NMDAS) for the total mitochondrial group (m.3243A>G and m.8344A>G) 
demonstrated patients with a higher disease burden had greater gait 
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impairment. Moderate associations (r = 0.4 - 0.6) were demonstrated with all 
gait characteristics except step time variability, although some failed to reach 
statistical significance due to the conservative approach to statistical analysis. 
The gait characteristics demonstrating significant associations with disease 
burden were not the same characteristics that were able to differentiate 
between the mitochondrial and control groups. This is likely to be due to the fact 
that they are measuring different impairments. However, gait speed, step length 
and step width variability were able to differentiate between the mitochondrial 
disease group and controls, and were associated with disease burden. Hence 
these three variables provide a selective group of characteristics that may be 
valuable when assessing relationships between gait and disease burden in 
patients with mitochondrial disease. 
The examination of associations between gait and individual questions within 
the NMDAS demonstrated relationships between exercise capacity, gait and 
cerebellar sub-scales highlighting the underlying pathophysiological contribution. 
Cerebellar ataxia demonstrated moderate relationships with all variables within 
the asymmetry, variability and postural control domains. The reporting of gait 
asymmetry as the only significant characteristic to demonstrate a relationship 
with myopathy is difficult to explain, especially as the associations reported 
between hip muscle strength and pace seem to contradict this finding. These 
conflicting results may be due to the low level of sensitivity within the myopathy 
question of the NMDAS, where muscle strength is measured using manual 
muscle tests (Sapega, 1990) as opposed to the gait measures. Another 
possible explanation may be the inclusion of upper and lower limb muscle 
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strength in the rating scale, although this is unlikely as myopathy in 
mitochondrial disease is usually widespread and not limited to isolated limbs. 
4.6.3  Does gait reflect the pathological consequences of mitochondrial 
disease? 
To explore the relationship between gait characteristics and pathology the study 
examined the relationships between gait and mutation load, baseline 
community energy expenditure, exercise capacity and hip strength. The 
m.3243A>G group were a high performing group demonstrating normal gait 
speed and therefore early gait impairments may relate to disease pathology, 
unlike the m.8344A>G group who were globally impaired which reflects a 
combination of disease pathology and subsequent compensations. Therefore 
this study concentrated on the m.3243A>G group for the exploration of 
pathophysiological consequences of disease.  
Relationships were reported between heteroplasmy levels and the gait 
characteristics of increased step width variability and step time asymmetry. Step 
width variability was also significantly greater in the m.3243A>G when 
compared to controls. It is possible that this feature of gait may reflect the 
underlying pathological changes and warrants further investigation. 
Ataxia is a common clinical symptom in patients with mitochondrial disease 
(Turnbull et al., 2010) and cerebellar impairment is a major cause of gait ataxia. 
Previous gait studies have demonstrated that balance impairment and 
increased gait variability are important findings in people with ataxia (Morton 
and Bastian, 2004; Ilg et al., 2007; Serrao et al., 2012; Rochester et al., 2014b). 
Gait variability describes the size of stride-to-stride fluctuations in walking and is 
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typically less than 5% in a healthy population with a smooth and consistent 
stepping motion (Schniepp et al., 2012). The cerebellum plays a key role in the 
control of timing and coordination of gait, the finding of increased gait variability 
is a possible result of cerebellar atrophy (Spencer et al., 2003; Diedrichsen et 
al., 2007). The findings of this study imply that cerebellar impairment is 
underpinning the gait disturbance observed in mitochondrial disease, with early 
changes in the generation of consistent steps leading to increased variability. 
The increased variability in step width demonstrates lateral instability and is 
implicated as a marker of impaired postural control within the gait model and 
studies within older adults (Brach et al., 2005). Given the clinical presentation of 
these genotypes (Chinnery et al., 1997; Mancuso et al., 2013; Nesbitt et al., 
2013) it is probable that muscle pathology and ataxia, either in isolation or in 
combination, are likely to contribute to the subtle gait changes observed. This is 
supported by the significant correlations seen with the cerebellar domain within 
the NMDAS and the selective association with mutation load. 
Muscle strength is often reflected in gait by step length (Schulz et al., 2007) 
which enables an adequate pace to be maintained during walking. Reduced 
step length in the mitochondrial group is likely to be a consequence of muscle 
weakness. This is supported by the moderate relationships of peak exercise 
capacity and hip muscle strength with step length, although it must be noted 
that hip muscle strength, despite demonstrating a moderate relationship with 
step length, did not demonstrate a significant relationship due to multiple 
comparisons. The lack of significant correlations with hip strength could be a 
result of the robust nature of gait to muscle weakness (van der Krogt et al., 
2012) and the position used for muscle strength testing (e.g. lying as opposed 
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to standing), which may have affected results. However, these results suggest 
that adequate muscle strength contributes to the maintenance of step length 
and walking speed in participants with mitochondrial disease.  
4.6.4 Does fatigue affect gait characteristics? 
This study hypothesized that gait characteristics would be able to detect muscle 
fatigue over a prolonged walk. Despite fatigue or exercise intolerance being 
present in all of the participants with mitochondrial disease, this study was 
unable to detect changes in gait characteristics over a 6-minute walk. Within an 
Italian cohort of mitochondrial patients fatigue was reported as the 4th most 
common symptom, with 35% of patients with the m.3243A<G mutation reporting 
fatigue (Mancuso et al., 2012). A Newcastle cohort reported fatigue that was 
even higher at 62 % (unpublished data). The differences in the prevalence of 
fatigue between these two cohorts is likely due to the different methods of 
assessing “fatigue” which remains difficult to define. The inability of gait 
variables to detect fatigue was disappointing but may be due to a number of 
factors: Firstly participants were asked to walk as far as they could in 6 minutes 
and provided with a prompt every minute. Receiving a verbal external prompt 
may have allowed the participants to pace themselves over the 6-minute walk. 
This pacing may have led to a submaximal performance of the test and 
therefore participants did not exhibit fatigue. The submaximal performance of 
the 6-minute walk by neuromuscular participants has been reported previously 
and protocols therefore have been adapted to include increased verbal 
encouragement, to ensure a maximal performance (McDonald et al., 2010). 
Secondly, the length of walk may also have been a limiting factor in such a high 
functioning patient group but a more lengthy investigation was not possible in 
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this study due to the already high participant burden. Therefore, fatigue remains 
difficult to assess, further work is required before measurement of gait can be 
used as a potential marker of fatigue.
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 Limitations  
Although this study is the first to provide a description of gait impairment in 
mitochondrial disease, it is still unknown how gait deteriorates over the lifetime 
of the patient or how responsive gait impairments are to potential therapeutic 
intervention. Also as part of this study it was only possible to investigate two 
genotypes and in very small numbers therefore it is not possible to extend the 
findings to other forms of mitochondrial disease. However, given that ataxia is 
documented in a third of our centre’s cohort of patients with less than half of 
these cases attributable to the genotypes studied here, it is possible that the 
findings are transferable to other genotypes. Further investigation is, however, 
required. 
This study was limited to two genotypes to reduce heterogeneity within the 
mitochondrial group; despite this the two genotypes appeared to present very 
differently when gait was assessed. This limitation was addressed by looking at 
the genotypes together and also separately. This method of analysis had the 
consequences of reducing the number in the m.8344A>G group dramatically 
and resulting in some comparisons being non-significant due to multiple 
comparisons.
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 Conclusion 
As commented in the Cochrane review, identification of sensitive outcomes is 
essential for trials investigating mitochondrial disease. This data shows that gait 
deficits are associated with mitochondrial disease and genotype in a selective 
pattern. These gait deficits also seem to reflect the clinical burden of disease 
and its pathological consequences. 
Gait is easily quantifiable and sensitive to change in other clinical populations. 
Therefore, quantification of discrete gait characteristics in patients with 
mitochondrial disease may improve the measurement of disease burden and 
provide further information concerning underlying pathology and progression. 
The results of this study suggest that further longitudinal investigations of gait 
are warranted as well as the investigation of the effect of gait deficits in 
mitochondrial disease on community mobility.  
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Chapter 5 An overview of the measures used in 
the observational studies included in this thesis 
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 Introduction  
The measures used in the studies in this thesis span the International 
Classification of Functioning, Disability and Health (World Health Organization, 
2001), with measurements extending from impairments such as exercise 
intolerance, to activities such as walking, and participation, via quality of life 
questionnaires. The relationships of these measures to disease severity have 
already been discussed in the previous results chapters. Their ability to detect 
change post an exercise intervention will be evaluated in the next two chapters.  
This chapter will review the accuracy of the clinical measures used in this thesis 
in recognising patients with mitochondrial disease and differentiating between 
mitochondrial genotypes. The results will provide valuable information 
concerning the sensitivity and specificity of measures and will help researchers 
and clinicians to use appropriate measures in future trials. 
 Subjects and methods 
The subjects and methods used are reported in chapter 3 and 4 of this thesis. 
The measures evaluated are: Exercise capacity, proximal muscle strength, 
functional outcome measures (5XSTS, TUG, 10MTW, 6MWD) and the gait 
characteristics at baseline. 
 Statistical analysis  
The sensitivity (true positive rate, TPR) and specificity (true negative rate, TNR) 
of the outcomes measured in the studies were analysed using Receiver 
operating characteristic (ROC) curve analysis.  
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Sensitivity was calculated using the equation below (TP = true positives, FN = 
false negatives); 
𝑇𝑃𝑅 =
𝑇𝑃
𝑇𝑃 + 𝐹𝑁
 
Specificity was calculated using the equation below (TN= true negative, FP = 
false positive); 
𝑇𝑁𝑅 =
𝑇𝑁
𝑇𝑃 + 𝐹𝑃
 
From this the area under the curve (AUC) was calculated using SPSS version 
20.  
Accuracy (ACC) was derived using the following equation (P = positives, 
disease group, N=negatives, disease free group); 
𝐴𝑐𝑐 =
𝑇𝑃 + 𝑇𝑁
𝑃 + 𝑁
  
 Results 
As reported previously all participants attended for all assessments although 
three participants were unable to complete muscle strength testing due to ill 
health. 
The following tables and graphs will report the sensitivity, specificity and 
accuracy of measures in predicting whether participants have mitochondrial 
disease and also if the measures have the ability to distinguish between the two 
mitochondrial genotypes. Table 5-1 demonstrates that a number of measures 
can be described as good or excellent (AUC > 0.8), with the measure of sit to 
stand showing high levels of sensitivity and specificity. When investigating the 
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ability of these measures to discriminate between genotypes four measures 
were deemed excellent (AUC > 0.9).
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Table 5-1: The relative accuracy, sensitivity and specificity of measures used within this thesis to discriminate between the control and disease 
groups. 
 ƚ Cut off chosen at the point of maximum accuracy. Where more than one point had the same accuracy, the most sensitive cut-off value was 
chosen. AUC - Area under the curve. (MD; n=24, Controls; n=12) 
Variable Cut off point ƚ  Accuracy Sensitivity Specificity Area Under the Curve p value 
Five times Sit to Stand (secs) > 8 89% 92% 83% 0.934 < .001 
Arteriovenous O2 difference (ml O2/dl) <19.4 83% 96% 58% 0.848 .001 
Timed Up and Go (secs) > 7 81% 79% 83% 0.840 .001 
Peak Exercise Capacity (ml/kg/min) < 23.5 81% 83% 75% 0.826 .002 
Hip flexor strength (nm/kg) <1.2 81% 91% 58% 0.819 .003 
Step length (m) <0.76 81% 83% 75% 0.813 .003 
Step width variability (mm) >17 78% 92% 50% 0.809 .030 
Hip extensor strength (nm/kg) <2.0 81% 86% 67% 0.804 .004 
Step velocity (m.sec-1) <1.51 78% 80% 75% 0.802 .004 
10m walk duration (secs) >7 78% 70% 92% 0.778 .007 
Anaerobic threshold (ml/kg/min) <17.6 75% 91% 42% 0.754 .016 
6 minute walk distance (m) <440 86% 100% 54% 0.752 .015 
Step time variability (ms) >11 78% 100% 33% 0.719 .035 
Cadence (steps.min-1) <127 69% 96% 17% 0.660 .123 
Step length variability (mm) >19 72% 71% 75% 0.632 .202 
Step time asymmetry (ms) >3 72% 100% 17% 0.618 .254 
Step width (m) >0.05 69% 93% 83% 0.563 .546 
Step length asymmetry (mm) >36 72% 100% 17% 0.559 .568 
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Figure 5-1: Area under the curve plots for functional outcome measures and 
exercise capacity and hip muscle strength to differentiate between mitochondrial 
disease patients and controls.  
The open circle marker denotes the cut-off point of highest accuracy. 
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Figure 5-2: Area under the curve plots for a discrete number of gait characteristics 
to differentiate between mitochondrial disease patients and controls.  
The open circle marker denotes the cut-off point of highest accuracy. (MD: n=24, 
Controls: n=12) 
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Table 5-2: The relative accuracy, sensitivity and specificity of measures used in this thesis to discriminate between the two genotypes 
(m.3243A>G and 8344A>G). 
 ƚ Cut off chosen at the point of maximum accuracy. Where more than one point had the same accuracy, the most sensitive cut-off value was 
chosen. AUC - Area under the curve. (m.3243A>G: n=18, m.8344, n=6). 
 
Variable Cut off point ƚ  Accuracy Sensitivity Specificity Area Under the Curve p value 
Step length variability (mm)  29 96% 100% 83% 0.963 .001 
Step length (m) 0.54 88% 100% 50% 0.917 .003 
Step time variability (ms) 27 96% 100% 83% 0.907 .003 
10m walk duration (secs) 12 88% 100% 50% 0.903 .004 
Step velocity (m.sec-1)  0.84 88% 100% 50% 0.898 .004 
6 minute walk distance (m) 313 92% 100% 67% 0.889 .005 
Timed Up and Go (secs) 10 92% 100% 67% 0.861 .009 
Step time asymmetry (ms) 24 96% 100% 83% 0.852 .011 
Step width variability (mm)  41 92% 100% 67% 0.815 .023 
Peak Exercise Capacity (ml.min.kg) 14 79% 89% 50% 0.815 .023 
Cadence (steps.min-1) 92 88% 100% 50% 0.787 .039 
Anaerobic threshold (ml/kg/min) 9.18 79% 83% 67% 0.787 .039 
Step length asymmetry (mm) 40.82 83% 100% 33% 0.769 .053 
Hip flexor strength (nm/kg)  0.4 88% 87% 83% 0.767 .062 
Hip extensor strength (nm/kg)  0.9 88% 100% 50% 0.722 .119 
Step width (m) 0.18 79% 100% 17% 0.667 .230 
Five times Sit to Stand (secs) 18.28 83% 100% 33% 0.634 .334 
Arteriovenous O2 difference (ml O2/dl) 9.45 71% 94% 0% 0.521 .883 
 172 
 
Figure 5-3: Area under the curve plots for functional outcome measures and 
exercise capacity and hip muscle strength to differentiate between two 
mitochondrial genotypes.  
The open circle marker denotes the cut-off point of highest accuracy. 
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Figure 5-4: Area under the curve plots for a discreet number of gait characteristics 
to differentiate between two mitochondrial genotypes.  
The open circle marker denotes the cut-off point of highest accuracy. 
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 Discussion 
Research thus far in Mitochondrial disease has led to a greater understanding 
of mitochondrial function and the genetic causes of mitochondrial disease. The 
study of disease progression and the evaluation of interventions has proven 
less successful due to the complex and varied nature of mitochondrial disease. 
This thesis has used a number of well-known clinical outcome measures to 
evaluate different aspects of disease as recommended by the World Health 
organisation’s International Classification of impairments, disabilities and 
handicaps. Comparison of all the measures used can assist in the 
recommendation of a refined battery of measures to be used in future clinical 
and research work. Careful selection of measures is imperative if disease 
progression and the effects of interventions are to be measured accurately. The 
correct use of measures will; i) enable early detection of impairments while they 
are still amenable to treatment; ii) discriminate between controls and patients 
with mitochondrial disease and iii) potentially between different mitochondrial 
genotypes. 
When discriminating between groups with and without mitochondrial disease 
the studies demonstrated that two exercise parameters (a-vO2 diff, ?̇?O2PEAK), hip 
muscle strength, two functional measures (5XSTS, TUG) and 3 gait 
characteristics (step velocity, step length and step width variability) were 
deemed to have good discriminative abilities. Differing levels of sensitivity and 
specificity were noted, however, which is likely to be due to the arbitrary nature 
of cut off values chosen. 
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Previous evaluations of exercise testing as a means of diagnosis in 
mitochondrial disease have reported levels of sensitivity of 63 - 75% and 
specificity of 70 - 90% (Tarnopolsky, 2004). These figures are similar to our 
findings despite our results only including maximal exercise testing. The high 
level of accuracy of oxygen extraction and peak exercise capacity identifying 
patients with mitochondrial disease found in this thesis is reassuring as these 
measures have been commonly used in previous exercise studies (Taivassalo 
et al., 2003; Taivassalo et al., 2006) and were surmised to reflect mitochondrial 
function. Although these measures were able to discriminate well between a 
healthy and diseased population they were less able to discriminate between 
different mitochondrial genotypes. This is unsurprising as both mitochondrial 
genotypes have impaired mitochondrial function and are therefore likely to have 
impaired exercise capacity. 
The poor ability of exercise testing to discriminate between different types of 
mitochondrial disease has also been alluded to in previous studies when 
comparing different myopathic diseases with mitochondrial disease (Dandurand 
et al., 1995; Dysgaard Jeppesen et al., 2003). These studies reported that 
exercise testing was not a sensitive diagnostic test for mitochondrial myopathies. 
Despite these findings it was agreed that exercise capacity is significantly 
reduced in patients with mitochondrial disease and that exercise capacity is a 
useful research outcome in therapeutic trials, especially ones where exercise is 
the intervention. The authors also reported that the specificity and sensitivity of 
the test was not as important as its reliability and reproducibility (Tarnopolsky, 
2004). 
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The different types of exercise testing combined with the many exercise 
variables reported in exercise studies do make comparisons between studies 
difficult. A consensus regarding the type of exercise test and the appropriate 
measures to report would improve comparisons between studies and allow 
improved analysis over a larger number of patients in these rare conditions. The 
demonstration of two exercise variables (a-vO2 diff, ?̇?O2PEAK) with good levels of 
accuracy will hopefully lead to fewer exercise parameters needing to be 
reported in future studies. 
Despite the nonspecific nature of functional outcome measures two of the 
measures used in this thesis had high levels of accuracy (5XSTS, TUG). These 
findings are harder to explain, as the previous results chapter (Chapter 3) 
reported that although all the functional measures were both able to 
demonstrate a difference between control and disease groups, the 5XSTS did 
not relate to the level of disease burden, exercise capacity or proximal muscle 
strength. It should be remembered that this measure, along with other 
functional measures, tests the composite result of multiple elements of a 
movement such as: strength, postural control, sensation. Due to the composite 
nature of functional outcomes, they are unable to indicate which impairment 
results in a limitation of function. It would seem that something about the sit to 
stand movement included in both of these measures is indicative of 
mitochondrial disease, even within a high functioning group of patients where 
myopathy was minimal and a relationship to disease burden could not always 
be exhibited.  
The simplicity, along with the lack of requirement for specialised equipment, of 
these functional measures makes their use in clinical practice possible. 
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However, the lack of sensitivity to change may be a barrier to use in a research 
environment. 
The 6MWD despite being a field measure of exercise capacity was unable to 
discriminate between the two groups (AUC < 0.8). This result supports the 
findings in the previous results chapter and the hypothesis that impaired 
walking in patients with mitochondrial disease is likely to be a result of multiple 
system involvement, as well as secondary deconditioning, and not just impaired 
mitochondrial function within muscle leading to reduced exercise capacity.  
Three gait characteristics (step length, step length variability and time variability) 
demonstrated excellent power (AUC>0.9) when discriminating between the two 
mitochondrial genotypes, highlighting the sensitive and selective nature of gait 
characteristics. This further emphasises the differences that have been 
previously reported in descriptions of the two genotypes. The gait variables 
reported represent the gait domains of pace and variability and may be 
indicators of primary pathological changes as opposed to secondary 
compensations.  
Unfortunately time constraints and participant burden meant that the reliability 
and reproducibility of measures used in these studies were not assessed. The 
reliability and reproducibility of a number of functional measures have been 
demonstrated in other disease populations, however, and hopefully this was 
maintained in these studies by limiting the number of assessors and following 
strict protocols. 
Investigating the accuracy of the measures used in this study has highlighted 
that, as expected, different measures were better at measuring different disease 
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attributes. In clinical trials it is imperative that the correct measures are used to 
measure what a researcher expects to be different, either between groups, over 
a time span, or following an intervention. As a result of these studies, future 
studies can explore the use of a more refined number of measures in these 
genotypes to enable discrimination between: Patients with mitochondrial 
disease and controls; different genotypes, disease burden and mutation load 
Table 5-3. The small sample size and the use of only two mitochondrial 
genotypes means that results should not be extrapolated to a larger more 
varied cohort. Further investigation into the use of clinical outcome and gait 
measures is required to confirm that functional outcome measures and analysis 
of gait are valid and accurate measures in other mitochondrial disorders.
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Table 5-3: Review of key clinical outcomes used in baseline studies.  
(X- AUC >0.9). 
Domain Variable 
Able to discriminate between 
control and MD group ( AUC > 
0.8 ) 
Able to discriminate 
between genotypes 
( AUC > 0.8 ) 
Correlates to diseases 
severity ( NMDAS ) 
Correlates to % mutation 
load 
Exercise capacity 
a-vO2 difference X 
 
X 
 
Peak exercise capacity X X X 
 
Anaerobic threshold 
 
X X 
 
      
Muscle Strength 
Hip flexor strength X 
   
Hip extensor strength X 
   
      
Gait 
Step length X X X 
 
Step velocity X X X 
 
Step time variability 
 
X 
  
Step length variability 
 
X 
  
Step width variability X X X X 
Step time asymmetry 
 
X X X 
      
Clinical Functional measures 
5XSTS X 
   
TUG X X X X 
10MTW 
 
X X 
 
6MWD 
 
X X 
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 Conclusion  
The studies in this thesis have demonstrated that a limited number of gait and 
functional measures are capable of discriminating between disease and control 
groups with varying levels of accuracy. The wider use of these measures will 
enable a better clinical picture of mitochondrial disease to be gained without the 
use of laboratory or expensive and extensive testing. The use of these 
measures in larger cohorts of patients will enable links between primary 
pathological changes and their likely effects on function to be clarified.  
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Chapter 6 The effect of a structured exercise 
intervention on the exercise and functional 
capacity of people with mitochondrial disease 
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 Introduction  
Currently no clear evidence is available to support the use of any intervention in 
the treatment of mitochondrial disease (Pfeffer et al., 2012). Many of the 
interventions routinely used in the clinical management of patients with 
mitochondrial diseases remain essentially supportive, with treatments being 
aimed at the medical management of symptoms of the disease such as 
diabetes, epilepsy and cardiac impairment.  
Medical treatments for the muscle symptoms related to mitochondrial disease, 
such as reduced exercise capacity, fatigue and muscle weakness, have been 
tried, but as yet there have been no randomised controlled trials that have 
reported any benefits (Pfeffer et al., 2012). The use of aerobic exercise has 
been shown to have long-term health benefits in the general population 
(Fletcher, 1999; Haskell et al., 2007; Lee et al.). Patients with mitochondrial 
disease are at greater risk of cardiovascular disease due to disease pathology 
and low levels of habitual activity (Apabhai et al., 2011), therefore aerobic 
exercise has been proposed as a potential treatment in this disease group 
(Pfeffer et al., 2012). 
Previous studies investigating the effects of exercise in mitochondrial disease 
have demonstrated improvements in muscle function by performing exercise 
tests and muscle biopsies (Cejudo et al., 2005; Taivassalo et al., 2006; Trenell 
et al., 2006). These studies have either included a wide variety of genotypes, or 
patients with a single deletion that have a myopathic phenotype (Taivassalo et 
al., 2001; Cejudo et al., 2005; Taivassalo et al., 2006). Until now the use of 
functional outcome measures to evaluate the effects of an exercise intervention 
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in mitochondrial disease has been limited and results inconclusive (Jeppesen et 
al., 2006b; Trenell et al., 2006). 
This case controlled interventional study will provide further evidence that 
exercise is safe and beneficial in another discrete group of mitochondrial 
patients.  The use of simple functional outcome measures alongside traditional 
measures of exercise capacity will be able to demonstrate that improvements in 
muscle function translate into improvements in functional activities and quality 
of life in patients with mitochondrial disease.
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 Study aims and hypothesis  
 Aims 
1. To determine the effects of aerobic exercise on the exercise capacity of 
two specific mitochondrial genotypes (m.3243A>G, m.8344A>G). 
2.  To investigate if changes in exercise capacity result in changes in the 
performance of day-to-day activities. 
 Primary hypothesis 
Exercise capacity will improve within a discrete group of mitochondrial patients 
after an aerobic exercise intervention. 
 Secondary hypotheses 
Improvements in exercise capacity will translate to improvements in 
functional tasks. 
Disease burden, quality of life and cognitive ability of participants with 
mitochondrial disease will improve following an aerobic exercise 
intervention. 
Muscle strength will remain unchanged following an aerobic exercise 
intervention.  
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 Subjects and Methods  
Sixty patients with mitochondrial disease were invited to participate in the 
exercise study from consecutive attendees at a specialist outpatient clinic 
between August 2010 and July 2011. Patients were clinically identified as 
having the m.3243A>G or m.8344A>G mitochondrial DNA mutation (Figure 6-1). 
All eligible patients were invited to participate based on the following clinical 
inclusion criteria: (i) clinical stability for >6 months; (ii) able to use an upright 
stationary bicycle ergometer; (iii) no current participation in regular physical 
activity (≤1 weekly session) and (iv) reported exercise intolerance and fatigue. 
Exclusion criteria were the presence of known cardiac involvement, co 
morbidities precluding exercise training, and contra-indications to Magnetic 
Resonance Imaging. 
A power calculation was determined from the change in peak oxygen 
consumption following a similar exercise intervention (Taivassalo et al., 2006). 
Mean 1 =1.36 (SD 0.4), Mean 2 = 1.51 (SD 0.4), Alpha =5%, Beta =80%. This 
calculated a sample size of nine. A minimum of twelve people per treatment 
arm were recruited to allow 3 participants from each group to leave the study 
and retain sufficient power for intervention evaluation.  
From the 36 participants in a previous observational study (chapter 3) a 
convenience sample of thirteen patients with mitochondrial disease and all the 
12 sedentary control participants were allocated to the exercise intervention 
study. One participant from each group failed to return for final testing due to 
time commitments.
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Figure 6-1: Consort diagram for the study of the effect of aerobic exercise on 
physiological and functional measures in mitochondrial disease. 
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All visits were undertaken between the two centres listed in chapter 2 over a 
period of two days. Over the two days both disease and control groups 
underwent; assessments of baseline physical activity, anthropometry, resting 
metabolism, peak exercise capacity, proximal muscle strength and functional 
assessment using recognised clinical functional outcome measures. In addition 
the disease burden of the mitochondrial participants was assessed, whilst the 
sedentary control volunteers underwent a review of their medical history, 
physical examination and completed the Physical Activity Readiness 
Questionnaire.  
After completion of a 16-week aerobic exercise intervention all initial 
assessments (except physical activity measurement) were repeated. An 
additional visit was performed midway through the intervention, to monitor that 
no adverse responses to exercise had occurred and to reassess the exercise 
capacity of participants. 
The following section includes brief explanations of the methods of assessment 
used in this study (Full details can be found in Chapter 2). 
6.3.1 Disease burden  
All subjects underwent a physical examination by an experienced clinician. 
Disease severity was assessed and disease burden was established using the 
Newcastle Mitochondrial Disease Adult Scale (NMDAS), a validated scoring 
system (Schaefer et al., 2006). Mutation load, an established marker of clinical 
outcome was derived from urinary epithelial cells (McDonnell et al., 2004; 
Shanske et al., 2004; Whittaker et al., 2009). 
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6.3.2 Anthropometry 
Body weight (kg) and standing height (m) were measured before and after the 
exercise intervention. Whole body composition was determined using air 
displacement plethysmography using a BodPod (Life Measurement Inc., 
Concord, CA, USA). 
6.3.3 Physical Activity  
Physical activity and energy expenditure were assessed objectively at baseline 
using a validated (St-Onge et al., 2007) multi-sensor array (SenseWear Pro3, 
Bodymedia Inc, Pennsylvania, USA 2.5). 
6.3.4 Resting Substrate metabolism  
Following an overnight fast (≥ 8 hours with no food or beverages) resting 
substrate oxidation was determined by expired gas analysis (CORTEX 
Biophysik, Leipzig, Germany) using a Hans Rudolf breathing mask while 
participants lay supine for 30 minutes in a quiet room.. 
6.3.5 Progressive Exercise testing  
A peak exercise test was performed as described in section 2.3.8. A number of 
parameters including VO2PEAK, anaerobic threshold (AT), peak workload (W) 
and systemic arteriovenous oxygen difference (a-vO2 diff) were measured. 
6.3.6 Dynamometry 
Proximal muscle power was measured using isokinetic dynamometry of the hip 
flexor and extensor muscles (CSMI HUMAC/ NORM testing and rehabilitation 
system).  
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6.3.7 Functional assessment 
Functional outcomes measures were performed in the Clinical Ageing Research 
Unit, Newcastle University. The following functional outcome measures were 
performed: Six-minute walk distance (American Thoracic Society Statement, 
2002); 10 metre timed walk (Bohannon, 1997); timed up and go test (Podsiadlo 
D et al., 1991 ) and the 5 times sit to stand (Lord et al., 2002; Whitney et al., 
2005). The order of tests was randomized except for the six-minute walk 
distance, which was always performed last to reduce the effects of fatigue on 
other tests.  
6.3.8 Cognitive Ability  
Cognitive function was tested using the revised Addenbrookes Cognitive 
Examination (ACE-R). A cut off 88 was used as an indication of mild cognitive 
impairment (Eneida et al., 2006). 
6.3.9 Quality of Life  
Quality of life was assessed using the short form (SF12) health survey (Ware et 
al., 1996) which already forms part of the Newcastle Mitochondrial Disease 
Adult Scale (Schaefer et al., 2006).
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 Aerobic training intervention 
Upon completion of baseline tests, participants undertook 16 weeks of aerobic 
exercise training. Exercise sessions were conducted at a local gym or at home. 
The first exercise session was supervised by a qualified physiotherapist. The 
exercise programme was based on the individual’s performance of the symptom 
limited peak exercise test. Participants were initially asked to perform 20 
minutes of cycling within a heart range that was equivalent to 60-70% of their 
VO2PEAK. If participants were unable to perform 20 minutes of continuous 
exercise they were encouraged to cycle for as long as they could with rests, 
until they had performed 20 minutes of cycling in total. Participants exercised 
(cycling) 3 times a week for the 16 weeks (48 sessions in total). All participants 
received weekly contact via phone or email. The intensity of the exercise 
sessions were tailored to the individual and increased progressively over the 16 
weeks. Progression was dictated by the participant, initially participants were 
encouraged to cycle for 20 minutes at designated heart rate range, and this was 
then increased by 5 minutes until they were able to perform 45 minutes of 
exercise. Participants were encouraged to increase resistance on bike to 
maintain heart rate within training range. Once 45 minutes continuous exercise 
was achieved at the designated heart rate range the range could be increased 
as able. Exercise was recorded in an exercise diary and monitored 
retrospectively via a POLAR watch monitor. 
Midway through the training period participants attended the clinical research 
facility to repeat the progressive exercise test performed at baseline. Training 
heart rates were adjusted to maintain training at a heart rate≈70% VO2PEAK for 
the remainder of the exercise intervention.
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 Statistical Analysis 
Normality of distribution was assessed using a Kolmogorov-Smirnov test. To 
compare within group differences before and after the exercise intervention, 
paired student t tests, or Related-Samples Wilcoxon Signed Rank Tests, were 
performed dependant on normality.  
To compare the responses to exercise of the mitochondrial and control groups 
individual change scores were calculated by subtracting the pre intervention 
score from the post intervention score of each participant. Individual change 
scores of the control and mitochondrial disease groups were then compared 
using independent sample t-tests or Mann-Whitney U tests for variables that 
had demonstrated a significant change following the intervention.  
Data is presented as means ± SD for continuous data and as numbers or 
percentages for categorical data unless otherwise stated. Statistical significance 
was achieved with a p value of < .05, or < .01 where multiple comparisons were 
performed.  
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 Results  
All participants attended baseline testing (Mitochondrial disease group n=13, 
control group n=12). At baseline one mitochondrial disease patient’s body 
composition data from the Bodpod was unable to be retrieved and one 
mitochondrial disease patient was unable to complete dynamometry due to an 
adverse response to the peak exercise test.  
One participant from each group was unable to complete the final test visit and 
therefore their data was excluded from the final analysis (Mitochondrial disease 
group n=12, control group n=11). All participants returning for the final 
assessment had completed the exercise intervention, with all participants 
completing ≥ 80% of the exercise sessions and no adverse events being 
reported. On review of exercise diaries two participants with mitochondrial 
disease were unable to cycle for 20 minutes continuously, but performed 20 
minutes with 1 or 2 rests. These participants also reported muscle discomfort 
post exercise on occasions. Recording of exercise in diaries was good but 
numerous reports were noted concerning POLAR watch recording, therefore 
participants were required to use heart rate monitor on cycles to monitor heart 
rate. Therefore numerous sessions were not captured by POLAR watch by both 
groups. 
Two mitochondrial patients were unable to complete the 6-minute walk on the 
final visit due to a risk of falling; one of these participants also was also unable 
to perform the other walking tests. 
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The following sections will report the baseline anthropological characteristics of 
the participants, followed by the responses to exercise of both groups. Finally a 
comparison of the response to exercise of the two groups is summarised.  
6.6.1 Characteristics of participants 
The groups were well matched for age (mitochondrial group 40 ± 11 vs. control 
38 ± 12, p= .671). The groups did not remain matched for sex post intervention 
due to the drop out of one person in each group (mitochondrial group; four 
women and eight men, control group; five women and six men). Baseline 
characteristics of the two groups are summarised in Table 6-1. Differences 
between the two groups are reported in both body weight and activity levels, 
with both being lower in the mitochondrial group. Despite the activity levels 
measured in the mitochondrial group being lower than the control group, when 
asked to self-report their activity levels the mitochondrial group reported much 
higher levels of activity. These results are in line with the larger cross-sectional 
study (chapter 3).  
Table 6-1: Baseline characteristics of participants. 
Variable 
Mitochondrial Group 
n=12 
Control Group 
n=11 
p value 
Age (Years) 40 (11) 38 (12) .671 
Weight (Kg) 62 (12) 79 (15) .005** 
BMI (Kg/m2) 21 (3) 27 (5) .002** 
Daily energy expenditure 
(cals) 
2092 (613) 2505 (362) .016* 
Daily step count 6078 (4935) 9241 (2575) .004** 
IPAQ (met/min/week) 7385 (9629) 3304 (3412) .604 
(IPAQ-International Physical Activity Questionnaire) 
The genotypes, symptoms and disease burden levels of the mitochondrial 
participants are summarised in Table 6-2. At baseline two participants had 
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cognitive impairment as categorised by an ACE-R score of less than 88, with 
one participant unable to complete the form due to poor vision. 
Quality of Life scores were lower in the mitochondrial group for the physical 
component as compared to the control group; physical composite score (PCS) 
(mitochondrial group 40 ± 13 vs. control 55 ± 5, p= .004), mental composite 
score (MCS) (mitochondrial group 46 ± 12 vs. control 48 ± 12, p= .588).  
Following the exercise intervention the weight of the mitochondrial group 
increased by 2% (p=. 031*) as compared to a 1% loss in the control group (p=. 
358). No change was seen in the disease severity post exercise intervention 
(NMDAS; pre-exercise, 22 ±15, post-exercise, 23±17, p=. 684). Also no change 
was reported in cognition and quality of life (ACE-R; 89 ± 11, 89 ±12, p= .983, 
SF12; Physical composite score 41 ± 13, 40 ± 12, p= .365; Mental composite 
score 45 ± 12, 45 ± 13, p= .913).
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Table 6-2: Baseline disease characteristics of mitochondrial participants. 
Genotype Age Sex Height (cm) Mass (kg) BMI Heteroplasmy (%) NMDAS Principle clinical features 
m.3243A>G  
58 F 173 52.1 17.4 59 12 Hearing loss, ataxia, constipation, underweight, myopathy, myalgia, exercise intolerance 
 
39 M 172 74.6 25.2 80 17 Hearing loss, diabetes, migraine, fatigue, hypothyroidism, ataxia, constipation, exercise 
intolerance 
 
37 F 164 50.7 18.9 48 10 Hearing loss, diabetes, exercise intolerance, ataxia, dysarthria, asthma 
 
42 M 176 83.7 27.0 82 12 Hearing loss, diabetes, migraine, ataxia, depression, exercise intolerance 
 
47 M 182 64.0 19.3 63 28 Hearing loss, diabetes, fatigue, ataxia, myalgia, depression, myopathy, neuropathy, ptosis, 
PEO 
 
38 F 164 54.2 20.1 53 11 Hearing loss, migraine, constipation, myopathy, fatigue, exercise intolerance, asthma 
 
22 M 183 59.2 17.7 89 17 Hearing loss, migraine, epilepsy, ataxia, constipation, underweight, exercise intolerance, 
fatigue 
 
36 M 179 72.4 22.6 80 4 Migraine, exercise intolerance 
 
50 M 162 64.6 24.6 87 23 Hearing Loss, exercise intolerance, ataxia, myopathy, fatigue, depression, retinopathy, 
epilepsy, encephalopathy, cognitive decline, stroke-like episodes  
 
55 F 153 45.8 19.5 68 25 Hearing loss, diabetes, myopathy, exercise intolerance, ataxia, constipation, depression, 
retinopathy, PEO, ptosis, short stature, mild dysphagia, hypertension 
m.8344A>G  
28 M 173 51.7 17.3 95 55 Hearing loss, fatigue, epilepsy, ataxia, retinopathy, constipation, dysarthria, myopathy, 
myoclonus, neuropathy, exercise intolerance, underweight 
 
25 M 176 68.0 22.0 94 48 Epilepsy, ataxia, retinopathy, depression, dysarthria, exercise intolerance, myopathy, 
myoclonus  
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6.6.2 The effects of an exercise intervention on resting metabolism  
Resting metabolism was unchanged by the exercise intervention in both groups 
with the exception of fat oxidation in the mitochondrial group, which was 
reduced (1.27 to 1.10 mg/kg/min, p=0.04). This change was not reflected in a 
significant change in the respiratory quotient at rest (0.86 to 0.88, p= 0.11) 
(Table 6-3).
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Table 6-3: Resting substrate metabolism pre and post exercise intervention. 
* p value<.05 and are denoted in bold type.  
Variable  Mitochondrial Disease (n=12) p value Control Group (n=11) p value 
 Pre intervention  Post intervention   Pre intervention  Post intervention  
Ventilation  7.7 (1.8) 7.8 (2.1) .770 7.55 (1.8) 8.0 (1.9) .294 
Carbohydrate Oxidation (mg.kg.min) 2.77 (0.95) 2.91 (0.86) .552 2.94 (0.87) 3.17 (0.69) .439 
Lipid Oxidation (mg.kg.min)  1.27 (0.41) 1.10 (0.42) .040* 0.79 (0.29) 0.66 (0.3) .258 
Respiratory Quotient 0.86 (0.05) 0.88 (0.05) .110 0.91 (0.05) 0.93 (0.04) .244 
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6.6.3 The effects of an exercise intervention on the exercise and functional 
performance of both mitochondrial and control groups 
All participants were able to complete a progressive exercise test before and 
after the exercise intervention, all but one participant achieved 80% of their 
predicted heart rate maximum. The respiratory exchange ratios produced by 
both groups were similar and greater than 1, demonstrating peak performance 
was reached. 
The effects of an aerobic exercise intervention on exercise performance  
The exercise intervention resulted in an improvement in all aspects of exercise 
capacity in both groups, although some variables failed to reach statistical 
significance. In the control group this may have been due to one control 
participant being unable to exercise one week prior to testing (Table 6-4, Figure 
6-2). The improvements noted in this study were greater in the mitochondrial 
group (peak exercise capacity improved by 16 ± 10% vs. 14 ± 30%, anaerobic 
threshold by 33 ± 30% vs. 24 ± 32%). Despite the greater improvement in the 
peak exercise capacity of the mitochondrial group it remained lower post 
intervention than the control group at baseline, increasing from 55 ± 21% to 66 
± 26% of the predicted peak exercise capacity. Whereas the control group at 
baseline achieved 93 ± 21% of their predicted peak exercise capacity. The 
anaerobic threshold as a percentage of the predicted peak exercise capacity in 
the mitochondrial group also remained low post the exercise intervention 
despite improving from 34 ± 15% to 44± 17%. This compared to a starting 
anaerobic threshold of 53 ± 14% of peak exercise capacity in the control group. 
The arteriovenous oxygen difference (a-vO2 diff) also increased in both groups 
(mitochondrial group 16% ± 18 vs. Controls 16% ± 38), suggestive of improved 
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oxygen extraction by muscles in both groups. However, as with other exercise 
measures, the arteriovenous oxygen difference remained lower in the 
mitochondrial group post intervention than in the control group at baseline. Peak 
wattage showed a similar percentage increase in both groups post training 
(mitochondrial group 14 ± 18% vs. control 13 ± 12%). Despite the increase in 
peak wattage achieved in testing following training, the post training peak 
wattage of the mitochondrial group remained approximately 50% of the 
sedentary controls.  
The proximal muscle strengths of both groups are reported in Table 6-5. Due to 
the large variability in the data the median and inter quartile ranges are reported. 
The results demonstrate that hip extensors were twice as strong as that of the 
hip flexors in both groups. The strength of both hip muscle groups in the 
mitochondrial group was 50% lower than the control group. Following the 
exercise intervention we saw an increase in the muscle strength in both groups, 
with a median % increase of >15% in hip extensor strength, despite being a 
clinically relevant change the change failed to reach statistical significance 
(p=0.062) (Dvir, 2004).
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Table 6-4: Results of progressive exercise tests for mitochondrial and control group’s pre and post aerobic intervention.  
p value <0.5 *, <.01** 
 
Mitochondrial patients (n=12) 
Mean ± SD 
p value 
Sedentary controls (n=11) 
Mean ± SD 
p value 
 
Pre 
exercise 
Post exercise % change  
Pre 
exercise 
Post exercise % change  
Peak Heart Rate 162 ± 29 161 ± 17 0 .665 184 ± 16 179 ± 14 3 .008** 
Peak oxygen consumption  
(l.min) 
1.3 ± 0.6 1.6 ± 0.8 19 .003** 2.2 ± 0.7 2.4 ± 0.6 13 .056 
Peak exercise capacity 
(ml/kg/min) 
20.2 ± 6.4 23.6 ± 8.6 16 .003** 27.7 ± 6.9 30.4 ± 5.6 14 .053 
Peak workload  
(W) 
92 ± 45 104 ± 54 14 .039* 172 ± 41 193 ± 44 13 .002** 
Peak Workload  
(W/kg) 
1.4 ± 0.5 1.6 ± 0.6 12 .060 2.2 ± 0.5 2.5 ± 0.5 14 .002** 
Anaerobic Threshold  
(ml/kg/min) 
12.6 ± 4.9 16.0 ± 6.0 29 .003** 15.5 ± 4.0 18.8 ± 3.9 32 .015* 
Arteriovenous O2 difference 
(100ml/kg) 
8.8 ± 3.0 10.0 ± 3.1 16 .007** 11.0 ± 2.8 11.9 ± 1.8 16 .200 
Maximum respiratory exchange 
ratio 
1.3 ± 0.1 1.3 ± 0.2 0 .926 1.3 ± 0.1 1.3 ± 0.04 0 .234 
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Figure 6-2: Scatter-plots of exercise variables pre and post exercise intervention  
(Error bars denote means and standard deviations). * denotes significant p values< .05, **p< .01). 
 
 202 
 
 
 
 203 
 
Table 6-5: Proximal muscle strength pre and post an aerobic exercise intervention.  
Data is presented as medians and interquartile ranges.  
 Mitochondrial patients (n=11)  p value Sedentary controls (n=11)  p value 
 Pre exercise Post exercise %change  Pre exercise Post exercise %change  
Hip flexor strength (nm) 27 (19-62) 34 (24-63) 19 0.894 104 (50-114) 96 (58-102) -6 0.230 
Hip extensor strength 
(nm) 
60 (48-145) 94 (67-127) 16 0.722 170 (141-226) 189 (155-232) 12 0.062 
Hip flexor strength 
(nm/kg) 
0.5 (0.4-0.8) 0.5 (0.4-0.8) 13 0.859 1.2(0.7-1.5) 1.1 (0.8-1.3) -4 0.397 
Hip extensor strength 
(nm/kg) 
1.2(0.9-2.0) 1.6 (1.2-1.9) 5 0.657 2.2 (1.5-2.8) 2.7 (2.2-2.8) 14 0.062 
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 The effects of exercise on the performance of functional activities  
The following section will describe the performance of functional tests at 
baseline and after the aerobic exercise intervention. Results are summarised in 
both Table 6-6 and Figure 6-3. The results in Table 6-6 report no clinically 
measurable or statistically significant changes in the performance of all but one 
of the functional tests. The 6-minute timed walk distance despite showing an 
improvement in the control group did not reach a distance deemed to be 
clinically relevant (13%) (Flansbjer et al., 2005). 
The scatter plots in Figure 6-3 demonstrate the greater heterogeneity within the 
mitochondrial group compared to the control group at baseline. This remained 
unchanged by the intervention. Unfortunately one participant with the 
m.8344A>G mutation was unable to repeat the walking tasks due to a fall 
resulting from a myoclonic jerk. This participant showed very high levels of 
walking impairment at baseline (10m timed walk > 25secs), which remained 
severely impaired after the exercise intervention, although not formally 
measured.
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Table 6-6: Functional outcome measures pre and post aerobic exercise intervention . 
Data is presented as medians and quartiles .* denotes a p value <.01. 
 Mitochondrial patients (n=12) 
% 
change 
p value 
Sedentary controls (n=11) 
% 
change 
p value 
 Pre exercise Post exercise Pre exercise Post exercise 
Five times sit to 
stand (secs) 
12 (11, 13) 10 (9,12) -11 0.158 7 (6, 8) 7 (7, 8) 9 0.929 
Timed up and go 
(secs) (MD n=11) 
8 (7, 9) 8 (7, 9) -5 0.423 7 (6, 7) 7 (6, 7) 4 0.213 
10 metre timed walk 
(secs) (MD n=11) 
7 (6, 8) 7 (6, 8) -2 0.477 7 (6, 7) 7(6, 7) <1 1.000 
6 minute walk (m)   
(MD n=10) 
459 (415, 568) 461 (418, 516) -1 0.612 500 (479, 530) 525 (500, 565) 5 0.032* 
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Figure 6-3: Scatter-plots for functional outcome measures pre and post exercise intervention.  
(Error bars denote means and standard deviations) 
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6.6.4 The differences in exercise response between two groups 
Further analysis was undertaken to compare the responses of the mitochondrial 
disease and control groups to the exercise intervention. Where variables had 
demonstrated a significant change after the exercise intervention the change 
scores for each group were then compared. The comparison of change scores 
demonstrated that the response to exercise was similar in both the 
mitochondrial disease and control groups (Table 6-7). This data should be 
viewed with caution as the study was designed to demonstrate a change in 
exercise capacity within the mitochondrial disease group, not to detect the 
change between the groups. 
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Table 6-7: Exercise and functional change with an exercise intervention in both control and patient groups.  
Data presented as mean ± SD. 
 Mitochondrial group Control group Mean difference p value 
(95% CI of the difference) Variables mean change ± SD mean change ± SD  
Fat oxidation (mg/kg/min) -0.17±0.25 -0.12±0.34 0.04 0.734 (-0.30, 0.22) 
Peak oxygen consumption (l.min) 0.3±0.2 0.2±0.3 0.1 0.477 (-0.1, 0.3) 
Peak exercise capacity (ml.min.kg) 3.4±3.0 2.7±4.1 0.7 0.658 (-2.4, 3.8) 
Peak workload (Wattage) 12±18 21±17 8 0.263 (-7, 24) 
Anaerobic threshold (ml.min.kg) 3.4±3.1 3.2±3.6 0.2 0.888 (-2.7, 3.1) 
Arteriovenous O2 difference (ml/kg/min) 1.2±1.3 0.9±2.2 0.3 0.682 (-1.2, 1.8) 
6minute walk distance (m) -9 ± 60 20±27 30 0.154 (-12, 71) 
Hip extensor strength (nm/kg) 0.1±0.6 0.3±0.5 0.2 0.372 (-0.28, 0.73) 
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 Discussion  
Mitochondrial disease results in a multitude of symptoms, such as muscle 
weakness and fatigue, which can lead to increased levels of inactivity. Exercise 
intervention studies have been shown to improve exercise capacity in patients 
with mitochondrial disease without adverse events (Taivassalo et al., 1998 ; 
Taivassalo et al., 2001; Cejudo et al., 2005; Taivassalo et al., 2006; Trenell et 
al., 2006). These previous exercise studies have confirmed the safety of 
exercise within mitochondrial populations with multiple genotypes or a discrete 
population of patients with a single large-scale mitochondrial DNA deletion.  
This case controlled intervention study evaluated the effects of aerobic exercise 
in another discrete group of clinically affected patients with mitochondrial 
disease due to the m.3243A>G and m.8344A>G point mutations. To our 
knowledge it is the first to evaluate changes in exercise capacity within this 
discrete group. Alongside measuring changes in exercise capacity the study 
investigated whether improvements in exercise capacity were reflected in 
changes in functional ability. 
The key finding of this study was that exercise capacity improved within this 
discrete population of patients with mitochondrial disease following an aerobic 
exercise intervention with no adverse effects. This improvement in exercise 
capacity was not reflected in improvements in the functional measures used in 
this study. 
6.7.1  Changes in the exercise performance of patients with mitochondrial 
disease 
The primary hypothesis in this study was that exercise capacity within this 
discrete sample of patients with mitochondrial disease would improve following 
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an aerobic exercise intervention. All aspects of exercise performance in both 
control and mitochondrial disease participants showed improvement, although 
statistical significance was not reached in all variables The improvements in 
peak exercise capacity in the mitochondrial group alongside improvements in 
anaerobic threshold and oxygen extraction are all in agreement with previous 
studies (Cejudo et al., 2005; Taivassalo et al., 2006; Jeppesen et al., 2009). 
Improvements in exercise capacity are presumed to be a result of better oxygen 
utilization due to mitochondrial biogenesis and increased respiratory enzyme 
activity as shown by Taivassalo et al and not increased fuel delivery as a result 
of changes in cardiac function (Taivassalo and Haller, 2004; Bates et al., 2013).  
As in previous exercise studies investigating patients with mitochondrial disease, 
the variation in individual changes in exercise capacity remained wide (change 
in VO2 PEAK 7 - 38%). This was despite limiting the study to two genotypes. This 
varied response is similar to previous studies with a wider genotype inclusion 
(Cejudo et al., 2005; Jeppesen et al., 2006b). The heterogeneity of response 
can be observed when examining individual participants; two male participants 
had mutation loads of 80% but achieved peak exercise capacities of over 35 
ml.min.kg, which is comparable to the control subjects and exercise levels of 
healthy untrained males (Cooper and Storer, 2001). However, two female 
participants of a similar age to the two high performers with lower mutation 
loads (48 and 53%) demonstrated much lower exercise capacities (12 and 21 
ml.min.kg) that remained low post the exercise intervention (14 and 21 
ml.min.kg). These variations in response emphasize the difficulty in predicting 
the relationships between mutation loads, exercise capacity and the benefits of 
exercise in this group (Cooper and Storer, 2001; Jeppesen et al., 2003; 
Taivassalo and Haller, 2004; Jeppesen et al., 2009). 
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Despite the percentage changes in exercise capacity in the two groups 
appearing similar, the post training exercise capacity of mitochondrial 
participants remained lower than the controls, with mitochondrial participants 
often failing to reach the pre exercise levels of the control group. Parameters 
such as anaerobic threshold despite not being indicative of pathology post 
exercise intervention remained at the levels of sedentary individuals (Cooper 
and Storer, 2001). The reasons for the varied and limited responses of people 
with mitochondrial disease reported in this and previous studies (Jeppesen et 
al., 2006b; Taivassalo et al., 2006) are still not fully understood, although it has 
been  assumed that the level of primary biological deficit must play a role. This 
assumption is not readily supported by the results of this study where 4 
participants with mutation loads of over 80% were able to reach over 90% of 
their predicted peak exercise capacity. One explanation for this discrepancy 
between mutation load and exercise capacity could be the use of urinary 
mutation load in this study, which although seen as an accurate predictor of 
muscle mutation load (Whittaker et al., 2009) in these cases, may not be 
indicative of the mutation load of muscle tissue. Further investigation of 
individuals where mutation loads do not appear to relate to disease burden are 
being explored within the group at Newcastle, to establish if these 
discrepancies in mutation loads can provide clues to the variability in disease 
burden reported.  
Another reason for the variable and limited response to exercise could be the 
type and intensity of the exercise intervention. The intensity of exercise 
sessions in this study was tailored to each participant (60-70% VO2PEAK) to 
achieve a change in exercise capacity; although in some cases this may not 
have been sufficient to achieve the maximum improvement possible. A previous 
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study investigating resistance training also showed an improvement in exercise 
capacity (Murphy et al., 2008). Interval training has also been reported to be 
able to optimise the peripheral and central adaptations to exercise and may 
provide a greater training response (Daussin et al., 2008), but its safety is yet to 
be proven in patients with mitochondrial disease. Finally it should be considered 
that the variability of response could just reflect the variability of response that is 
seen in healthy controls or due to test-retest errors (Bouchard and Rankinen, 
2001; Shephard et al., 2004). The variability of response reported in the disease 
free population may also explain the lack of response of some exercise 
parameters to training, although adherence to the training program may have 
been another contributor, with one participant reporting a failure to train one 
week prior to final testing. Also it should be noted that exercise was individually 
prescribed for each participant, this may have resulted in participants 
performing similar relative levels of training but probably very different absolute 
levels. 
The performance of participants with the m.8344A>G mutation is of particular 
interest to clinical practice; despite both individuals having low exercise capacity 
levels at baseline they demonstrated an above average response to the 
exercise intervention with improvements in oxygen consumption of 36 and 24% 
of baseline. This improvement is similar to changes reported in people without 
disease (Saltin and Gollnick, 1983) and other disease populations where very 
de-conditioned individuals demonstrated the most benefits to exercise (Petajan 
et al., 1996). The improvement seen in the most affected participants is 
encouraging as it demonstrates that cycling may provide a method of 
maintaining cardiovascular fitness of patients with mitochondrial disease with a 
high disease burden (NMDAS scores of 48 and 55). This has been previously 
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reported in Stroke and Parkinson Disease patients with limited mobility where 
other methods of training were limited or unsafe (Lee et al., 2008; Lauhoff et al., 
2013). 
The wide variety of exercise capacities and responses to the exercise seen in 
this study reiterates the difficulties in researching and reporting on the effects of 
exercise in this heterogeneous disease group. Further work is still required to 
establish the dose and type of exercise required to achieve most benefit in this 
group. Currently trials involving higher intensity stimuli and mixtures of 
resistance and aerobic exercise alongside muscle biopsy analysis are being 
undertaken to further understand the mechanisms that lead to the varied 
responses to exercise, and confirm the safety of more intensive but potentially 
more beneficial training protocols, in this disease group (Jones. K, unpublished).  
Alongside exercise capacity, proximal muscle strength was another impairment 
investigated in this trial. This is the first study to our knowledge to measure 
changes in muscle strength using dynamometry in this disease group. Proximal 
muscle strength improved but failed to reach statistical significance due to the 
high variability at baseline and variability in the response to the exercise 
intervention. Previous studies in patients with mitochondrial disease have 
demonstrated improvements in strength (Cejudo et al., 2005; Murphy et al., 
2008). Comparisons with these studies are limited, as the methods of training 
and methods of measurement were different. Previous studies including 
resistance, or a mixture of aerobic and resistance training, used different 
methods of strength measurement and different muscle groups were tested 
(quadriceps, upper limb muscles). Studies in post Stroke and elderly 
populations have also demonstrated improvements in muscle strength and 
power post an aerobic intervention (Keysor and Jette, 2001; Quaney et al., 
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2009). An improvement in muscle strength was not predicted at the outset of 
this study as muscle usually adapts specifically to training. Despite this 
presumption an increase in muscle strength was reported post aerobic training 
in the hip extensors of participants. This improvement in muscle strength may 
have occurred partly due to the use of a recumbent bike for training, which 
required greater lower limb activity (Walsh Riddle and Blumenthal, 1989 ). The 
recumbent bike was chosen due to safety requirements and enabled the 
inclusion of participants with higher disease burden, with symptoms such as 
reduced balance and ataxia, who would not have been able to use an upright 
bike safely (Lee et al., 2008). Another potential reason for the improvement in 
muscle strength was the high levels of weakness found in the mitochondrial 
population (50% of control group). Therefore, due to the high level of weakness, 
any exercise intervention would have had an element of resistance training 
(Dibble et al., 2009). This assumption is supported when examining individual 
muscle strength responses to exercise; three females with low baseline hip 
extensor muscle strength managed to increase their hip muscle strength by 
100%.  
The use of a disease free control group in this study allowed the study to 
compare the performance of patients with mitochondrial disease and sedentary 
controls. As numbers were small, and responses variable, the study was unable 
to state whether the variable level of response was typical. As proximal 
myopathy is a common manifestation within the two genotypes selected for this 
study (Chinnery et al., 1997; Kärppä et al., 2005; Mancuso et al., 2013) the 
variability seen in muscle strength and the wide variety of responses to a low 
intensity exercise intervention warrants further investigation in a larger cohort of 
patients. This study chose to investigate hip musculature due to the high 
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incidence of proximal myopathy in mitochondrial disease. The wealth of 
normative dynamometry data and ease of testing of knee musculature (Julia et 
al., 2010) makes it an alternative joint for measurement. Further testing is 
required to ascertain the merits of measurement at the knee and hip.  
This study extends previous knowledge concerning the exercise response of 
patients with mitochondrial disease by using another largely homogenous group 
(10 participants with the m.3243A>G point mutation) who have not been 
previously studied in isolation. This group differs from previous populations 
studied, as all participants reported symptoms of disease and no unaffected 
patients with low mutation loads were included (Jeppesen et al., 2006b). 
Despite all participants with mitochondrial disease being clinically affected they 
were able to complete the exercise intervention safely without any adverse 
events.  
The improvements seen in exercise capacity replicate the findings reported by 
other research groups, albeit in another defined mitochondrial group 
(Taivassalo et al., 2001; Cejudo et al., 2005; Jeppesen et al., 2006b). It is likely 
that these improvements are due to improvements in oxygen extraction due to 
mitochondrial biogenesis. Improvements were similar in both groups, confirming 
that the changes in exercise capacity are likely to be due to reversal of 
deconditioning, rather than alteration of the primary biological defect. This 
assumption cannot be confirmed by this study as no muscle biopsy analysis 
was performed. Improvements reported in muscle strength were unexpected 
and require further investigation to understand the mechanisms that resulted in 
this beneficial clinical response.  
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6.7.2 Did improvements in exercise capacity improve the function of 
patients with mitochondrial disease? 
The discussion so far has been concerned with the improvements of 
impairments such as exercise capacity and muscle strength. It is recognised 
that clinical studies should not only assess impairments but other areas 
included in the international classification of variables and outcomes (Cup 2007). 
Therefore a secondary aim of the study was to assess whether the expected 
improvements in exercise capacity were transferable into improvements in 
functional tasks.  
Measurements of function in this study were limited to investigating the effects 
of exercise on lower limb function due to the type of intervention and time 
constraints. The functional outcome measures chosen for the study measure 
common symptoms reported in mitochondrial disease, such as proximal 
myopathy, exercise capacity and impairments in mobility. The ability to walk and 
get out of a chair are important activities and are vital to a person’s 
independence (Mitchell, 2006). Unfortunately the measures used in this study 
were unable to detect changes in these activities despite the improvements 
noted in exercise capacity and muscle strength. The lack of improvement 
reported in function in this study is in line with the findings of previous studies in 
another mitochondrial group, although the use of different functional measures 
makes direct comparison difficult (Cejudo et al., 2005; Jeppesen et al., 2006b). 
An exercise trial in mitochondrial disease that did report a change in exercise 
capacity alongside a change in the functional measure 6MWD performed by 
Trenell (Trenell et al., 2006). In this trial half the participants had the 
m.3243A>G mutation and were high functioning. Despite their high level of 
functioning a statistical improvement was detected by the 6MWD (unlike in this 
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current study), although this improvement cannot be reported as a clinical 
change (2002; Flansbjer et al., 2005). These contradictory findings mimic 
findings in other neurological populations such as stroke, Multiple Sclerosis and 
Parkinson’s disease, with some trials demonstrating an increase in exercise 
capacity with improvements in functional measures such as the TUG and 
6MWD (Keysor and Jette, 2001; Quaney et al., 2009; Sabapathy et al., 2011; 
Lauhoff P et al., 2013), whilst other studies found no improvement in function 
(Lee et al., 2008; Collett et al., 2011; Mayo et al., 2013). A number of Cochrane 
reviews have found no functional benefit from exercise in neuromuscular 
conditions (Voet et al., 2010; Voet NBM, 2013) whereas other systematic 
reviews were able to report exercise to be beneficial in improving function in 
isolated neuromuscular conditions (Ørngreen et al., 2005; Haller et al., 2006; 
Cup et al., 2007; Abresch et al., 2009 ). The conflicting results of all these trials 
are probably due to the functional measures used, as function is unlikely to be 
changed by improvement in a single impairment such as exercise capacity or 
muscle strength. 
The use of the functional measures performed in this study have been 
discussed in a previous chapter, where they were reported to relate to 
community walking ability (Podsiadlo D et al., 1991 ), activities of daily living 
(Wade, 1992 ; Potter et al., 1995), risk of falling (Shumway-Cook et al., 2000) 
and lower limb strength. This study has highlighted the commonly reported 
problems of floor and ceiling effects when using functional outcome measures 
(Bohannon and Williams Andrews, 2011). In this study two participants were not 
able to perform all the walking tasks on repeat testing due to safety issues, and 
the gait speed of the remaining participants was within the normal range, 
making demonstration of further improvement difficult. The lack of improvement 
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in function in this study may be due to a number of reasons including; the floor 
and ceiling effects reported in the previous paragraph, the use of a small group 
of patients with a wide variety of disease burden, along with multiple system 
involvement, and the type of intervention.  
The following paragraphs will discuss each functional outcome measure 
individually and explore possible reasons for the results of this study. 
The 6-minute walk test (6MWD) performance of the participants with the 
m.3243A>G mutation demonstrated that the mitochondrial population covered a 
distance similar to an elderly population (Bohannon, 2007). Despite the 
distance being considerably less than the control group, the distance failed to 
improve with the exercise intervention. The 6-minute walk distance is a field test 
for sub maximal exercise capacity and therefore this lack of improvement was 
disappointing. The reason for a lack of improvement is again likely to be due to 
the small numbers included in the study and wide variations in performance. 
Walking requires multi-system involvement to perform efficiently (Hausdorff, 
2007). Impairments in other systems (such as cerebellar, motor and sensory 
systems) reported in mitochondrial disease are also likely to limit walking ability, 
hence the distance covered during the 6 minute walk test. Further 
understanding of the walking impairments reported in patients with 
mitochondrial disease and how these impairments affect walking would assist 
researchers and clinicians in their choice of more appropriate measures to 
evaluate interventions. The intervention chosen in this study was cycling, which 
provided no training effect on balance and walking impairments, unlike aerobic 
training such as walking or treadmill training. Therefore if impairments in 
balance are significant, the lack of improvement reported in the 6MWD is 
unsurprising despite the improvement in exercise capacity. However, we should 
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not rule out the possibility that the lack of improvement may also be due to the 
adoption of a slower pace to conserve energy and prevent fatigue in the 
mitochondrial participants, as these are common features of this disease group 
(Mancuso et al., 2012). If the adoption of a slower pace is an established 
pattern of behaviour in patients with mitochondrial disease it may necessary to 
incorporate a behavioural programme alongside an aerobic intervention and 
provide increased encouragement during testing to achieve a greater change in 
function. This is currently being studied in other neuromuscular conditions (Voet 
et al., 2010). 
Unlike the 6MWD the 10-metre timed walk (10MTW) found that only 4 
participants performed the test at a speed equivalent to an elderly population 
(Bohannon and Williams Andrews, 2011). Therefore detecting change in this 
measure may have been impeded by a ceiling effect. 
The five times sit to stand measure has previously been reported to not only 
assess muscle strength, but can also reflect the functioning of multiple systems 
that include coordination, balance and sensation (Lord et al., 2002) The 
mitochondrial group performance of the task is similar to an elderly population 
(Bohannon et al., 2007). Yet again the m.8344A>G subgroup performed the 
functional task with more difficulty than the participants with the m.3243A>G 
mutation, but were able to perform this test without risk of falling. The lack of 
statistical change again could be due to the small numbers involved and the 
type of intervention with the specificity of response to training likely leading to 
improvement in exercise capacity but not strength or function (ACSM, 2006). 
Although improvements in muscle power were seen in the study, it is unlikely 
that the improvements reported would be large enough to produce a change in 
the performance of a sit to stand movement. This is supported by Gross et al, 
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who showed that even though elderly women had half the strength of younger 
women they were still able to generate enough force to perform a sit to stand 
movement, and that a critical threshold needs to be crossed before a change in 
function can be observed (Gross et al., 1998; Lexell, 2000). The results from 
this study suggest that a relevant cut off point needs to be established to predict 
at what point the sit to stand movement is compromised and investigate the 
relative contributions of impairments to the loss of this vital function. 
Alongside the limitations of the measures used, the small numbers of 
participants, and the high level of functioning of the mitochondrial patients, the 
type and location of the intervention may also have contributed to the lack of 
change in function reported in the participants. Although improvements in 
function have been reported in previous studies after an aerobic intervention 
(Keysor and Jette, 2001; Quaney et al., 2009), many of these studies involved 
task specific training such as supported treadmill training (Newman et al., 2007). 
These would have stressed participants balance systems which cannot be said 
to occur with a cycling intervention (Buchner et al., 1997 ). Also improvements 
following an exercise programme in other studies have been reported to be 
more significant if the exercise is directly supervised or group based, rather than 
one that is home based or unsupervised (Snook and Motl, 2009; Mayo et al., 
2013). Despite the intervention in this study being performed in a supervised 
environment (local gym), we were unable to directly supervise every training 
session due to the geographical spread of our participants (ranging from 
Brighton to Glasgow).  
In summary, the functional measures used in this study were unable to detect 
improvements in function following an exercise intervention. This is likely to be 
due to i) the small number of participants in the study, which had been designed 
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to detect a change in exercise capacity, ii) the high level of functioning in all but 
two of the participants, and iii) the type of intervention. Despite the lack of 
change in functional tasks, future use of functional measures should not be 
dismissed, due to the multi-system nature of these measures and mitochondrial 
disease (McFarland et al., 2002; Turnbull et al., 2010). Also the lack of change 
reported in the functional measures mirrored that reported in disease severity. 
Further studies are required using functional measures on a larger cohort of 
patients to establish if the relationship between changes in functional measures 
and disease burden is robust. The establishment of a battery of functional 
measures would be valuable in providing further methods of monitoring disease 
progression and the effectiveness of interventions in this multi-system disease 
in a meaningful way for both clinicians and patients. 
6.7.3 Are disease burden, quality of life and cognition improved following 
an aerobic exercise intervention? 
This study was unable to demonstrate improvements in disease burden, quality 
of life or cognition following an aerobic intervention. Previous exercise studies 
have attempted to measure quality of life (Cejudo et al., 2005; Jeppesen et al., 
2006b; Taivassalo et al., 2006; Jeppesen et al., 2009) but none have measured 
changes in disease burden or cognitive function. 
Quality of life has been reported to improve in previous exercise studies 
although this has not always been statistically significant (Cejudo et al., 2005; 
Taivassalo et al., 2006). The measurement of quality of life is notoriously 
difficult and numerous methods are available to measure this abstract concept 
(Wade, 2003 ). This study, due to the high level of participant burden chose the 
SF12 to measure quality of life, as this measure already formed part of the 
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disease severity scale (NMDAS). This questionnaire is a shortened version of 
the SF36 used by Taivassalo et al, who previously detected an improvement in 
quality of life in patients with mitochondrial disease following an exercise 
program (Taivassalo et al., 2006), and has been shown to relate to disease 
burden (Orsucci et al., 2012). The lack of improvement reported in this study 
may have been due to the reduced sensitivity of the SF12 and that the quality of 
life scores of our participants were higher than those previously reported. The 
development of a disease specific quality of life questionnaire in Newcastle may 
provide a more relevant and sensitive measure of quality of life (Elson et al., 
2013). 
The ability of this study to measure the effect of an aerobic intervention on 
cognitive performance was prevented as only two participants presented with a 
cognitive impairment. This is in stark contrast to the incidence reported in 
previous studies (Kartsounis et al., 1992; Finsterer, 2009). It is known that 
aerobic exercise can improve cognitive function in other populations such as 
those post stroke and the healthy elderly (Weuve et al., 2004; Angevaren M, 
2008; Quaney et al., 2009; Kramer.Arthur F et al., 1999), but the effect of 
exercise on cognition has not been investigated previously in mitochondrial 
disease. Unfortunately as only two participants at baseline demonstrated 
cognitive impairment the study was unable to comment on the effect of aerobic 
exercise on cognition of the group, although cognitive scores did not improve in 
these two participants. The relatively small number of participants with cognitive 
impairment in this study may be due to the fact that either this population 
represents a high functioning subgroup of patients, or that the ACE-R was not 
sufficiently sensitive to detect deficits in cognitive function. As the ACE-R was 
devised as a brief screening tool, and not to provide in depth 
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neuropsychological assessment, this is unremarkable (Eneida et al., 2006). The 
NMDAS also includes a number of neuro-psychometric tests; the use of these 
more robust tests detected only 3 participants with cognitive deficits, which 
confirms the high level of cognitive function in the cohort of patients in this 
study. The intervention in this study required participants to exercise 
independently in a community setting and therefore seems to have limited 
recruitment to a group of patients with minimal cognitive impairment. 
In summary, quality of life is a complicated construct (Wade, 2003 ) which is 
unlikely to be changed by improvement in one impairment (exercise capacity). 
In addition, slowly progressive conditions such as mitochondrial disease appear 
to lead to a re-setting of quality of life scores, this may explain the near normal 
quality of life scores reported in our cohort at baseline (Burns et al., 2012).
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 Limitations  
Although this is the first study to evaluate the effect of an exercise intervention 
on the functional capacity of patients with mitochondrial disease the numbers 
involved remain small due to the rarity of the condition and the limited number 
of patients eligible to participate. A power calculation was performed to 
ascertain the number of participants required to be able to demonstrate a 
change in exercise capacity; this number may not have been sufficient to show 
a change in functional tests or to compare changes between groups. 
The two groups, although originally matched for age and sex, did not remain so, 
due to the withdrawal of two participants. These differences in the groups were 
further exacerbated by differences in physical activity, exercise and functional 
capacity at baseline. The differences reported were deemed to be acceptable, 
as studies have demonstrated that the differences in the physical and exercise 
capacity reported are typical in this disease population (Taivassalo et al., 2003; 
Apabhai et al., 2011). 
The mitochondrial group showed a considerable heterogeneity, despite limiting 
the study to two genotypes, and unfortunately contained only two participants 
with the m.8344A>G mutation whose abilities were different to the m.3243A>G 
participants. The inclusion of both genotypes was felt to be appropriate as both 
have high levels of muscle involvement (Chinnery et al., 1997) that has been 
shown to improve with exercise (Taivassalo et al., 2001; Trenell et al., 2006). 
The great variation in symptoms seen in this study group is typical of the 
mitochondrial disease cohort in Newcastle and was thought to represent a 
typical variation in the presentations of two genotypes. This study has 
highlighted the differences in performance of these two genotypes, suggesting 
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that future studies would benefit by restricting participants to one genotype. The 
rarity of mitochondrial disease will make this difficult and will require 
collaboration with other specialist centres within this country and around the 
world to achieve the number of participants necessary. 
The study was a case controlled study using sedentary controls unaffected by 
mitochondrial disease; no comment can be made on the whether a group with 
mitochondrial disease would have remained unchanged without an exercise 
intervention as no disease control group was used. The likelihood of any 
change in abilities was, however, thought to be unlikely over the 4 months of 
the intervention as mitochondrial disease is a slowly progressive condition.  
Participants had to be able to complete an unsupervised exercise intervention; 
therefore selection of a higher functioning group of mitochondrial patients may 
have occurred in this study thereby creating bias. Despite the patients in the 
study functioning at a high level, the level of disease burden was high (mutation 
load) and physical abilities were different to the control group.  
No conclusions can be drawn about the exact mechanisms that resulted in the 
improved exercise capacity in this study as no muscle biopsies were performed 
as part of this trial. Previous studies have reported changes to exercise capacity 
similar to the changes reported in this trial; therefore it is reasonable to presume 
that the mechanism of change is improved oxygen extraction due to 
mitochondrial biogenesis or improved efficiency of the mitochondrial respiratory 
chain. 
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 Future work  
Further work is required to assess the effects of different exercise interventions 
on other mitochondrial genotypes to ensure that exercise is safe for all types of 
mitochondrial disease. The wide range of exercise ability reported in 
mitochondrial disease and the variable responses to exercise are still not fully 
understood. Further studies are needed to enable the prescription of individual 
exercise programmes at a level that is beneficial for all patients.  
The assessment of the reliability, validity, and sensitivity, along with measures 
of minimal detectable change, of functional outcome measures is required 
within this population to enable measures to be more informative in future 
clinical trials. Greater use of functional measures in the clinical management of 
this disease group will allow clinicians and researchers to gain further 
information about how disease progression and interventions affect the activity 
and participation of patients with mitochondrial disease.
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 Conclusion 
This study demonstrates that aerobic exercise is safe and well tolerated within 
another two mitochondrial genotypes. Exercise capacity improved in the 
mitochondrial and control groups to a similar level, which confirms that the 
improvements reported in this group of patients are likely to be due to reversal 
of deconditioning rather than alterations in the primary biological deficit. 
The improvement in exercise capacity reported was not translated into 
improvements in the functional tasks measured. The functional measures used 
mirrored measures of disease burden and quality of life and therefore may have 
the potential to be used as proxy measures of disease burden. The lack of 
change in functional capacity in this study should encourage researchers to 
investigate other interventions with multi-faceted approaches. The inclusion of 
task orientated and balance interventions alongside aerobic and resistance 
exercises may lead to improvements in patients’ abilities as they challenge all 
the systems potentially involved in mitochondrial disease and this therefore 
warrants further study.  
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Chapter 7 The effect of aerobic exercise on gait 
characteristics of patients with mitochondrial 
disease 
  
230 
 Introduction  
Exercise as an intervention for people with mitochondrial disease has previously 
been shown to be beneficial for muscle symptoms such as muscle fatigue, 
muscle weakness and reduced exercise capacity, alongside benefits in quality 
of life (Cejudo et al., 2005; Jeppesen et al., 2006b; Taivassalo et al., 2006; 
Trenell et al., 2006; Jeppesen et al., 2009). Previous exercise studies in 
mitochondrial disease have assessed changes in muscle at a molecular and 
physiological level, but few have assessed whether these changes translated 
into improvement in activities of daily living such as walking. Although 
improvement in exercise capacity may be the primary goal of the researcher, 
translation into improved walking capacity is more likely to be of interest to the 
participant and if demonstrable may result in improved compliance with 
interventions. 
Walking is critical to independent function and involves the integration of many 
neurological systems to produce a coordinated movement. Gait analysis 
provides a quantifiable, selective and sensitive measurement tool that is 
capable of monitoring disease progression, is associated with primary pathology 
and is vital for independent living (Baltadjieva et al., 2006; Verghese et al., 2007; 
Rochester et al., 2012; Rochester et al., 2014b).  
Measurement of walking speed is commonly used in clinical and research 
settings, but only measures the endpoint of changes in gait and, while highly 
sensitive, lacks specificity. Individual characteristics of gait, however, have been 
used as markers of pathology and been shown to detect changes post an 
intervention (Rochester et al., 2014b). The previous cross-sectional study of gait 
in mitochondrial disease demonstrated that impairments in selective gait 
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characteristics were linked to mitochondrial disease, genotype, and that they 
related to the pathological changes and also to the burden of disease (Galna et 
al., 2013b). 
To our knowledge this is the first case controlled study utilising gait 
characteristics as measures of change after an intervention in mitochondrial 
disease. The use of gait characteristics as a measure of disease progression 
and as a research tool to evaluate interventions will allow us to further our 
knowledge concerning which aspects of walking are most affected by disease 
and which are amenable to intervention.
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  Study aims and hypotheses  
Aim  
To determine whether changes in aerobic capacity following an aerobic 
exercise intervention translate into changes in gait characteristics of people with 
mitochondrial disease.  
Primary hypothesis 
Changes in exercise capacity will result in improvement in impaired gait 
characteristics.  
Dual task performance will improve following an aerobic exercise intervention. 
Improvements in exercise capacity following an aerobic exercise intervention 
will translate into improved gait efficiency over a prolonged walk.
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 Subjects and methods  
7.3.1 Subjects and study design 
Sixty mitochondrial patients were invited to participate in the exercise study 
from consecutive attendees at a specialist outpatient clinic between August 
2010 and July 2011. Patients were clinically identified as having the 
m.3243A>G or m.8344A>G mitochondrial DNA mutation Figure 7-1. 
All eligible patients were invited to participate based on the following clinical 
inclusion criteria: (i) clinical stability for >6 months; (ii) ability to use an upright 
stationary bicycle ergometer; (iii) no current participation in regular physical 
activity (≤1 weekly session) and (iv) reported exercise intolerance and fatigue. 
Exclusion criteria were the presence of known cardiac involvement, co 
morbidities precluding exercise training, and contra-indications to Magnetic 
Resonance Imaging. 
From the 36 participants in the previous observational study (chapter 3) a 
convenience sample of thirteen patients with mitochondrial disease and the 12 
sedentary control participants continued onto an exercise intervention study. 
One participant from each group failed to return for final testing due to time 
commitments. 
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Figure 7-1: Consort diagram for the study of the effect of aerobic exercise on 
physiological, functional and gait measures in mitochondrial disease. 
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All visits were undertaken at the two centres listed in the methods section over 
a period of two days (Chapter 2) (Figure 7-2). Over the two days both disease 
and control groups underwent assessments of; baseline physical activity, 
anthropometry, resting metabolism, peak exercise capacity, proximal muscle 
strength and gait analysis. In addition the disease burden of the mitochondrial 
participants was assessed, whilst the sedentary control volunteers underwent a 
review of their medical history, physical examination and completed the 
Physical Activity Readiness Questionnaire. 
After completion of a 16-week aerobic exercise intervention all initial 
assessments (except physical activity measurement) were repeated. An 
additional visit was performed midway through the intervention, to ensure that 
no adverse responses to exercise had occurred and to reassess the exercise 
capacity of participants. 
The following section will include a brief explanation of the methods used in this 
study. (Full details can be found in Chapter 2).
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Figure 7-2: Summary of study visits and intervention. 
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7.3.2 Disease Burden  
All subjects underwent a physical examination by an experienced clinician. 
Disease severity was assessed and disease burden was established using the 
Newcastle Mitochondrial Disease Adult Scale (Schaefer et al., 2006). Mutation 
load, an established marker of clinical outcome, was derived from urinary 
epithelial cells (Whittaker et al., 2009). 
7.3.3 Anthropometry 
Body weight (kg) and standing height (m) were measured before and after the 
exercise intervention (Section 2.3.5). Whole body composition was determined 
using air displacement plethysmography (Section 2.3.6). 
7.3.4 Physical Activity  
Physical activity and energy expenditure were assessed objectively using a 
validated multi-sensor array (SenseWear Pro3, Bodymedia Inc, Pennsylvania, 
USA 2.5)(St-Onge et al., 2007).  
7.3.5 Progressive Exercise testing  
A stepped incremental workload exercise test was performed using analysis of 
expired air gases and non-invasive bio reactance cardiac output, to elicit a 
symptom limited maximum oxygen uptake and heart rate response.  
7.3.6 Muscle Strength 
Proximal muscle power of the hip flexor and extensor muscles was measured 
using an isokinetic dynamometer (CSMI HUMAC®/NORM testing and 
rehabilitation system).  
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7.3.7 Quantitative gait assessment 
Gait was assessed using a 7m long × 0.6m wide instrumented mat (Platinum 
model Gaitrite, software version 4.5, CIR systems, USA).  
Participants were asked to perform 3 different walking tasks (single task, dual 
task and a continuous walk over 6 minutes). During the single task walks 
participants were instructed to perform three 12m walks at their “comfortable 
pace”. The mat was placed in the centre of the 12 m walkway to ensure that 
steady gait speed was measured. The concurrent task for the dual task walks 
consisted of a cognitive task (digit span recall). 
The 6-minute walk involved participants walking continuously around a 25m 
oval circuit. Gait was repeatedly recorded as they walked over the mat placed 
on one side of circuit.  
Gait was quantified using a predefined model hypothesized to reflect 
independent features of neural control and characterise the features of gait 
associated with mitochondrial disease and its genotypes (Lord et al., 2013b). 
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 Aerobic training intervention  
Upon completion of baseline tests, participants undertook 16 weeks of aerobic 
exercise training. Exercise sessions were conducted at a local gym. Participants 
attended sessions 3 times a week for the 16 weeks (48 sessions in total). The 
intensity of these were tailored to the individual and increased progressively 
over the 16 weeks. Full details of the monitoring and progression of the exercise 
intervention can be found in section 6.4.  
Midway through the training period participants attended the clinical research 
facility to repeat the progressive exercise test performed at baseline. Training 
heart rates were adjusted to maintain training at a heart rate ≈70% VO2PEAK for 
the remainder of the exercise intervention.
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 Statistical Analysis  
The small numbers and variability in some gait parameters required a 
conservative approach to statistical analysis to be undertaken. The failure of 
one m.8344A>G participant to complete all walking tests led to the remaining 
participant with the m.8344A>G mutation being reported separately, with the 
remaining mitochondrial participants only containing people with the 
m.3243A>G mutation. This decision was made due to the large difference in 
performance of the two genotypes noted in the cross-sectional study (Galna et 
al., 2013b). 
To compare within group differences, before and after the exercise intervention, 
Related-samples Wilcoxon Signed Rank Tests were performed. 
Continuous data is presented as medians and interquartile ranges unless 
otherwise stated. Statistical significance was achieved with a p value of < 0.5, 
or < 0.1 where multiple comparisons were performed.
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  Results  
All consented participants attended baseline testing (Mitochondrial group n=13, 
control group n=12). At baseline one mitochondrial patient was unable to 
complete dynamometry due to an adverse response to the peak exercise test 
and two mitochondrial participants were unable to complete walking with the 
addition of a dual task due to an increased risk of falling. One of these 
participants was unable to complete any of the walking tasks during the final 
visit due to a high risk of falling. The data of this participant was, therefore, 
excluded from the final analysis. One participant from each group failed to 
attend the final visit; therefore the final results are reported for two groups of 11 
participants (MD group, m.3243A>G n=10, m.8344A>G n=1, control n=11). 
All participants completed the exercise intervention, with all participants 
completing ≥ 80% of the exercise sessions and no adverse events were 
reported.  
The following sections will report the baseline anthropological, clinical and gait 
characteristics of the participants and the responses of both groups to the 
exercise intervention. Results are presented comparing the control group with 
the m.3243A>G. The sole m.8344A>G participant’s data is reported separately. 
7.6.1 Characteristics of participants  
The baseline clinical features and disease burden of the mitochondrial 
participants shown in Table 7-1 demonstrate the wide variety of clinical features 
reported in the mitochondrial group, with a high mitochondrial mutation load and 
disease burden seen in the participants with the m.3243A>G mutation (% 
heteroplasmy; median 74,quartiles 60, 82, NMDAS score; median 15, quartiles 
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11, 22). Only one participant with the m.3243A>G mutation demonstrated 
cognitive impairment. The m.8344A>G participant showed a much higher 
disease burden with a mutation load of 95% and a NMDAS score of 55.  
Baseline demographics of all mitochondrial participants and controls are shown 
in Table 7-2. Differences at baseline between the m.3243A>G group and 
controls are clearly seen, with the m3243A<G group having a lower weight and 
baseline physical activity level. 
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Table 7-1: Baseline clinical features of exercise participant with mitochondrial diseases. 
PEO-Progressive external opthalmoplegia. 
Genotype Age Sex Heteroplasmy (%) NMDAS Principle clinical features 
m.3243A>G  58 F 59 12 Hearing loss, ataxia, constipation, underweight, myopathy, myalgia, exercise intolerance 
 39 M 80 17 Hearing loss, diabetes, migraine, fatigue, hypothyroidism, ataxia, constipation, exercise intolerance 
 37 F 48 10 Hearing loss, diabetes, exercise intolerance, ataxia, dysarthria, asthma 
 42 M 82 12 Hearing loss, diabetes, migraine, ataxia, depression, exercise intolerance 
 47 M 63 28 Hearing loss, diabetes, fatigue, ataxia, myalgia, depression, myopathy, neuropathy, ptosis, PEO 
 38 F 53 11 Hearing loss, migraine, constipation, myopathy, fatigue, exercise intolerance, asthma 
 22 M 89 17 Hearing loss, migraine, epilepsy, ataxia, constipation, underweight, exercise intolerance, fatigue 
 36 M 80 4 Migraine, exercise intolerance 
 50 M 87 23 
Hearing Loss, exercise intolerance, ataxia, myopathy, fatigue, depression, retinopathy, epilepsy, 
encephalopathy, cognitive decline, stroke-like episodes  
 55 F 68 25 
Hearing loss, diabetes, myopathy, exercise intolerance, ataxia, constipation, depression, retinopathy, 
PEO, ptosis, short stature, mild dysphagia, hypertension 
m.8344A>G  28 M 95 55 
Hearing loss, fatigue, epilepsy, ataxia, retinopathy, constipation, dysarthria, myopathy, myoclonus, 
neuropathy, exercise intolerance, underweight 
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Table 7-2: Baseline demographics and activity levels of control and mitochondrial participants.  
All data are reported as medians and (quartiles). Differences between control and m3243A<G groups are shown as * p<0.05, ** p<0.01. 
IPAQ=International Physical Activity Questionnaire 
Variable Control Mitochondrial participants p value 
 (n=11) 
(m.3243A>G) 
(n=10) 
(m.8344A>G) 
(n=1) 
m.3243A>G v control 
Age (years) 37 (28, 45) 41 (38, 49) 28 .349 
Height (cm)  170 (166, 177) 173 (164, 178) 173 .918 
Mass (kg) 81.1 (71.9, 84.7) 61.6 (52.6, 70.4) 51.7 .013* 
BMI (Kg/m2) 25 (24, 29) 20 (19, 24) 17 .006** 
Fat Free Mass (kg) 57.5 (46.8, 60.5) 45.6 (36.6, 58.6) 40.3 .173 
% Fat  29 (23, 38) 27 (18, 29) 22 .387 
     
Energy Expenditure 
(calories per day)  
2520 (2219, 2795)* 1928 (1789, 2340) 1745 .043* 
Steps taken per day  8754 (7728, 10,536)* 6385 (4280, 7076) 1465 .013* 
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7.6.2 Gait characteristics of participant’s pre and post exercise 
intervention. 
 Gait characteristics during single task walking. 
Gait variables during a single task walk pre and post intervention are reported 
for patients with the m.3243A>G mutation and sedentary controls in Table 7-3. 
Step width variability was the only gait variable to demonstrate a difference 
between the m.3243A>G and control group at baseline with gait speed being 
within normal limits. 
Gait variables during a single task walk demonstrated no significant changes 
post the exercise intervention in either group, except for step length variability in 
the control group. To demonstrate the variable responses of both groups’ 
scatterplots are shown below for 3 gait variables (Figure 7-3).
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Table 7-3: Gait characteristics during single task walking pre and post exercise intervention. 
* denotes a significant difference within group over time, †=.002 denoting a significant difference between groups at baseline. 
Gait variable Mitochondrial patients (m.3243A>G) (n=10) Median 
change 
score 
% change p value 
Controls (n=11) Median 
change 
score 
% change p value 
 Baseline Post intervention Baseline Post intervention 
Step velocity (ms-1) 1.43 (1.33, 1.64) 1.50 (1.38, 1.60) -0.006 -1 .575 1.55 (1.49, 1.64) 1.51 (1.46, 1.59) -0.04 -2 .155 
Step length (m) 0.74 (0.69, 0.86) 0.74 (0.68, 0.87) -0.005 -1 .575 0.77 (0.76, 0.80) 0.78 (0.73, 0.81) 0.002 <1 .477 
Cadence (steps.min-1) 116 (109, 123) 116 (109, 120) -1 -1 .959 119 (115, 123) 118 (111, 122) -1 -1 .213 
           
Step time asymmetry 
(ms) 
8 (4, 16) 10 (4, 16) 1 52 .333 9 (5, 11) 11 (9, 12) 2 24 .131 
           
Step length variability 
(mm) 
22 (18, 26) 17 (14, 25) 1 4 .959 18 (16, 21) 16 (13, 18) -3 -16 .021* 
Step time variability 
(ms) 
15 (13, 18) 12 (11, 16) -2 -14 .386 14 (10, 16) 12 (9, 12) -3 -24 .091 
           
Step width (cm) 9.4 (7.7, 10.7) 9.8 (7.5, 0.106) 0.1 1 .721 9.3 (8.5, 10.4) 9.6 (7.9, 11.4) 0.3 <1 .790 
Step width variability 
(mm) 
27 (24, 34)† 27 (20, 32) -2 -7 .203 17 (16, 21) 19 (17, 21) 3 14 .424 
Step length asymmetry 
(mm) 
11 (7, 14) 13 (7, 17) 2 20 .721 17 (9, 26) 12 (11, 23) -1 -3 .534 
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Figure 7-3: Scatterplots of median change scores of mitochondrial disease and control participants during single task walking. 
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 Gait characteristics during a dual task walk. 
Dual task walking at baseline demonstrated a difference in the same variable as 
reported during single task walking; step width variability. No significant 
changes were demonstrated post intervention in the either group (Table 7-4). 
Scatterplots of a selective group of variables are shown (Figure 7-4) to 
demonstrate the variety in change scores. These show a mixed picture, with 
gait velocity reduced post intervention in all but two mitochondrial participants, 
but step width variability and time symmetry increased.
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Table 7-4: Dual task walking performance pre and post exercise intervention. 
 †= .02 significant difference between groups at baseline. 
Gait variable Mitochondrial patients (m.3243A>G) 
(n=10) 
Median 
change 
score 
% change p value 
Controls (n=11) 
Median 
change 
score 
% change p value 
 Baseline Post intervention Baseline Post intervention 
Step velocity (ms-1) 1.46 (1.22, 1.52) 1.39 (1.20, 1.53) -0.03 -2 .169 1.50 (1.42, 1.59) 1.46 (1.39, 1.60) -0.18 -1 .859 
Step length (m) 0.74 (0.67, 0.75) 0.71 (0.67, 0.79) -0.007 -1 .241 0.75 (0.73, 0.77) 0.76 (0.70, 0.78) -0.004 -1 .929 
           
Cadence (steps.min-1) 117 (108, 121) 112(106,120) -1 -1 .169 121 (114, 123) 119 (111, 122) -1 <-1 .675 
           
Step time asymmetry 
(ms) 
8 (3, 10) 10 (7, 15) 4 125 .285 5 (3, 6) 9 (5, 14) 2 34 .155 
           
Step length variability 
(mm) 
22 (19, 28) 26 (21,29) 2 7 .285 18 (16, 22) 20 (16, 27) 2 10 .534 
Step time variability 
(ms) 
16 (15, 18) 16 (14.17) -2 -11 .093 14 (12, 15) 12 (11, 15) -1 -9 .657 
           
Step width (cm) 9.0 (7.6, 11.7) 9.1 (7.3, 10.6) -0.5 -4 .386 9.0 (8.7, 10.5) 8.7 (8.3, 12.4) -0.2 -2 1.00 
Step width variability 
(mm) 
25 (22, 28) † 27 (22, 31) 2 8 .333 19 (16, 22) 18 (14, 23) 1 3 1.00 
Step length 
asymmetry (mm) 
13 (5, 21) 5 (2,15) -2 -16 .721 17 (5, 26) 15 (12, 28) 4 32 .131 
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Figure 7-4: Scatterplots of median change scores of mitochondrial disease and control participants during dual task walking. 
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 Gait characteristics during a continuous, prolonged walk. 
A different gait characteristic (step time variability) demonstrated a difference at 
baseline between the groups during a continuous walk. One gait characteristic 
demonstrated a change post intervention (step width). This was, however, only 
within the control group, with the majority of participants in this group having a 
narrower gait post intervention, whereas the mitochondrial response remained 
varied (Table 7-5)(Figure 7-5). 
These results combined demonstrate that both mitochondrial and control 
groups were similar in all aspects of gait except variability at baseline, with the 
mitochondrial group demonstrating a more variable gait. Gait characteristics of 
the groups remained essentially unchanged over all three walking tests post 
exercise intervention. Investigation of individual change scores showed a varied 
response, the small numbers of participant’s involved prevents further 
interpretation of these results.
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Table 7-5: Pre and post intervention gait characteristics over a 6 minute walk.  
†denotes p=.002 between groups at baseline time point.* significant difference within group pre and post intervention. 
Gait variable Mitochondrial patients (m.3243A>G) (n=10) Median 
change 
score 
% change p value Controls (n=11) Median 
change 
score 
% change p value 
 Baseline Post intervention Baseline Post intervention 
Step velocity (ms-1) 1.29 (1.22, 1.57) 1.31 (1.24, 1.52) 0.03 2 .646 1.47 (1.35, 1.51) 1.49 (1.38, 1.56) 0.06 4 .110 
Step length (m) 0.73 (0.65, 0.81) 070 (0.66,0.81) 0.003 <1 .878 0.74 (0.71, 0.77) 0.75 (0.71, 0.80) 0.02 2 .248 
           
Cadence  
(steps.min-1) 
115 (108, 119) 111(106, 119) <1 <1 .799 114 (111, 118) 117 (111, 122) 2 2 .424 
           
Step time 
asymmetry (ms) 
8 (5, 17) 9 (5, 15) 2 13 .575 10 (5, 13) 10 (7, 15) 0.4 15 .374 
           
Step length 
variability (mm) 
20 (19, 23) 21 (18, 24) -1 -3 .721 17 (16, 22) 18 (16, 22) 0.2 1 .722 
Step time variability 
(ms) 
17 (13, 18) † 14 (12, 22) -1 -5 .721 11 (10, 12) 12 (10, 13) 1 7 .790 
           
Step width (cm) 10.4(8.3, 11.3) 10.5(9.5, 12.5) 0.7 5 .114 10.9 (9.0, 12.2) 9.2 (8.5, 11.3) -0.6 -8 .041* 
Step width 
variability (mm) 
28 (24, 30) 28 (24, 32) 1 3 .333 23 (19, 26) 22 (18, 27) -1 -3 .374 
Step length 
asymmetry (mm) 
11 (10, 14) 13 (5, 21) 1 11 .721 12 (9, 21) 12 (2, 18) -4 -27 .182 
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Figure 7-5: Scatterplots of median change scores of mitochondrial disease and control participants during a prolonged walk  
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 Dual task interference on gait characteristics  
Dual task interference was calculated using equation shown below (Rochester 
et al., 2014a): 
𝐷𝑢𝑎𝑙 𝑡𝑎𝑠𝑘 𝑖𝑛𝑡𝑒𝑟𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
𝑑𝑢𝑎𝑙 𝑡𝑎𝑠𝑘 − 𝑠𝑖𝑛𝑔𝑙𝑒 𝑡𝑎𝑠𝑘 
𝑠𝑖𝑛𝑔𝑙𝑒 𝑡𝑎𝑠𝑘 
   
Table 7-6 demonstrates that dual task interference was similar between the two 
groups at baseline and no change was reported within the mitochondrial 
disease group post intervention. A difference in interference was reported in 
step length variability within the control group.
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Table 7-6: Dual task interference pre and post exercise intervention. 
Gait variable Mitochondrial patients (m.3243A>G) Median 
change 
score 
p 
value 
Controls Median 
change 
score 
p value 
 Baseline Post intervention  Baseline Post intervention  
Step velocity (ms-1) -0.06 (-0.12, 0.04) -0.08 (-0.13, -0.04) <0.001 .386 -0.06 (-0.07, -0.03) -0.04 (-0.06,-0.002) 0.008 .534 
Step length (m) -0.04 (-0.1, -0.002) -0.07 (-0.1, -0.03) -0.007 .575 -0.04 (-0.06, -0.02) -0.03 (-0.05,-0.01) 0.003 .657 
         
Cadence (steps.min-1) -0.01 (-0.03, 0.03) -0.02 (-0.04, -0.002) -0.01 .241 -0.02 (-0.03,0.09) 0.002 (-0.01, 0.02) 0.007 .534 
         
Step time asymmetry 
(ms) 
-0.50 (-0.59, 0.12) 0.37 (-0.39, 2.07) 0.1 .508 -0.24 (-0.60, 0.84) 0.26 (-0.4, 0.4) 0.3 .477 
         
Step length variability 
(mm) 
0.11 (-0.14, 0.29) 0.27 (0.03, 0.53) 0.1 .333 -0.03 (-0.06, 0.11) 0.35 (0.04, 0.72) 0.5 .033* 
Step time variability 
(ms) 
-0.003 (-0.12, 0.24) 0.11 (-0.1, 0.3) 0.1 .878 -0.03 (-0.19, 0.32) 0.18 (-0.17, 0.53) 0.05 .534 
         
Step width (m) 0.05 (-0.1, 0.15) -0.04 (-0.08, 0.05) 0.004 .799 -0.008 (-0.04, 0.08) 0.08 (0.01, 0.13) 0.05 .647 
Step width variability 
(mm) 
-0.12 (-0.24,0.03) 0.10 (-0.14, 0.14) 0.31 .241 -0.02 (-0.07,0.12) -0.08 (-0.28, 0.16) -0.2 .722 
Step length 
asymmetry (mm) 
-0.33 (-0.48, 0.39) -0.37 (-0.71, 0.02) 0.03 .455 -0.13 (-0.58, 0.71) 0.14 (-0.08, 1.38) 0.2 155 
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 Changes in gait characteristics patients with mitochondrial disease during a 
continuous 6-minute walk. 
This study investigated whether an aerobic exercise intervention reduced 
deterioration in gait characteristics over a prolonged walk of 6 minutes. 
Comparisons were made between the gait characteristics during the first two 
and last two minutes of the 6-minute walk. At baseline no differences were 
reported between the gait characteristics between the first and last two minutes 
of a 6-minute walk (p> .05). Comparisons of median change scores pre and 
post intervention revealed no differences in gait variables.
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Table 7-7: Gait variables at the beginning and end of a 6 minute walk in participants with mitochondrial disease, pre and post intervention. 
Median (Quartiles). p value= comparison of median change scores pre and post intervention. 
Gait variable  6 minute walk pre intervention  
Median 
change 
score 
6 minute walk post intervention 
Median 
change 
score  p value   
  Minute 1&2 Minute 5&6   Minute 1&2  Minute 5&6   
Step velocity (ms-1) 1.37 (1.27, 1.55) 1.27 (1.17, 1.59) -0.04 1.35 (1.34, 1.53) 1.27(1.19, 1.52) -0.03 .878 
Step length (m) 0.72 (0.67, 0.81) 0.74 (0.64, 0.81) -0.01 0.71 (0.67, 0.82) 0.69 (0.65, 0.80) -0.01 .721 
Cadence (steps.min-1) 115 (110,119) 115 (107,118) -2 114 (109,120) 111 (105,118) -1 .721 
Step time asymmetry (ms) 9.5 (5.6,15.1) 9.2 (1.5, 19.3) -2 8.8 (6.4, 15.5) 9.5 (7.2, 12.2) 0.4 .721 
Step length variability (mm) 21.1 (18.5, 26.8) 19.3 (17.3,23.0) -0.4 21.8 (18.0, 24.4) 23.2 (17.2, 25.2) 0.2 .333 
Step time variability (ms) 17.9 (14.5, 20.2) 15.7 (13.6, 19.3) -1 16.2 (13.6, 18.8) 14.9 (13.4, 20.0) 0.04 .575 
Step width (cm) 9.4 (8.8, 10.8) 10.9 (8.0, 12.2) 4 10.6 (8.6, 12.0) 10.7 (9.7, 12.2) 0.004 .508 
Step width variability (mm) 28.4 (23.3, 30.7) 24.2(22.3,28.5) -3 27.2 (22.8, 35.3) 27.6 (24.3, 28.9) -1 .878 
Step length asymmetry (mm) 7.7 (4.1, 14.4) 11.7 (6.3,16.4) -0.1 10.4 (7.3, 19.6) 11.3 (6.7, 22.2)  < 0.1 .799 
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7.6.3 The effect of an aerobic exercise intervention on demographics, 
exercise parameters and gait characteristics. 
Demographic features remained unchanged after the exercise intervention 
except for mass and BMI within the mitochondrial group (mass; 61.6 (52.6, 70.4) 
vs. 62.1 (53.4, 70.9), p= .047). This represents less than a 1% change in the 
median. The cognitive performance remained the same (94 (92, 97) vs. 95 (92, 
98) (p= .833), as did the disease severity (NMDAS) (15 (11, 22) vs. 13 (10, 21) 
(p=. 631).  
As reported in the previous chapter the exercise parameters and hip strength 
improved in both mitochondrial and control groups post an aerobic exercise 
intervention in both the genotypes assessed (Table 6-4,Table 6-5). 
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7.6.4 The effect of an exercise intervention on demographics, exercise and 
gait characteristics of the m.8344A>G participant 
Only one participant with the m.8344A>G mutation was able to complete the 
gait analysis under single task conditions. The m.8344A>G participant’s gait 
was shown to be more globally affected than the m.3243A>G group and 
therefore their results are presented separately (Table 7-8).  
The baseline demographics show an increase in weight, fat free mass, and 
percentage fat, post exercise intervention (weight (kg); 52-55; fat free mass (kg) 
40-41; % fat 22-26). Improvements are observed in peak exercise capacity 
(peak heart rate; 165-144, peak exercise capacity (ml/kg/min); 13.2-15.3; 
anaerobic threshold (ml/kg/min); 8.1-11.3; peak workload (watts/kg); 0.8-0.7, 
arterial venous O2 difference; 5.9-6.7). Proximal hip strength demonstrated a 
mixed response with an improvement in hip extensor (0.63-0.72 nm/kg) and a 
reduction in hip flexor (0.25-0.15 nm/kg). A small reduction was observed in 
disease severity (NMDAS score 55-52). 
The following table demonstrates an improvement in all aspects of gait for the 
sole participant with the m.8344A>G mutation, with improvements observed in 
velocity, step length and step width alongside a reduction in variability and 
asymmetry. 
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Table 7-8: Changes in gait characteristics of the participant with the m.8344A>G 
mutation.  
Gait variable Baseline  Post exercise  
Step velocity (ms-1) 0.71 1.07 
Step length (m) 0.53 0.66 
   
Cadence (steps.min -1) 80 98 
   
Step time asymmetry (ms) 51.7 19.6 
   
Step length variability (mm) 56.7 37.9 
Step time variability (ms) 87.98 28.64 
   
Step width (m) 0.17 0.11 
Step width variability (mm) 60.6 35.8 
Step length asymmetry (mm) 41.1 20.9 
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 Discussion 
Mitochondrial diseases result in a wide variety of symptoms that have the 
potential to affect gait. The previous cross-sectional study demonstrated that 
patients with mitochondrial disease present with selective gait deficits. These 
deficits relate to the pathological consequences of mitochondrial disease, and 
clinically measured disease burden, in a selective manner (Galna et al., 2013b). 
Exercise intervention studies within mitochondrial populations have been shown 
to improve exercise capacity, muscle strength, fatigue and function (Cejudo et 
al., 2005; Taivassalo et al., 2006; Trenell et al., 2006; Mancuso et al., 2012). 
Efficient gait is essential for independent living and functional activities 
(Studenski et al., 2003). Measurement of gait has been used previously to 
identify pre-clinical symptoms, monitor disease progression (Lord et al., 2013a; 
Rochester et al., 2014b) and evaluate exercise interventions within neurological 
and elderly populations (Newman et al., 2007; King and Horak, 2009; 
VanSwearingen et al., 2011; Reisman et al., 2013). This case controlled 
intervention study investigated the changes in gait characteristics post an 
aerobic exercise intervention as a marker of disease progression, fatigue and 
cognitive function. 
The key findings of the study were that gait characteristics remained unchanged 
following an aerobic exercise intervention in the group of patients with the 
m.3243A>G mutation. Improvements were detected in participant with the 
m.8344A>G mutation with more globally affected gait, but these results are 
difficult to extrapolate to a wider group. Gait characteristics of the mitochondrial 
group with the m.3243A>G mutation mirrored measures of disease burden 
rather than exercise capacity.  
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The following sections will discuss the effects of the exercise intervention in this 
population and elucidate a possible explanation for the limited effects on gait of 
the exercise intervention used in this study. 
7.7.1 The effects of an aerobic exercise intervention on the exercise 
performance of patients with mitochondrial disease 
As previously discussed (chapter 6), all aspects of exercise performance 
improved following the exercise intervention in the mitochondrial group and the 
sub set of patients with the m.3243A>G mutation. The improvements in 
exercise characteristics were in agreement with previous studies and were 
probably due to peripheral adaptation of muscle tissue to exercise. Despite 
changes in exercise capacity, disease burden and cognition remained 
unchanged. 
7.7.2 The effects of an aerobic exercise intervention on the gait 
characteristics of patients with mitochondrial disease 
In this study gait characteristics during all three walks (single, dual task and 
continuous) remained unchanged following an exercise intervention in 
participants with the m.3243A>G mutation, despite improvements in exercise 
capacity and hip strength. These findings were not replicated in the one 
participant with the m.8344A>G mutation demonstrating a more globally 
impaired gait. In this participant improvements were reported in step velocity 
with increased cadence and step length, without increases in variability, 
asymmetry and step width. These improvements are likely to be due to 
improvements in secondary compensations to disease rather than primary 
pathology. 
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This study is the first study to use gait characteristics as a method of evaluating 
an intervention in mitochondrial disease. It therefore remains unclear if the 
results of this study are typical of this population, or a result of the type of 
intervention or gait measures used. To evaluate the results of this study, it is 
necessary to review the baseline characteristics of the study population and the 
use of gait measures within this and other populations following an exercise 
intervention. 
The mitochondrial population participating in this exercise study was a subset of 
the previous cross sectional study. Fewer gait impairments were reported 
compared to the larger cross sectional study possibly due to the population 
being higher functioning and smaller in number. Gait speed was within normal 
limits, with only the gait variables of step time and width variability 
demonstrating differences compared to the sedentary control group. It is likely 
that having such a high functioning population at baseline meant that gait 
measures were unlikely to demonstrate a change due to ceiling effects within 
the measures despite an improvement in endurance.  
Although this is the first study to use specific gait measures in this population, 
gait has previously been used to evaluate exercise studies in other neurological 
and elderly populations(Macko et al., 2005; Herman et al., 2007; Bello et al., 
2008; Lee et al., 2008; van Eijkeren et al., 2008; Frazzitta et al., 2009; 
VanSwearingen et al., 2011). Results from these studies are difficult to compare 
due to the inconsistent use of gait measures and the propensity to use gait 
speed, rather than characteristics that may link to specific pathological changes 
(Macko et al., 2005; Herman et al., 2007; van Eijkeren et al., 2008; Cadore et al., 
2013). Of the studies that did include multiple gait characteristics in the 
evaluation of exercise (Frenkel-Toledo et al., 2005; Newman et al., 2007; Bello 
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et al., 2008; Frazzitta et al., 2009), all involved treadmill training or walking as 
an intervention and therefore it is uncertain whether changes were due to 
aerobic training or the task specific nature of the intervention (King and Horak, 
2009). Despite the differences in populations, and the gait measures and 
exercise interventions used, some aspects of these studies may warrant 
discussion in relation to this study. 
Cycling as an exercise intervention has previously demonstrated improvement 
in walking in a number of neurological populations, such as Parkinson disease 
(Lauhoff P et al., 2013), Multiple Sclerosis (Rampello et al., 2007) and stroke 
(Lennon et al., 2008). In this study, as in others, cycling enabled participation of 
a wider ability group, as participants could still perform the intervention 
confidently despite mild balance impairments. The inclusion of a wider inclusion 
group is important in rare diseases such as mitochondrial disease where 
numbers are limited. In previous studies using cycling as an intervention, 
improvements have been reported in muscle strength (Lovell DI et al., 2010 ), 
gait efficiency (Lauhoff P et al., 2013), balance and walking distance (Kileff and 
Ashburn, 2005), some of which were reported in the previous study in this 
thesis (chapter 6). Dibble et al reported that any activity is beneficial in 
participants that are deconditioned and the type of intervention did not dictate 
that improvement (Dibble et al., 2009). This result supports the findings of 
improved gait characteristics reported in the most affected participant of this 
study (m.8344A>G mutation), where improvement was substantial in all aspects 
of gait. These findings warrant further investigation despite the likely reason for 
improvements being the reduction in the secondary consequences of a 
sedentary lifestyle such as improved exercise tolerance (Rampello et al., 2007), 
rather than primary pathology. The effects of aerobic exercise have been shown 
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to extend beyond improvement in cardiovascular fitness to include 
improvements in cognition (Yaffe K et al., 2001;; van Gelder et al., 2004), motor 
relearning and neuroplasticity (Fisher and Sullivan, 2001; Herman et al., 2007; 
Bello et al., 2008), it is therefore possible that disease specific benefits may 
have occurred in this participant over and above the maintenance of fitness. As 
only one participant reported this improvement these results should be viewed 
with caution.  
Cycling has been shown to be useful in deconditioned subjects where walking 
may be limited. However, multi component exercise programs which include 
task orientated interventions such as Nordic walking and treadmill training have 
been shown to be potentially more beneficial in many neurological and elderly 
populations at improving walking than cycling alone (Buchner et al., 1997 ; 
Sabapathy et al., 2011; VanSwearingen et al., 2011). Also interventions that 
result in the improvement of specific impairments such as strength and exercise 
do not necessarily improve function (Lee et al., 2008), with improvements in 
strength only leading to improved walking where weakness is profound (Cup et 
al., 2007). It can also be expected that to improve walking participants need to 
walk (Buchner et al., 1997 ). A recent Cochrane review of the treatment of 
balance impairments in elderly also reported that there was no evidence that 
general physical activity such as cycling improved balance (Howe et al., 2011). 
It is therefore likely that a high functioning group of mitochondrial patients, as in 
this study will require a more specific intervention that targets changes in the 
nervous system by challenging balance and gait performance.  
Interventions such as treadmill training have been shown to alter gait variability, 
asymmetry and speed in neurological conditions such as Parkinson’s Disease 
(Frenkel-Toledo et al., 2005) and Stroke (Moore et al., 2010; Reisman et al., 
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2013). Treadmill training and walking programmes in patients with Parkinson’s 
disease are thought to act as an external cue for patients and result in reduced 
variability in gait, or have an effect on motor relearning as patients concentrate 
on walking and override deficits in basal ganglia (van Eijkeren et al., 2008). 
Although the length of time these improvements remain post training is still 
under debate (Mehrholz et al., 2010). These task specific exercises may be of 
greater benefit in high functioning groups (van Eijkeren et al., 2008) due to the 
specific nature of training and the greater challenge placed on balance systems 
and may warrant further investigation in a population of mitochondrial patients. 
In summary the gait characteristics mirrored disease severity not exercise 
capacity following an aerobic exercise intervention. The near normal gait of the 
study population and the type of intervention may have restricted the ability of 
this study to demonstrate that gait characteristics have potential to measure 
change during intervention studies in mitochondrial disease. 
7.7.3 Can changes in fatigue and cognition following an aerobic exercise 
intervention be demonstrated by changes in gait characteristics? 
Originally this study aimed to demonstrate that gait characteristics would be 
able to predict changes seen in cognition and fatigue following an aerobic 
intervention in the mitochondrial participants. Unfortunately only one participant 
with the m.3243A>G mutation demonstrated a cognitive deficit at baseline and 
no change was detected in the cognitive function of the mitochondrial group 
after the exercise intervention using a clinical measure of cognition. Dual task 
interference also remained unchanged post intervention, so we are 
consequently unable to report that dual task walking reflects cognitive function 
in patients with mitochondrial disease.  
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The lack of cognitive impairment within this group is surprising as previous 
studies have reported that cognitive impairment is a common manifestation of 
mitochondrial disease (Kartsounis et al., 1992; Finsterer, 2009). Aerobic 
exercise has been shown to improve cognitive function in other disease 
populations (Weuve et al., 2004; Quaney et al., 2009). Deterioration in dual task 
performance has been linked to cognitive decline, attention and executive 
function (Sheridan et al., 2003; Yogev et al., 2005). The lack of cognitive 
impairment in the study population limited the ability to investigate the effects of 
an exercise intervention on changes in cognitive function and the relationship 
with gait performance. 
In summary this study was unable to draw any firm conclusions on the use of 
aerobic exercise as an intervention to reduce cognitive decline in this 
population. Further work is required to ascertain the mechanisms of gait 
impairment in mitochondrial disease and whether cognitive impairment is a 
contributor to gait impairments in this group of patients.  
The use of gait characteristics to measure fatigue is a novel one, in the previous 
cross sectional study it was hypothesised that gait characteristics would 
deteriorate over time as the participant’s muscles became fatigued. The 
performance of an aerobic intervention was hypothesised to improve muscle 
function and therefore reduce the deterioration in gait characteristics over time. 
Gait characteristics over a 6-minute walk remained unchanged and remained 
the same post exercise intervention. These results could be due to the length of 
walk not resulting in muscle fatigue or the fact that fatigue is not the primary 
cause of the gait changes seen in these patients. The repeated testing pre and 
post intervention over a time period of 4 months demonstrated that cycling 
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neither improved nor worsened gait characteristics over a 6-minute walk. As no 
disease control group was included, this study was unable to report that gait 
would have remained unchanged without the exercise intervention. Although 
this is thought to be unlikely as participants included in the study had been 
stable for 6 months and mitochondrial disease is slowly progressive. Again, the 
likely causes for the lack of change in gait were that, the mitochondrial 
population used in the study were only mildly affected and therefore the 6-
minute timed walk was unable to measure fatigue. These limitations have 
already been discussed in the cross-sectional study looking at gait 
characteristics in the larger cohort of patients.  
Fatigue and exercise intolerance are common symptoms, with fatigue present in 
35% of patients with a m.3243A>G mutation and reported as the 4th most 
common clinical manifestation of disease (Mancuso et al., 2012), with 62% of a 
Newcastle cohort of mitochondrial patients reporting a score over 40 in the 
Fatigue Impact Scale (Gorman et al., 2015). The 6-minute walk is commonly 
used as a clinical measure of physical fitness and mobility in numerous 
populations (Lord and Menz, 2002; Duncan et al., 2003). The study sought to 
evaluate whether, the selective nature of gait characteristics would provide 
insights into the potential mechanisms of an exercise intervention to reduce 
fatigue and whether gait could be used as a surrogate measure of fatigue. 
Currently the mechanisms of fatigue in mitochondrial disease are unclear, with 
the focus of previous work relating it to exercise intolerance (Mancuso et al., 
2012), although recent work appears to also indicate that fatigue in 
mitochondrial disease may also have more central components (Gorman et al., 
2015). Gait characteristics such as cadence, hip extension and step width are 
reported to relate to the energy cost of walking (Wert et al., 2010). Impairments 
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in gait characteristics in mitochondrial disease may result in an inefficient gait 
pattern which may lead to increased fatigue and hence reduced activity levels. 
Gait analysis in this population as a measure of fatigue needs to be investigated 
in a patient group with higher fatigue and disease burden. Investigation within a 
more severely affected group may provide different results to those reported in 
this study.  
Further work investigating gait over greater time periods and within patients with 
higher levels of fatigue may provide more insight into the effect of fatigue on gait. 
Measurement in the community my provide this. The introduction of 
technologies that allow gait measurement in real life situations mean that gait 
should still be considered as a selective, sensitive, reliable and unobtrusive 
means of evaluating interventions in mitochondrial disease.
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 Limitations 
Despite this study being the first investigation of gait characteristics post an 
intervention the numbers involved remain very small, with the m.8344A>G 
group being reduced to one. The numbers included were based on a power 
calculation devised to detect a “within group” change in exercise capacity; this 
may not have been large enough to detect changes in gait. To overcome the 
small numbers a conservative approach was adopted for statistical analysis and 
the m.8344A>G participant was reported separately, thereby increasing the 
homogeneity of the mitochondrial group. As the m.8344A>G group only 
included one participant little can be deduced about the effects of exercise on 
gait in this genotype, although improvements were noted in this individual. 
Due to the rarity of these conditions randomisation was not thought to be 
appropriate as it may have limited recruitment and hence self-selection was 
used to provide the exercise participants. This may well have resulted in the 
participants volunteering for the study, coming from a very high functioning 
population that was mobile and without cognitive impairment.  
As the mitochondrial population presented with minimal impairments this study 
was unable to fully explore the use of dual task walking as a measure of 
changes in cognitive function and the potential use of gait analysis to measure 
fatigue.
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 Future work  
Longitudinal studies are required to quantify the natural progression of gait 
impairments in mitochondrial disease and to assess the value of gait as a 
sensitive marker of disease progression. 
The measurement of gait variability is a novel technique and hence no clear 
figures are available to ascertain what would be constituted as a meaningful 
change? The more widespread use of gait variables as measures of disease 
burden and progression could prove valuable in detecting small changes in 
function over time and post interventions. 
Other types of exercise intervention and specific gait rehabilitation require 
investigation in patients with mitochondrial disease to establish the potential for 
rehabilitation of gait in this population.
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 Conclusion 
In summary, this study demonstrated that improvements in muscle function due 
to an aerobic exercise intervention were not translated into improved gait 
performance in a group of high functioning patients with the m.32423A>G 
mutation. The lack of change in gait is likely to be due to a number of reasons, 
with the most obvious ones being the lack of demonstrable gait impairments 
prior to the intervention and the small numbers included in the study.  
As the gait impairments reported reflect neurological pathological changes, 
while the intervention improved muscle function, the lack of resulting 
improvement in gait is unsurprising. Interventions, which target both 
neurological and muscular impairments, may more effective at maintaining and 
improving gait efficiency in this group and should be considered for future 
studies.  
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Chapter 8 Discussion 
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This research has demonstrated that a discrete population with mitochondrial 
disease was sedentary, that they had lower levels of exercise capacity and that 
this reduced exercise capacity could be safely ameliorated with aerobic 
exercise. However a link between improved exercise capacity and improved 
functional ability has not been clearly demonstrated. The novel findings of this 
thesis are that; i) functional outcomes have the potential to be used in future 
research studies and clinical practice to demonstrate impairment in activities 
and; ii) that gait analysis is capable of providing selective measurement of these 
impairments with the capacity to relate to pathology. 
This discussion will explore the use of measures in mitochondrial disease and 
their potential use in future clinical practice and research. Finally it will review 
the benefits and limitations of aerobic exercise as a therapy in mitochondrial 
disease and explore other therapies that could be of value in this population. 
The multi systemic presentation of mitochondrial disease with its great range of 
symptoms, severity and the limited relationship between genotype and 
phenotype (Chinnery et al., 1997; McFarland and Turnbull, 2009; Nesbitt et al., 
2013), has meant that monitoring disease progression and evaluating 
interventions has been problematic (Chinnery et al., 2006; Pfeffer et al., 2012). 
These difficulties have been further exacerbated by the rarity of patients and the 
small numbers participating in clinical trials. The commencement of the UK 
MRC Mitochondrial disease patient cohort study has partly addressed this issue 
by enabling the collection of data over a prolonged period of time in a large 
number of mitochondrial disorders and acting as a cohort of patients willing to 
participate in clinical trials (Nesbitt et al., 2013).  
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Despite great strides being made in understanding the causes of mitochondrial 
disease and methods to limit transmission, the measurement of patient’s 
abilities has thus far been limited to a disease rating scale (NMDAS) (Schaefer 
et al., 2006) and assessment of exercise capacity (Jeppesen et al., 2006b; 
Taivassalo et al., 2006; Trenell et al., 2006). The use of the NMDAS has proven 
successful in providing an indication of disease severity, progression and quality 
of life, but the total score fails to identify which aspects of disease are most 
affected or changing and provides little assistance in identifying possible 
interventions that may be of benefit. So far the use of exercise capacity as a 
measure of mitochondrial function has been limited to the small numbers of 
patients partaking in exercise trials due to the cost and time required for testing. 
The use of exercise capacity as a measure in mitochondrial disease has clearly 
demonstrated impairment and has led to the development of exercise as a 
potential treatment in these conditions (Taivassalo et al., 2006; Jeppesen et al., 
2009). Despite its invaluable contribution as a measure, especially in studies 
including exercise as an intervention, it is still unclear if improved exercise 
capacity is beneficial in increasing activity or participation (World Health 
Organization, 2001). 
The methods of measurement used in this thesis (functional outcome measures 
and gait analysis) have demonstrated that they are capable of identifying people 
with mitochondrial disease, discriminate between genotypes and mirror 
changes in disease severity. The future use of these measures is exciting as 
their ease of use will enable clinicians and researchers to collect further data on 
a much larger, more diverse group of patients with mitochondrial disease as 
part of the clinical review of patients. Also it should be remembered that 
changes in measures such as exercise capacity, although exciting to a 
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researcher, are often of little interest to a patient, unless they result in 
improvement in function or quality of life. With this in mind the development of 
measurements within the domains of activity and participation are vital to 
clinicians and patients alike in understanding the effects of this disease.  
Despite functional measures providing a method of assessing numerous 
impairments via a single functional task it should not be assumed that one 
measure will fit all. Unfortunately this appears to have happened in other areas 
of neuromuscular research where the use of the 6MWD seems to have become 
extremely prevalent. The studies in this thesis have demonstrated that more 
than one measure may be required to enable detection of change in disease 
burden in patients with mitochondrial disease. As with any other measure, the 
researcher should always bear in mind what it is they want to measure, and 
what they expect to change, when choosing a functional outcome. Due to the 
variety of symptoms and abilities of patients with mitochondrial disease, one 
measure will never fit all. Therefore it is likely that a battery of outcomes will be 
required to cover all the possible presentations reported in this population. This 
thesis was limited to investigation of lower limb function; therefore further work 
will be required to include upper limb and non-ambulant function.  
Although the recent Cochrane review (Pfeffer et al., 2012) advised a 
rationalisation of primary outcomes in future studies, hopefully the studies 
contained in this thesis have demonstrated that although many inter-
relationships occur between different measures, each has properties of value in 
measuring a different aspect of disease. In fact, to evaluate a multivariate 
construct such as function, where decline is observed as patterns of change 
occurring in strength, balance, endurance and other impairments, at different 
rates, it is essential to measure impairments and function simultaneously.  
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The use of multiple functional measures as suggested above still has limitations. 
Functional outcomes are simple, crude tests and represent the end results of 
impairments and therefore do not shed light into the potential mechanisms of 
change in performance. The use of gait analysis appears to give researchers 
and clinicians a way forward in detecting early changes in function and potential 
mechanisms for these changes. 
Gait impairment is already recognised as one of the most common problems in 
neurological conditions (Nutt et al., 2011). Further evaluation of gait in 
mitochondrial disease will provide researchers with numerous avenues for 
research. If linked with other neurological investigations such as MRI, it has the 
potential to confirm the impact of neurological pathology on walking in 
mitochondrial disease. In addition gait analysis provides clinicians the ability to 
quantify changes in walking not visible to the naked eye whilst gait speed may 
still be normal. This creates the potential to enable clinicians to intervene much 
earlier with treatment before secondary compensations become entrenched and 
therefore intervention is more likely to be successful.  
Until now methods of measuring function have been limited to measurement of 
tasks within a laboratory environment and therefore do not accurately reflect 
function in the community. With the development of new technologies the 
measurement of functional tasks and gait in the real world is now possible. The 
use of these new techniques will provide much greater insight into how 
mitochondrial disease affects patients, as measurement can be performed over 
an extended time period and represents total activity/ambulation. This is seen 
as a gold standard (Busse et al., 2004).  
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The intervention of aerobic exercise in this thesis was shown to be beneficial in 
another discrete group of mitochondrial patients. Due to the specific response of 
the body to different types of exercise and the multivariate construct of function 
it was unsurprising that improvement in exercise capacity, did not translate to 
improvement in other activities. So has the benefit of exercise and its potential 
as a therapy in mitochondrial disease been over stated? Although exercise 
capacity in this study didn’t improve to the extent necessary to improve function, 
this does not mean that it would not be effective in a more severely affected 
group of patients. Also the known benefits of physical exercise in the able 
bodied for health maintenance and disease prevention is just as, if not more 
vital in patients with mitochondrial disease where cardiac and metabolic 
dysfunction and sedentary behaviour are prevalent. Therefore the current 
practice of recommending physical activity to patients should be continued. 
As aerobic training alone appeared to be unhelpful in changing function it is 
imperative that future studies investigate other methods of training that may be 
beneficial in this group. The functional and gait measures that were used in this 
thesis demonstrated difficulties with getting in and out of a chair and walking. 
When examining walking more closely by gait analysis, impairments were 
detected in gait variability. Therefore other interventions that challenge postural 
stability and cerebellar dysfunction (Martin et al., 2009) should be considered. 
Essentially this population requires a multifaceted approach that specifically 
tackles impairments that have been exposed with these improved measurement 
tools. These types of programmes have already resulted in improvements in 
other populations, where strength, balance and task related exercises have 
been performed alongside aerobic training (Tiedemann et al., 2011). These 
interventions are more likely to result in improvement, as they are able to 
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produce dynamic changes in the central nervous system by active participation 
in specific tasks at a level of difficulty and intensity individual to the patient 
(Fisher and Sullivan, 2001; Ip et al., 2013). 
As in all populations, continued participation in exercise is challenging. To 
maximise adherence it is necessary for exercise provision to be individual to 
that person and change with their condition. To further ensure participation 
exercise needs to be part of everyday life, accessible and enjoyable. The 
advent of computer based, activity related games provides another method of 
delivering exercise to a group who may not have the confidence to perform 
exercise in the community (Phillips et al., 2009). Exploring the use of these 
games that often use large movements in a goal-orientated manner may 
provide a readily available exercise tool with 50 % of homes now containing a 
game console (Deloitte Media Consumer Survey 2013). 
In summary these studies have clarified the value of cycling as a form of 
aerobic exercise in mitochondrial disease. The alternative methods of 
measurement used here, have highlighted that investigation of other, more 
specific, interventions would be beneficial in mitochondrial disease.
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  Future work  
This thesis can only be seen as a starting point for the use of functional 
outcome measures and gait analysis in mitochondrial disease, with the results 
revealing many further questions to be investigated.  
Despite the measures used in this thesis being shown to discriminate between 
disease and genotype, further work is required to ensure their reliability, 
reproducibility and the level of change that is deemed clinically relevant in this 
population. Measures also need to be investigated that cover the whole 
spectrum of mitochondrial disease. The investigation of upper limb function and 
the measurement of aspects of disease within a non–ambulant population are 
also still necessary. 
This preliminary work in gait analysis has provided interesting insights into early 
gait impairments in this disease. Further work now needs to be performed in a 
larger cohort, over a longer time period to identify whether this method of 
measurement changes with disease progression and whether this will provide 
clues for the use of different type of interventions. The investigation of different 
types of aerobic exercise is essential in this disease group, as treatments such 
as treadmill training may provide the best of both worlds, improving 
mitochondrial function in both muscular and neurological systems and has been 
shown to arrest neuro-degeneration in animal and human models (Tillerson et 
al., 2003; Fisher et al., 2004; Voss et al., 2010). 
The small numbers of some genotypes and the great variety of symptoms 
reported in mitochondrial disorders continue to prevent large-scale trials. 
Researchers will need to collaborate more in the future to produce the 
participants required for such trials. However, the value of publishing  small 
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scale or single case reports in these disorders should not be forgotten and have 
provided the starting point for interventions previously in these diseases 
(Taivassalo et al., 1999b) and in fact may be the way forward in research in this 
disease. 
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 Conclusion  
Exercise and rehabilitation interventions need to be specific, tailored to each 
patient and constantly adapted to address the changes reported by patients as 
disease progression occurs. To evaluate these interventions and map disease 
progression measurements must be accurate, relevant and reproducible. Multi 
system diseases such as mitochondrial disease will always require numerous 
measurements to monitor disease progression and evaluate interventions. It is 
important that measures include all aspects of disease from impairment of 
bodily structures to activities and participation. Only by linking theses areas of 
measurement will we understand how mechanisms of disease result in loss of 
function and the effect they have on our patient’s daily lives. With this 
knowledge researchers have the potential to develop more relevant and 
successful interventions.
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Appendix A Information Sheets  
      
 
REC reference number:  
Committee:  
 
  
 
 
Dr M I Trenell PhD, MSc, BSc (hon) 
Diabetes UK RD Lawrence Fellow 
Newcastle Magnetic Resonance Centre  
Campus for Ageing and Vitality 
Newcastle University 
NE3 5JB 
 
Tel: 0191 2411158 
M.I.Trenell@newcastle.ac.uk       
 
 
Participant Information Sheet 
 
Effect of aerobic exercise on cardiac function and movement in people 
with mitochondrial disease (exercise control group) 
 
You are being invited to participate in this research project. Please take time to 
read the following information carefully. It explains why the research is being 
carried out and what it involves. If you have any questions about the information, 
you are very welcome to ask for a further explanation. 
 Part 1 tells you about the purpose of this study and what will happen 
during the study. 
 Part 2 gives more detailed information about the conduct of the study. 
Discuss with others if you wish and take time to decide regarding your 
participation. 
 
    Thank you for reading this 
 
Part 1 
 
 
What is the purpose of the research project? 
The aim of this research is to demonstrate that aerobic exercise training is an 
effective approach to therapy in certain patients with mitochondrial disease. 
Based on our previous research studies, we believe that such training will 
improve muscle strength, mitochondrial function, exercise tolerance and overall 
quality of life. In this project we will be looking at the effects exercise has on the 
hearts of people with mitochondrial disease, and a group of people without the 
condition so we can make a comparison between people with a mitochondrial 
disease and those who don’t have the condition. 
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Why have I been chosen?  
You have been chosen as you are between the ages of 18 and 60 years and 
are considered to be fit and healthy, do not do any exercise and do not suffer 
from a mitochondrial disease.  
 
 
 
Do I have to take part? 
 
Your participation is purely voluntary. If you decide to take part, you are still free 
to withdraw at any time without giving reasons and without any current or future 
care being affected in any way. If you do decide to take part, you will be given 
this information sheet to keep and be asked to sign a consent form indicating 
your willingness to participate in the research. 
 
 
What will this research project involve? 
You will be asked to attend the Newcastle Magnetic Resonance Centre at 
Newcastle General Hospital, or Royal Victoria Infirmary on 4 occasions over 4 
months to have a metabolism examination. You will also be asked to attend 
exercise sessions 3 times a week for 16 weeks.  
 
Visit 1:You will be asked to sign the consent form saying that you would like to 
take part in this research study and then complete two screening 
questionnaires. You will then do a cycling test. During this test you will 
cycle at the same pace but how hard you are cycling will increase every 
minute. You will keep on cycling until you decide to stop or until pedalling 
becomes difficult. Whilst you are cycling you will be asked to wear a 
mouthpiece and a heart rate monitor. The exercise test will last between 
10 - 15 minutes. At the end of the test you will feel tired but will recover 
quickly.  
Total Visit Time: 1hour 
 
Visit 2: A blood sample will be taken. 
 
Magnetic resonance imaging (MRI) will be used to measure the function 
of        your heart. This exam takes 1 hour in total and is non-invasive 
(which means there will be no harm to you).  However if you have any 
steel pins or a pacemaker inside your body, or are pregnant, you will not 
undergo this exam.   
  
           You will then be asked to lie quietly on a bed whilst your resting 
metabolism is measured. After this you will repeat a cycle test similar to 
the previous day. 
 
 This will be followed by some walking tests in the gait laboratory, where 
you will be asked to:  
a) Walk short distances while we will measure your speed and 
step length  
b) Walk for 6 minutes so we can measure the distance you have 
walked in this time. 
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           c) Perform a repeated sit to stand movement while being timed. 
  
The maximal strength of your thigh muscles will be measured on weight 
machines, as shown here in the picture.  
 
You will also be asked to complete some questionnaires regarding 
fatigue, quality of life and cognition  
 
Total visit time: 6 hours 
 
 
 
 
 
Following this you will be assigned an exercise programme.  
 
You will be asked to attend 3 exercise classes per week over 16 weeks. Each 
exercise session will involve you doing endurance training on a stationary 
bicycle at moderate intensity (70-80% of your maximal heart rate) 3 times per 
week for a total of 30 minutes per session increasing as you are able. If you are 
unable to tolerate 30 minutes of continuous exercise, you will do exercise 
intervals (for example, 3 x 10 minutes with rest periods in between). 
You will also be asked to attend the centre at 4 weeks for the following 
procedures:  
 
Visit 3: A blood sample will be taken. 
  
 We will discuss with you how your exercise has been going  
 
 We will repeat the cycle and strength tests done at visit 2 
 
 Total visit time: 2hours 
.  
 
After 16 weeks, the metabolic evaluations performed at Visits 2 will be repeated, 
making a maximum of 4 study visits in total..  
 
 
Expenses and payments 
 
Throughout the exercise studies, you will be provided with: 
  
1. Membership to gym near your home;  
2. Heart rate monitor to measure the intensity of cycling exercise during trial 
3. Overnight accommodation  will be provided for visits to assessments 
where         necessary. All travel expenses to and from Newcastle will be 
provided by the trial funds. 
 
 
What do I have to do? 
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It will be important that you attend over 90% of the exercise sessions. You will 
be asked not to drink alcohol or exercise the day before the three test days.  
Each of the metabolic assessments will be in the morning before breakfast – 
you should not eat before you come to the centre. Food will be provided for you 
after the examination.  
 
 
 
What are the side effects of treatment received when taking part? 
 
This study involves exercise so there are no side effects (such as may occur 
with drugs).  
 
 
Are there any other possible disadvantages of taking part? 
 
Giving up time to participate has to be considered. 
 
What are the possible benefits of taking part? 
 
Being more physically active may be beneficial to your heart function and if 
sustained after the study, may help in preventing other complications such as 
heart disease and diabetes. You will have supervised exercise sessions (like a 
personal trainer) who will teach you about your body, show you how to exercise 
correctly and help you become more physically fit.  
 
What happens at the end of the research project? 
 
At the end of the project, we shall be able to inform you of how the exercise 
affected your heart. 
 
What if there is a problem? 
 
If you have any concern or complaint about any aspect of the study this will be 
dealt with immediately by Dr Trenell. Contact details are given at the end of Part 
1.  
 
Will my taking part in the project be kept confidential? 
 
All information obtained during the course of the research project will be kept 
strictly confidential. Your own GP will be informed of your participation in the 
project. 
 
What will happen to the results of the research study? 
 
The results of the project will be presented in national and international 
neuromuscular meetings and will be published in one of the neurology journals. 
You will not be identified in any report or publication. You will be welcome to 
have a copy of the results once they are published. 
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Who has reviewed the study? 
 
Ethical review of the study has been conducted by Sunderland Research Ethics 
Committee. 
 
Who are the contacts for further information? 
 
Further information can be obtained from: 
 
Dr Mike Trenell 
Diabetes UK RD Lawrence Fellow 
Newcastle Magnetic Resonance Centre  
Campus for Ageing and Vitality 
Newcastle University 
NE3 5JB 
 
Tel: 0191 2411158 
M.I.Trenell@ncl.ac.uk    
 
Or 
 
Mr G Bell 
Clinical Trial Co-ordinataor 
MRC Centre for neuromuscular research 
Institute of Human Genetics 
Newcastle upon Tyne  
NE1 3BZ 
 
Tel: 0191 241 8649 
Geoffrey.bell@ncl.ac.uk                            
       
 
Thank you.                                                                                                        
 
******************************** 
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Part 2 
 
 
What if relevant new information becomes available? 
 
If new information is published during the course of a study this can sometimes 
change how the research should go forward. However, for this study it is most 
unlikely that this would occur. The study design is unique, and there are very 
few research groups worldwide able to carry out magnetic research of this kind.  
 
What will happen if I don’t want to carry on with the study? 
 
You would be able to withdraw from the study at any time. Measurements 
already made would still be used if you were to agree to this.  
 
What if there is a problem? 
 
a) Complaints 
If you have any concern or complaint about any aspect of this study you should 
contact Dr Trenell by phone on 0191 241 1158, or write to him at the address at 
the end of Part 1 of this document. If you remain unhappy you can contact Dr 
Lesley Hall, Research Governace Manager,Newcastle upon Tyne Hospitals 
NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP; 
Tel 0191 233 6161 
b) Harm 
In the unlikely event that something does go wrong and you suffer in any way 
the arrangements are as follows. If negligence of staff led to harm, then this 
would be covered by the Newcastle upon Tyne Hospitals Trust clinical 
negligence scheme. You may have to meet legal costs. If any harm was non-
negligent then the hospital trust may consider a discretionary payment.   
 
 
Will my taking part in the project be kept confidential? 
 
All information obtained during the course of the research project will be kept 
strictly confidential. This will be achieved by storing information in password-
protected computer files, and appointment information in locked filing systems 
within the Magnetic Resonance Centre. No individually identifiable information 
will be stored outside the Centre.  
 
Analysis of the detailed results of the research will be done by Dr Trenell, Jane 
Newman, Dr Hollingsworth, Professor Turnbull and Dr Bates. At this stage no 
personal information is part of the dataset. Results will be sent to participants, 
presented at scientific meetings and published in scientific journals without 
personal identification of any volunteer although thanks to the volunteers will be 
recorded.  
 
Your own General Practitioner will be informed of your help with this study, 
should you agree to this. The detailed results of the research tests will not be 
sent to anybody outside the Magnetic Resonance Centre.  
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What will happen to blood samples? 
 
The samples will be tested for CK, liver function, insulin, sugar fat, and other 
food derived substances. We will also be performing a test called a ‘BNP assay’ 
– this would allow us to detect any changes in your heart function during the 
period of the study.  Samples will be stored until it is certain that the test results 
are accurate, and then they will be disposed of. During storage, samples are 
identified only by a code number, not your name. No genetic or other tests will 
be carried out on the samples.  
 
What will happen to results of the research? 
 
The results will be presented at scientific meetings for discussion by other 
experts in this field. They will be written up in the form of a scientific paper and 
this will be intended to be published in a suitable scientific journal. As soon as 
the results are fully analysed after the end of the entire study you will receive a 
letter describing what we have found. 
 
Who is organising and funding the research? 
 
This project is funded from a project grant from the Medical Research Council. 
The design and organisation of the study is the responsibility of Dr Trenell and 
Professor Turnbull who are internationally recognised as experts in this field.  
 
There is no payment to any of the researchers involved in this study. They are 
employed by Newcastle University to work in the NHS, to teach and to research 
and have no financial link with the study.  
 
Who has reviewed the study? 
 
Ethical review of the study has been conducted by Sunderland Research Ethic 
Committee.  
 
Design of this information sheet 
 
This document is written in accordance with the requirements of the European 
Clinical Trials Directive 2001/20/EC, the ICH Good Clinical Practice guidelines 
and the UK Medicines for Human Use (Clinical Trials) Regulation 2004.  
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Newcastle Upon Tyne 
NE2 4HH 
 
      
Patient Information Sheet 
 
Effect of aerobic exercise on cardiac function and movement in people 
with mitochondrial disease 
 
You are invited to participate in this medical research project. Please take time 
to read the following information carefully. It explains why the research is being 
done and what it involves. If you have any questions about the information, you 
are very welcome to ask for further explanation. Thank you for reading this. 
 Part 1 tells you about the purpose of this study and what will happen 
during the study. 
 Part 2 gives more detailed information about the conduct of the study. 
Discuss with others if you wish and take time to decide regarding your 
participation. 
 
Part 1 
 
 
What is the purpose of the research project? 
To demonstrate that aerobic exercise training is an effective approach to 
therapy in certain patients with mitochondrial myopathy. Based on our previous 
research studies, we believe that such training will improve muscle strength, 
mitochondrial function, exercise tolerance and overall quality of life. In this 
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project we will be looking at the effects exercise has on the hearts of people 
with Mitochondrial disease. 
 
Why have I been chosen?  
Because you are between the ages of 18 and 70 years and have had a 
previous a muscle biopsy showing a defect in skeletal muscle mitochondrial 
DNA.  
 
 
Do I have to take part? 
 
Your participation is purely voluntary. If you decide to take part, you are still free 
to withdraw at any time without giving reasons and without any bad feelings. If 
you do decide to take part, you will be given this information sheet to keep and 
be asked to sign a consent form. 
 
 
What will the research project involve? 
You will be asked to attend the Newcastle Magnetic Resonance Centre at 
Newcastle General Hospital, or Royal Victoria Infirmary on 4 occasions over 4 
months to have a metabolism examination. If you take part in the exercise 
group you will also be asked to attend exercise sessions 3 times a week for 16 
weeks.  
 
Visit 1:Day 1. 
 You will be asked to sign the consent form saying that you would like to 
take part in this research study and then complete two screening 
questionnaires. You will then do a cycling test. During this test you will 
cycle at the same pace but how hard you are cycling will increase every 
minute. You will keep on cycling until you decide to stop or until pedalling 
becomes difficult. Whilst you are cycling you will be asked to wear a 
mouthpiece and a heart rate monitor. The exercise test will last between 
10 - 15 minutes. At the end of the test you will feel tired but will recover 
quickly. A disease scale will be performed involving some questionnaires. 
A brief heart scan using ultrasound (echocardiogram) will be performed. 
Total Visit Time: 1.5hour 
 
Visit 1: Day 2. 
A blood sample will be taken. This will be sent to the laboratory and 
checked for routine levels, as well as a test called a BNP assay – this is 
an analysis of your blood that could help us detect any changes in your 
heart function. We will repeat this check at the end of the study. 
 
Magnetic resonance imaging (MRI) will be used to measure the function 
of        your heart. This exam takes 1.5 hours in total, and is very safe (no 
harm to  
           you), however if you have any steel pins or pacemaker inside your body, 
           or are pregnant or have significant kidney disease, you will not undergo 
this exam.  A small drip (cannula) will be placed in a vein in your arm so 
that we can use a type of dye during the scan. The cannula will be 
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placed by an experienced doctor or nurse and will be removed after the 
scan.   
           You will then be asked to lie quietly on a bed whilst your resting 
metabolism is measured. After this you will repeat a cycle test similar to 
the previous day. 
 
 This will be followed by some walking tests in the gait laboratory, where 
you will have to:  
a) Walk short distances and we will measure your speed and step 
length  
b) Walk for 6 minutes and we will measure the distance walked  
           c) Be timed doing a repeated sit to stand movement 
  
The maximal strength of your thigh muscles will be measured on 
weight machines as shown here in the picture.  
 
You will be asked to complete some questionnaires regarding 
fatigue, quality of life and cognition. 
 
You will be provided with an activity monitor to wear for 7 days whilst 
performing your normal daily activities.  
 
Total visit time: 6 hours 
 
 
You will be assigned to one of two groups.  
 
The first group will attend 3 exercise classes per week over 16 weeks. Each 
exercise session will involve you doing endurance training on a stationary 
bicycle at moderate intensity (70-80% of your maximal heart rate) 3 times per 
week for a total of 30 minutes per session increasing as able to 40 minutes. If 
you are unable to tolerate 30 minutes of continuous exercise, you will do 
exercise intervals (for example, 3 x 10 minutes with rest periods in between). 
This group will also attend the centre at 4 weeks.  
 
Visit 2 :A blood sample will be taken. 
 We will discuss with you how your exercise has been going. 
We will repeat the cycle and strength tests done on visit 2 
 
  Total visit time: 2hours 
 
   
 
The second group will not attend the exercise classes or be required to 
undertake any exercise over the 16 weeks.  
 
After 16 weeks, the metabolic evaluations performed at Visits 2 will be repeated, 
making 4 study visits in total (for the exercise group).  
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If you are placed in the group which does not attend any exercise classes, at 
the end of the study you will be given the opportunity to participate in exercise 
sessions, though this attendance is not compulsory. No further tests will be 
undertaken if you choose to take part in these exercise sessions. 
 
Expenses and payments 
 
Throughout the exercise studies, you will be provided with: 
  
4. Membership to gym near your home;  
5. Heart rate monitor to measure the intensity of cycling exercise  during 
trial 
6. Overnight accommodation  will be provided for visits to assessments 
where         necessary. All travel expenses to and from Newcastle will be 
provided by the trial funds. 
 
 
What do I have to do? 
 
You will continue with your usual treatment(s) during the project. It will be 
important that you attend over 90% of the exercise sessions. You will be asked 
not to drink alcohol or exercise the day before the three test days.  
Each of the metabolic assessments will be in the morning before breakfast – 
you should not eat before you come to the centre. Food will be provided for you 
after the examination.  
 
 
 
What are the side effects of treatment received when taking part? 
 
This study involves exercise so there are no side effects (such as may occur 
with drugs).  
 
Are there any other possible disadvantages of taking part? 
 
Giving up time to participate has to be considered. 
 
What are the possible benefits of taking part? 
 
Being more physically active may be beneficial to your heart ,mitochondrial 
function and if sustained after the study, may help in preventing other 
complications such as heart disease and diabetes. You will have supervised 
exercise sessions (like a personal trainer) which will teach you about your body, 
show you how to exercise correctly and help you become more physically fit.  
 
What happens at the end of the research project? 
 
At the end of the project, we shall be able to inform you of how the exercise 
affected your heart and mitochondrial function 
 
What if there is a problem? 
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If you have any concern or complaint about any aspect of the study this will be 
dealt with immediately by Dr Trenell. Contact details are given at the end of Part 
1.  
 
Will my taking part in the project be kept confidential? 
 
All information obtained during the course of the research project will be kept 
strictly confidential. Your own GP and the Mitochondrial Disorders Service will 
be informed of your participation in the project. 
 
What will happen to the results of the research study? 
 
The results of the project will be presented in national and international 
neuromuscular meetings and will be published in one of the neurology journals. 
You will not be identified in any report or publication. You will be welcome to 
have a copy of the results once they are published. 
 
Who has reviewed the study? 
Ethical review of the study has been conducted by the Sunderland Research 
Ethic Committee.  
 
Who are the contacts for further information? 
 
Further information can be obtained from: 
 
Dr Mike Trenell 
Diabetes UK RD Lawrence Fellow                        
  
MRC Muscle Performance and Training Laboratory  
Newcastle General Hospital,  
Westgate Road, 
Newcastle upon Tyne        
Tel 0191 248 1150  
 
Thank you.                                                                                                        
 
******************************** 
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Part 2 
 
 
What if relevant new information becomes available? 
 
If new information is published during the course of a study this can sometimes 
change how the research should go forward. However, for this study it is most 
unlikely that this would occur. The study design is unique, and there are very 
few research groups worldwide able to carry out magnetic research of this kind.  
 
What will happen if I don’t want to carry on with the study? 
 
You would be able to withdraw from the study at any time. Measurements 
already made would still be used if you were to agree to this.  
 
What if there is a problem? 
 
c) Complaints 
If you have any concern or complaint about any aspect of this study you should 
contact Dr M Trenell by phone on 0191 248 1150, or write to him at the address 
at the end of Part 1 of this document. If you remain unhappy you can contact 
the Research Governace Framework Manager of the Newcastle upon Tyne 
Hospitals NHS Foundation Trust (Dr L Hall, Joint Research Office, Level 6, 
Leazes Wing, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon 
Tyne NE1 4LP; Tel 0191 233 6161).  
 
d) Harm 
In the unlikely event that something does go wrong and you suffer in any way 
the arrangements are as follows. If negligence of staff led to harm, then this 
would be covered by the Newcastle upon Tyne Hospitals NHS Foundation Trust 
clinical negligence scheme. You may have to meet legal costs. If any harm was 
non-negligent then the hospital trust may consider a discretionary payment.   
 
Will my taking part in the project be kept confidential? 
 
All information obtained during the course of the research project will be kept 
strictly confidential. This will be achieved by storing information in password-
protected computer files, and appointment information in locked filing systems 
within the Magnetic Resonance Centre. No individually identifiable information 
will be stored outside the Centre.  
 
Analysis of the detailed results of the research will be done by Dr Trenell, Jane 
Newman, Dr Hollingsworth, Professor Turnbull and Dr Bates . At this stage no 
personal information is part of the dataset. Results will be sent to participants, 
presented at scientific meetings and published in scientific journals without 
personal identification of any volunteer although thanks to the volunteers will be 
recorded.  
 
Your own General Practitioner will be informed of your help with this study, and 
this is normal practice. Your specialist liver consultant will also be aware. The 
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detailed results of the research tests will not be sent to anybody outside the 
Magnetic Resonance Centre.  
 
 
 
 
 
What will happen to blood samples? 
 
The samples will be tested for CK, liver function, insulin, sugar fat, and other 
food derived substances. We will also be performing a test called a ‘BNP assay’ 
– this would allow us to detect any changes in your heart function during the 
period of the study.  Samples will be stored until it is certain that the test results 
are accurate, and then they will be disposed of. During storage samples are 
identified only by a code number, not your name. No genetic or other tests will 
be carried out on the samples.  
 
What will happen to results of the research? 
 
The results will be presented at scientific meetings for discussion by other 
experts in this field. They will be written up in the form of a scientific paper and 
this will be intended to be published in a suitable scientific journal. As soon as 
the results are fully analysed after the end of the entire study you will receive a 
letter describing what we have found, and what implications it has for people 
with mitochondrial disorders 
 
Who is organising and funding the research? 
 
This project is funded from a project grant from the Newcastle Hospitals Trust 
Joint Research Committee. The design and organisation of the study is the 
responsibility of Dr Trenell, Professor Turnbull who are internationally 
recognised as experts in this field.  
 
There is no payment to any of the researchers involved in this study. They are 
employed by Newcastle University to work in the NHS, to teach and to research 
and have no financial link with the study.  
 
Who has reviewed the study? 
 
Ethical review of the study has been conducted by the Newcastle and North 
Tyneside Research Ethic Committee No. 1.  
 
Design of this information sheet 
 
This document is written in accordance with the requirements of the European 
Clinical Trials Directive 2001/20/EC, the ICH Good Clinical Practice guidelines 
and the UK Medicines for Human Use (Clinical Trials) Regulation 2004.  
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Appendix B  Consent forms 
      
 
    
REC reference number:  
Committee:  
 
CONSENT FORM for participants 
Title of Study: The effect of aerobic exercise on cardiac function and movement in people 
with Mitochondrial disease(exercise control group) 
 
Name of Researcher: 
Dr M I Trenell PhD, MSc, BSc (hon) 
Diabetes UK RD Lawrence Fellow 
Newcastle Magnetic Resonance Centre  
Campus for Ageing and Vitality 
Newcastle University 
NE3 5JB 
 
Tel: 0191 2411158 
M.I.Trenell@newcastle.ac.uk 
 
                   
Please write your initials in the box 
 
 
1. I confirm that I have read and understand the information sheet dated May 2010  
(Version 2.0) for the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
 
 
2.  I understand that my participation is voluntary and that I am free to withdraw 
 at any time, without giving any reason, without  my medical care or legal   
rights being affected.          
 
3. I agree to sections of my medical records being viewed by members of the    
 research team for this study        
 
 
 
4.  I agree to my GP being informed to my participation in the study 
 
 
5.  I agree to take part in the above study.   
 
 
________________________  
Name of Patient    
 
______________________ ________________
 ____________________ 
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 Date Signature 
 
_________________________ ________________
 ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ ________________
 ____________________ 
Researcher Date Signature 
 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
 
Version 2.0 May 2010 
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REC reference number:  
Committee:  
 
CONSENT FORM for patients 
Title of Study: The effect of aerobic exercise on cardiac function and movement in people with 
Mitochondrial disease 
 
Name of Researcher: 
Dr M I Trenell PhD, MSc, BSc (hon) 
Diabetes UK RD Lawrence Fellow 
Newcastle Magnetic Resonance Centre  
Campus for Ageing and Vitality 
Newcastle University 
NE3 5JB 
 
Tel: 0191 2411158 
M.I.Trenell@newcastle.ac.uk 
 
                   
Please write your initials in the box 
 
 
1. I confirm that I have read and understand the information sheet dated May 2010   
(Version 3.0) for the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
 
 
2.  I understand that my participation is voluntary and that I am free to withdraw 
  at any time, without giving any reason, without  my medical care or legal   
rights being affected.          
 
3. I agree to sections of my medical records being viewed by members of the    
  research team for this study        
 
 
 
4.  I agree to my GP being informed to my participation in the study 
 
 
5.  I agree to take part in the above study.   
 
 
________________________  
Name of Patient    
 
______________________ ________________
 ____________________ 
 Date Signature 
 
 
 
 
 
Version 2.0 May 2010 
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_________________________ ________________
 ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ ________________
 ____________________ 
Researcher Date Signature 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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Appendix C PARQ 
Physical Activity Readiness 
Questionnaire 
 
 
Name:  ____________________ 
 
Date of Birth: ____________________ 
 
  Please choose 
1 Has your doctor ever said that you have a heart 
condition and that you should only do physical activity 
recommended by a doctor? 
 
YES NO 
2 Do you ever feel pain in your chest when you do 
physical activity? 
 
YES NO 
3 Have you ever had chest pain when you are not doing 
physical activity? 
 
YES NO 
4 Do you ever feel faint or have spells of dizziness? 
 
YES NO 
5 Do you have a joint problem (also back problem) that 
could be made worse by exercise? 
 
 
YES NO 
6 Have you ever been told that you have high blood 
pressure? 
 
YES NO 
7 Are you currently taking any medication? 
If so, what? __________________ Reason _______ 
 
YES NO 
8 Are you pregnant, have you had a baby in the last 6 
months, or do you plan to have a baby this year? 
 
YES NO 
9 Is there any other reason why you should not 
participate in physical activity? 
If so, what? __________________________________ 
 
YES NO 
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Appendix D  IPAQ 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do as 
part of their everyday lives. The questions will ask you about the time you spent being 
physically active in the last 7 days. Please answer each question even if you do not 
consider yourself to be an active person. Please think about the activities you do at 
work, as part of your house and yard work, to get from place to place, and in your 
spare time for recreation, exercise or sport. 
 
Think about all the vigorous and moderate activities that you did in the last 7 days. 
Vigorous physical activities refer to activities that take hard physical effort and make 
you breathe much harder than normal. Moderate activities refer to activities that take 
moderate physical effort and make you breathe somewhat harder than normal. 
 
PART 1: JOB-RELATED PHYSICAL ACTIVITY 
The first section is about your work. This includes paid jobs, farming, volunteer work, 
course work, and any other unpaid work that you did outside your home. Do not include 
unpaid work you might do around your home, like housework, yard work, general 
maintenance, and caring for your family. These are asked in Part 3. 
 
1. Do you currently have a job or do any unpaid work outside your home? 
 
 Yes 
 
 No Skip to PART 2: TRANSPORTATION 
 
The next questions are about all the physical activity you did in the last 7 days as part 
of your paid or unpaid work. This does not include traveling to and from work. 
 
2.  During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, heavy construction, or climbing up stairs as 
part of your work? Think about only those physical activities that you did for at 
least 10 minutes at a time. 
 
_____ days per week 
 
 No vigorous job-related physical activity Skip to question 4 
 
3. How much time did you usually spend on one of those days doing vigorous 
physical activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
4. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate physical activities like carrying light loads as part of your work? 
Please do not include walking. 
 
_____ days per week 
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 No moderate job-related physical activity Skip to question 6 
 
 
5. How much time did you usually spend on one of those days doing moderate 
physical activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
6. During the last 7 days, on how many days did you walk for at least 10 minutes 
at a time as part of your work? Please do not count any walking you did to 
travel to or from work. 
 
_____ days per week 
 
 No job-related walking Skip to PART 2: TRANSPORTATION 
 
7. How much time did you usually spend on one of those days walking as part of 
your work? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
 
These questions are about how you traveled from place to place, including to places 
like work, stores, movies, and so on. 
 
8. During the last 7 days, on how many days did you travel in a motor vehicle 
like a train, bus, car, or tram? 
 
_____ days per week 
 
 No traveling in a motor vehicle Skip to question 10 
 
9. How much time did you usually spend on one of those days traveling in a train, 
bus, car, tram, or other kind of motor vehicle? 
 
_____ hours per day 
_____ minutes per day 
 
Now think only about the bicycling and walking you might have done to travel to and 
from work, to do errands, or to go from place to place. 
 
10. During the last 7 days, on how many days did you bicycle for at least 10 
minutes at a time to go from place to place? 
 
_____ days per week 
 
 No bicycling from place to place Skip to question 12 
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11. How much time did you usually spend on one of those days to bicycle from 
place to place? 
 
_____ hours per day 
_____ minutes per day 
 
12. During the last 7 days, on how many days did you walk for at least 10 minutes 
at a time to go from place to place? 
 
_____ days per week 
 
 No walking from place to place Skip to PART 3: 
HOUSEWORK, HOUSE 
MAINTENANCE, AND 
CARING FOR FAMILY 
 
13. How much time did you usually spend on one of those days walking from place 
to place? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
 
This section is about some of the physical activities you might have done in the last 7 
days in and around your home, like housework, gardening, yard work, general 
maintenance work, and caring for your family. 
 
14. Think about only those physical activities that you did for at least 10 minutes at 
a time. During the last 7 days, on how many days did you do vigorous 
physical activities like heavy lifting, chopping wood, shoveling snow, or digging 
in the garden or yard? 
 
_____ days per week 
 
 No vigorous activity in garden or yard Skip to question 16 
 
 
15. How much time did you usually spend on one of those days doing vigorous 
physical activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
16. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate activities like carrying light loads, sweeping, washing windows, and 
raking in the garden or yard? 
 
_____ days per week 
 
 No moderate activity in garden or yard Skip to question 18 
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17. How much time did you usually spend on one of those days doing moderate 
physical activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
18. Once again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate activities like carrying light loads, washing windows, scrubbing floors 
and sweeping inside your home? 
 
_____ days per week 
 
 No moderate activity inside home Skip to PART 4: 
RECREATION, SPORT 
AND LEISURE-TIME 
PHYSICAL ACTIVITY 
 
19. How much time did you usually spend on one of those days doing moderate 
physical activities inside your home? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
 
This section is about all the physical activities that you did in the last 7 days solely for 
recreation, sport, exercise or leisure. Please do not include any activities you have 
already mentioned. 
 
20. Not counting any walking you have already mentioned, during the last 7 days, 
on how many days did you walk for at least 10 minutes at a time in your 
leisure time? 
 
_____ days per week 
 
 No walking in leisure time Skip to question 22 
 
21. How much time did you usually spend on one of those days walking in your 
leisure time? 
 
_____ hours per day 
_____ minutes per day 
 
22. Think about only those physical activities that you did for at least 10 minutes at 
a time. During the last 7 days, on how many days did you do vigorous 
physical activities like aerobics, running, fast bicycling, or fast swimming in 
your leisure time? 
 
_____ days per week 
 
 No vigorous activity in leisure time Skip to question 24 
 
23. How much time did you usually spend on one of those days doing vigorous 
physical activities in your leisure time? 
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_____ hours per day 
_____ minutes per day 
 
24. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate physical activities like bicycling at a regular pace, swimming at a 
regular pace, and doubles tennis in your leisure time? 
 
_____ days per week 
 
 No moderate activity in leisure time Skip to PART 5: TIME 
SPENT SITTING 
 
25. How much time did you usually spend on one of those days doing moderate 
physical activities in your leisure time? 
_____ hours per day 
_____ minutes per day 
 
 
PART 5: TIME SPENT SITTING 
 
The last questions are about the time you spend sitting while at work, at home, while 
doing course work and during leisure time. This may include time spent sitting at a 
desk, visiting friends, reading or sitting or lying down to watch television. Do not include 
any time spent sitting in a motor vehicle that you have already told me about. 
 
26. During the last 7 days, how much time did you usually spend sitting on a 
weekday? 
 
_____ hours per day 
_____ minutes per day 
 
27. During the last 7 days, how much time did you usually spend sitting on a 
weekend day? 
 
_____ hours per day 
_____ minutes per day 
 
 
This is the end of the questionnaire, thank you for participating. 
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Appendix E Order of gait and functional measures 
Counterbalanced condition order list 
Subject Task 1 Task 2 Task 3 Task 4 Task 5 Task 6 
GLMEC 001 P S T S Dual walk Single walk Dual + 1 walk TuG 6m walk 
GLMEC 002 P Single walk Dual walk Dual + 1 walk S T S TuG 6m walk 
GLMEC 003 P TuG Single walk Dual walk Dual + 1 walk S T S 6m walk 
GLMEC 004 P S T S TuG Dual walk Single walk Dual + 1 walk 6m walk 
GLMEC 005 P S T S Single walk Dual walk Dual + 1 walk TuG 6m walk 
GLMEC 006 P TuG S T S Single walk Dual walk Dual + 1 walk 6m walk 
GLMEC 007 P Single walk Dual walk Dual + 1 walk TuG S T S 6m walk 
GLMEC 008 P S T S TuG Single walk Dual walk Dual + 1 walk 6m walk 
GLMEC 009 P Dual walk Single walk Dual + 1 walk TuG S T S 6m walk 
GLMEC 010 P TuG S T S Dual walk Single walk Dual + 1 walk 6m walk 
GLMEC 011 P Dual walk Single walk Dual + 1 walk S T S TuG 6m walk 
GLMEC 012 P TuG Dual walk Single walk Dual + 1 walk S T S 6m walk 
GLMEC 001 PC Dual walk Single walk Dual + 1 walk S T S TuG 6m walk 
GLMEC 002 PC TuG Dual walk Single walk Dual + 1 walk S T S 6m walk 
GLMEC 003 PC Single walk Dual walk Dual + 1 walk S T S TuG 6m walk 
GLMEC 004 PC TuG S T S Single walk Dual walk Dual + 1 walk 6m walk 
GLMEC 005 PC S T S Single walk Dual walk Dual + 1 walk TuG 6m walk 
GLMEC 006 PC Single walk Dual walk Dual + 1 walk TuG S T S 6m walk 
GLMEC 007 PC TuG Single walk Dual walk Dual + 1 walk S T S 6m walk 
GLMEC 008 PC Dual walk Single walk Dual + 1 walk TuG S T S 6m walk 
GLMEC 009 PC S T S TuG Single walk Dual walk Dual + 1 walk 6m walk 
GLMEC 010 PC S T S TuG Dual walk Single walk Dual + 1 walk 6m walk 
GLMEC 011 PC S T S Dual walk Single walk Dual + 1 walk TuG 6m walk 
GLMEC 012 PC TuG S T S Dual walk Single walk Dual + 1 walk 6m walk 
GLMEC 001 C Dual walk Single walk Dual + 1 walk S T S TuG 6m walk 
GLMEC 002 C Dual walk Single walk Dual + 1 walk TuG S T S 6m walk 
GLMEC 003 C S T S TuG Single walk Dual walk Dual + 1 walk 6m walk 
GLMEC 004 C TuG S T S Single walk Dual walk Dual + 1 walk 6m walk 
GLMEC 005 C Single walk Dual walk Dual + 1 walk TuG S T S 6m walk 
GLMEC 006 C TuG S T S Dual walk Single walk Dual + 1 walk 6m walk 
GLMEC 007 C S T S TuG Dual walk Single walk Dual + 1 walk 6m walk 
GLMEC 008 C Single walk Dual walk Dual + 1 walk S T S TuG 6m walk 
GLMEC 009 C TuG Dual walk Single walk Dual + 1 walk S T S 6m walk 
GLMEC 010 C S T S Dual walk Single walk Dual + 1 walk TuG 6m walk 
GLMEC 011 C S T S Single walk Dual walk Dual + 1 walk TuG 6m walk 
GLMEC 012 C TuG Single walk Dual walk Dual + 1 walk S T S 6m walk 
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Appendix G  Relationships between gait variables and NMDAS 
 
Spearman correlations (p value ) 
 
Pace Rhythm Asymmetry Variability Postural control 
NMDAS component Step Velocity Step Length Cadence 
Step time 
asymmetry 
Step length 
variability 
Step time 
variability 
Step width 
Step width 
variability 
Step length 
asymmetry 
Vision -.398 (-0.054) -.460(.024) -.198 (.353) .345 (.099) .253 (.233) .032 (.883) .446 (.029) .272 (.198) .378 (.068) 
Hearing -.130 (.546) -.064 (.765) .046 (.832) -.071 (.741) -.214 (.315) -.144 (.502) .256 (.227) .259 (.221) .309 (.141) 
Speech -.469 (.021) -.431 (.035) -.423 (.039) .382 (.066) .307 (.145) .240 (.259) .352 (.092) .377 (.069) .333 (.112) 
Swallowing -.291 (.167) -.239 (.260) -.117 (.585) .030 (.888) .120 (.578) .048 (.825) .309 (.142) .450 (.027) .503 (.012) 
Handwriting -.581 (.003) -.472 (.020) -.449 (.028) .379 (.068) .521 (.009) .408 (.048) .388 (.061) .511 (.011) .394 (.057) 
Cutting -.526 (.008) -.539 (.007) -.338 (.107) .344 (.100) .633 (.001) .599 (.002) .247 (.244) .420 (.041) .354 (.090) 
Dressing -.513 (.010) -.494 (.014) -.459 (.024) .513 (.010) .570 (.004) .532 (.007) .267 (.207) .551 (.005) .358 (.086) 
Hygiene -.518 (.010) -.500 (.013) -.465 (.022) .518 (.010) .572 (.003) .535 (.007) .291 (.167) .555 (.005) .346 (.098) 
Exercise -.662 (.000) -.699 (.000) -.348 (.096) .485 (.016) .513 (.010) .504 (.012) .357 (.087) .367 (.078) .440 (.032) 
Gait -.546 (.006) -.570 (.004) -.408 (.048) .446 (.029) .459 (.024) .331 (.114) .437 (.033) .601 (.002) .287 (.174) 
Psychiatric -.389 (.060) -.419 (.041) -.052 (.811) .151 (.481) .167 (.434) .027 (.901) .163 (.447) .065 (.764) .684 (.000) 
Migraine .248 (.243) .214 (.316) .019 (.929) .089 (.680) -.202 (.344) -.450 (.027) -.453 (.026) -.041 (.849) .209 (.327) 
Seizures -.432 (.035) -.435 (.034) -.362 (.082) .610 (.002) .417 (.043) .146 (.496) -.015 (.944) .416 (.043) .397 (.055) 
Stroke like episodes .009 (.966) -.014 (.950) .140 (.515) .131 (.540) -.345 (.098) -.372 (.074) -.143 (.504) .005 (.983) .121 (.575) 
Encephalopathic .022 (.920) 0.000 (1.000) .152 (.477) .131 (.543) -.348 (.095) -.370 (.075) -.152 (.477) 0.000 (1.000) .131 (.543) 
Gastrointestinal .408 (.048) .326 (.120) .255 (.230) -.196 (.359) -.463 (.023) -.597 (.002) -.260 (.219) -.212 (.321) .006 (.979) 
Diabetes -.024 (.911) .141 (.512) .045 (.833) -.496 (.014) .022 (.918) .201 (.347) .234 (.271) -.022 (.920) -.112 (.603) 
Respiratory .138 (.521) .265 (.212) -.013 (.950) .152 (.480) .126 (.557) .011 (.959) -.336 (.108) -.061 (.777) -.139 (.516) 
Cardiovascular -.433 (.034) -.315 (.133) -.529 (.008) .389 (.060) .364 (.080) .174 (.417) .214 (.316) .484 (.017) .132 (.537) 
Visuals -.419 (.041) -.455 (.026) -.096 (.656) .137 (.524) .320 (.127) .165 (.440) .465 (.022) .321 (.126) .528 (.008) 
Ptosis .122 (.569) .054 (.801) .412 (.046) -.073 (.736) -.277 (.189) -.190 (.373) -.189 (.378) .095 (.658) .347 (.096) 
 316 
 
      
 
Pace Rhythm Asymmetry Variability Postural control 
NMDAS component Step Velocity Step Length Cadence 
Step time 
asymmetry 
Step length 
variability 
Step time 
variability 
Step width 
Step width 
variability 
Step length 
asymmetry 
CPEO -.410 (.047) -.464 (.022) -.209 (.326) .282 (.182) .337 (.108) .355 (.089) .373 (.073) .519 (.009) .264 (.213) 
Dysphonia/Dysarthria -.423 (.039) -.379 (.068) -.405 (.050) .267 (.207) .296 (.160) .274 (.196) .323 (.123) .318 (.130) .209 (.326) 
Cerebellar -.424 (.039) -.379 (.068) -.296 (.160) .434 (.034) .518 (.009) .513 (.010) .423 (.039) .634 (.001) .446 (.029) 
Neuropathy -.494 (.014) -.391 (.059) -.448 (.028) .479 (.018) .222 (.298) .196 (.360) .228 (.284) .450 (.027) .321 (.126) 
Pyramidal -.087 (.686) -.087 (.686) 0.000 (1.000) .305 (.147) .044 (.840) .087 (.686) .065 (.762) .196 (.359) .109 (.613) 
Extrapyramidal -.346 (.097) -.346 (.097) -.316 (.132) .346 (.097) .346 (.097) .346 (.097) .346 (.097) .346 (.097) -.105 (.624) 
Cognition -.464 (.022) -.461 (.023) -.345 (.099) .339 (.105) .160 (.456) .056 (.796) .087 (.685) .245 (.248) .615 (.001) 
Total -.645 (.001) -.588 (.003) -.418 (.042) .459 (.024) .334 (.110) .143 (.506) .364 (.081) .600 (.002) .615 (.001) 
Statistical significant results (p<.01) are shown in bold. 
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